{
  "f8493e8370d943ca": {
    "filename": "Data.txt",
    "text": "Name:  ___             Unit No:   ___\r \rAdmission Date:  ___              Discharge Date:   ___\r \rDate of Birth:  ___             Sex:   M\r \rService: UROLOGY\r \rAllergies: \rNo Known Allergies / Adverse Drug Reactions\r \rAttending: ___.\r \rChief Complaint:\rProstate cancer, obstructive symptoms\r \rMajor Surgical or Invasive Procedure:\rTURP, bipolar\r \rHistory of Present Illness:\r___, who was seen in preparation today for his upcoming \rTUR\rprostate scheduled for ___.  His TUR prostate is part of his\rongoing treatment program set up for his stage T3A and B\radenocarcinoma of the prostate, associated with high residual\rurine volumes in the 400s.  He has been on Lupron therapy since\r___ and his residual urine volume today is 234 mL.  Indeed\rrectal exam reveals a tumor outside the capsule.  A history and\rphysical was done and I went over the operation with the patient\rand his wife including the fact that part of his obstructive\rproblem is lack of dynamic voiding due to scarring and\rinfiltration of the tumor into the bladder neck area.  \rTherefore,\rremoving the obstruction may not completely free up his voiding\rsuch that he may still have an elevated residual urine volume,\rbut it should be better than it is today.  In addition, I will\rleave a small amount of extra tissue at the apex to assure\ragainst incontinence as the entire prostatic area may be \rsomewhat\rrigid and removing all of the prostatic tissue could result in\rincontinence.  Putting all this together, the operation will be\rdone carefully to open it up as much as possible without any\rincontinence problems.\r \rPast Medical History:\r- history of low-grade colitis diagnosed on colonoscopy at\r___ in ___, started on Canasa suppository\rand was on them for about a month, but has not used them in over\r___ years.  He saw occasional trace blood in the stool, but\rnothing regularly.  He has not had a colonoscopy since ___\r- hypertension.\r \rSocial History:\r___\rFamily History:\rFather had coronary disease and his mother had\r___ disease.  Paternal uncle had stomach cancer and his\rmaternal grandfather had stomach cancer.\r \rPhysical Exam:\rAFVSS\rNAD, pleasant and conversive\rnon-labored breathing\rsoft, non-tender, non-distended\r3-way catheter in place, draining clear yellow urine\rWWP\rgrossly non-focal\r \rBrief Hospital Course:\rMr. ___ was admitted to Dr. ___ service after \rbipolar transurethral resection of prostate. No concerning \rintraoperative events occurred; please see dictated operative \rnote for details. He patient received ___ antibiotic \rprophylaxis. The patient's postoperative course was \runcomplicated. He received intravenous antibiotics and \rcontinuous bladder irrigation overnight. On POD1 the CBI was \rdiscontinued and Foley catheter was kept in place with plans for \rfollow up the following week in clinic for vodiding trial. His \rurine was clear and and without clots. He remained afebrile \rthroughout his hospital stay.  At discharge, the patient had \rpain well controlled with oral pain medications, was tolerating \rregular diet, ambulating without assistance.  He was given \rpyridium and oral pain medications on discharge and a course of \rantibiotics along with explicit instructions to follow up in \rclinic with Dr. ___.\r \rMedications on Admission:\r Lisinopril 20 mg daily, hydrochlorothiazide 12.5\rdaily, Flomax 0.4 mg b.i.d.  \r \rDischarge Medications:\r1. bacitracin zinc 500 unit/gram Ointment Sig: One (1) Appl \rTopical TID (3 times a day) as needed for penile irritation: \rapply to tip of penis for pain relief.\rDisp:*1 tube* Refills:*0*\r2. docusate sodium 100 mg Capsule Sig: One (1) Capsule PO BID (2 \rtimes a day) as needed for constipation.\rDisp:*60 Capsule(s)* Refills:*0*\r3. acetaminophen 325 mg Tablet Sig: ___ Tablets PO Q6H (every 6 \rhours) as needed for pain, fever>100.\rDisp:*60 Tablet(s)* Refills:*0*\r4. Cipro 500 mg Tablet Sig: One (1) Tablet PO twice a day for 10 \rdays: to be taken until catheter removed.\rDisp:*20 Tablet(s)* Refills:*0*\r5. oxycodone 5 mg Tablet Sig: One (1) Tablet PO every ___ hours \ras needed for pain: for pain not relieved with tylenol or \ribuprofen.\rDisp:*20 Tablet(s)* Refills:*0*\r \rDischarge Disposition:\rHome\r \rDischarge Diagnosis:\rProstate cancer, obstructive symptoms\r \rDischarge Condition:\rStable, Good\rA/Ox3\rFunctionally independent\r \rDischarge Instructions:\rINSTRUCTIONS:\r-Do not lift anything heavier than a phone book (10 pounds) or \rdrive until you are seen by your Urologist in follow-up\r-You may continue to periodically see small amounts of blood in \ryour urine--this is normal and will gradually improve\rMEDICATIONS:\r      -Resume all of your pre-admission medications, except HOLD \raspirin until you see your urologist in followup AND your foley \rhas been removed (if not already done)\r      -Complete a course of antibiotics (Ciprofloxacin)\r      -You will be discharged home with a medication called \rPYRIDIUM that will help with the \"burning\" pain you may \rexperience when voiding. This medication may turn your urine\rbright orange.\r      -Colace has been prescribed to avoid post surgical \rconstipation and constipation related to narcotic pain \rmedication. Discontinue if loose stool or diarrhea develops. \rColace is a stool softener, NOT a laxative\r-Do not eat constipating foods for ___ weeks, drink plenty of \rfluids to keep hydrated\r-No vigorous physical activity or sports for 4 weeks or until \rotherwise advised\r-Tylenol should be your first line pain medication, a narcotic \rpain medication has been prescribed for breakthrough pain >4. \rReplace Tylenol with narcotic pain medication.\r-Max daily Tylenol (acetaminophen) dose is 4 grams from ALL \rsources, note that narcotic pain medication also contains \rTylenol\r-Do not drive or drink alcohol while taking narcotics and do not \roperate dangerous machinery. Also, if the Foley catheter and Leg \rBag are in place--Do NOT drive (you may be a passenger).\r \rFollowup Instructions:\r___\r"
  },
  "aaff63c0692243b2": {
    "filename": "Data.txt",
    "text": "Name:  ___             Unit No:   ___\r \rAdmission Date:  ___              Discharge Date:   ___\r \rDate of Birth:  ___             Sex:   M\r \rService: UROLOGY\r \rAllergies: \rNo Known Allergies / Adverse Drug Reactions\r \rAttending: ___.\r \rChief Complaint:\rProstate cancer, obstructive symptoms\r \rMajor Surgical or Invasive Procedure:\rTURP, bipolar\r \rHistory of Present Illness:\r___, who was seen in preparation today for his upcoming \rTUR\rprostate scheduled for ___.  His TUR prostate is part of his\rongoing treatment program set up for his stage T3A and B\radenocarcinoma of the prostate, associated with high residual\rurine volumes in the 400s.  He has been on Lupron therapy since\r___ and his residual urine volume today is 234 mL.  Indeed\rrectal exam reveals a tumor outside the capsule.  A history and\rphysical was done and I went over the operation with the patient\rand his wife including the fact that part of his obstructive\rproblem is lack of dynamic voiding due to scarring and\rinfiltration of the tumor into the bladder neck area.  \rTherefore,\rremoving the obstruction may not completely free up his voiding\rsuch that he may still have an elevated residual urine volume,\rbut it should be better than it is today.  In addition, I will\rleave a small amount of extra tissue at the apex to assure\ragainst incontinence as the entire prostatic area may be \rsomewhat\rrigid and removing all of the prostatic tissue could result in\rincontinence.  Putting all this together, the operation will be\rdone carefully to open it up as much as possible without any\rincontinence problems.\r \rPast Medical History:\r- history of low-grade colitis diagnosed on colonoscopy at\r___ in ___, started on Canasa suppository\rand was on them for about a month, but has not used them in over\r___ years.  He saw occasional trace blood in the stool, but\rnothing regularly.  He has not had a colonoscopy since ___\r- hypertension.\r \rSocial History:\r___\rFamily History:\rFather had coronary disease and his mother had\r___ disease.  Paternal uncle had stomach cancer and his\rmaternal grandfather had stomach cancer.\r \rPhysical Exam:\rAFVSS\rNAD, pleasant and conversive\rnon-labored breathing\rsoft, non-tender, non-distended\r3-way catheter in place, draining clear yellow urine\rWWP\rgrossly non-focal\r \rBrief Hospital Course:\rMr. ___ was admitted to Dr. ___ service after \rbipolar transurethral resection of prostate. No concerning \rintraoperative events occurred; please see dictated operative \rnote for details. He patient received ___ antibiotic \rprophylaxis. The patient's postoperative course was \runcomplicated. He received intravenous antibiotics and \rcontinuous bladder irrigation overnight. On POD1 the CBI was \rdiscontinued and Foley catheter was kept in place with plans for \rfollow up the following week in clinic for vodiding trial. His \rurine was clear and and without clots. He remained afebrile \rthroughout his hospital stay.  At discharge, the patient had \rpain well controlled with oral pain medications, was tolerating \rregular diet, ambulating without assistance.  He was given \rpyridium and oral pain medications on discharge and a course of \rantibiotics along with explicit instructions to follow up in \rclinic with Dr. ___.\r \rMedications on Admission:\r Lisinopril 20 mg daily, hydrochlorothiazide 12.5\rdaily, Flomax 0.4 mg b.i.d.  \r \rDischarge Medications:\r1. bacitracin zinc 500 unit/gram Ointment Sig: One (1) Appl \rTopical TID (3 times a day) as needed for penile irritation: \rapply to tip of penis for pain relief.\rDisp:*1 tube* Refills:*0*\r2. docusate sodium 100 mg Capsule Sig: One (1) Capsule PO BID (2 \rtimes a day) as needed for constipation.\rDisp:*60 Capsule(s)* Refills:*0*\r3. acetaminophen 325 mg Tablet Sig: ___ Tablets PO Q6H (every 6 \rhours) as needed for pain, fever>100.\rDisp:*60 Tablet(s)* Refills:*0*\r4. Cipro 500 mg Tablet Sig: One (1) Tablet PO twice a day for 10 \rdays: to be taken until catheter removed.\rDisp:*20 Tablet(s)* Refills:*0*\r5. oxycodone 5 mg Tablet Sig: One (1) Tablet PO every ___ hours \ras needed for pain: for pain not relieved with tylenol or \ribuprofen.\rDisp:*20 Tablet(s)* Refills:*0*\r \rDischarge Disposition:\rHome\r \rDischarge Diagnosis:\rProstate cancer, obstructive symptoms\r \rDischarge Condition:\rStable, Good\rA/Ox3\rFunctionally independent\r \rDischarge Instructions:\rINSTRUCTIONS:\r-Do not lift anything heavier than a phone book (10 pounds) or \rdrive until you are seen by your Urologist in follow-up\r-You may continue to periodically see small amounts of blood in \ryour urine--this is normal and will gradually improve\rMEDICATIONS:\r      -Resume all of your pre-admission medications, except HOLD \raspirin until you see your urologist in followup AND your foley \rhas been removed (if not already done)\r      -Complete a course of antibiotics (Ciprofloxacin)\r      -You will be discharged home with a medication called \rPYRIDIUM that will help with the \"burning\" pain you may \rexperience when voiding. This medication may turn your urine\rbright orange.\r      -Colace has been prescribed to avoid post surgical \rconstipation and constipation related to narcotic pain \rmedication. Discontinue if loose stool or diarrhea develops. \rColace is a stool softener, NOT a laxative\r-Do not eat constipating foods for ___ weeks, drink plenty of \rfluids to keep hydrated\r-No vigorous physical activity or sports for 4 weeks or until \rotherwise advised\r-Tylenol should be your first line pain medication, a narcotic \rpain medication has been prescribed for breakthrough pain >4. \rReplace Tylenol with narcotic pain medication.\r-Max daily Tylenol (acetaminophen) dose is 4 grams from ALL \rsources, note that narcotic pain medication also contains \rTylenol\r-Do not drive or drink alcohol while taking narcotics and do not \roperate dangerous machinery. Also, if the Foley catheter and Leg \rBag are in place--Do NOT drive (you may be a passenger).\r \rFollowup Instructions:\r___\r"
  },
  "0a77ff04bd8797a5": {
    "filename": "Data.txt",
    "text": "Name:  ___             Unit No:   ___\r \rAdmission Date:  ___              Discharge Date:   ___\r \rDate of Birth:  ___             Sex:   M\r \rService: UROLOGY\r \rAllergies: \rNo Known Allergies / Adverse Drug Reactions\r \rAttending: ___.\r \rChief Complaint:\rProstate cancer, obstructive symptoms\r \rMajor Surgical or Invasive Procedure:\rTURP, bipolar\r \rHistory of Present Illness:\r___, who was seen in preparation today for his upcoming \rTUR\rprostate scheduled for ___.  His TUR prostate is part of his\rongoing treatment program set up for his stage T3A and B\radenocarcinoma of the prostate, associated with high residual\rurine volumes in the 400s.  He has been on Lupron therapy since\r___ and his residual urine volume today is 234 mL.  Indeed\rrectal exam reveals a tumor outside the capsule.  A history and\rphysical was done and I went over the operation with the patient\rand his wife including the fact that part of his obstructive\rproblem is lack of dynamic voiding due to scarring and\rinfiltration of the tumor into the bladder neck area.  \rTherefore,\rremoving the obstruction may not completely free up his voiding\rsuch that he may still have an elevated residual urine volume,\rbut it should be better than it is today.  In addition, I will\rleave a small amount of extra tissue at the apex to assure\ragainst incontinence as the entire prostatic area may be \rsomewhat\rrigid and removing all of the prostatic tissue could result in\rincontinence.  Putting all this together, the operation will be\rdone carefully to open it up as much as possible without any\rincontinence problems.\r \rPast Medical History:\r- history of low-grade colitis diagnosed on colonoscopy at\r___ in ___, started on Canasa suppository\rand was on them for about a month, but has not used them in over\r___ years.  He saw occasional trace blood in the stool, but\rnothing regularly.  He has not had a colonoscopy since ___\r- hypertension.\r \rSocial History:\r___\rFamily History:\rFather had coronary disease and his mother had\r___ disease.  Paternal uncle had stomach cancer and his\rmaternal grandfather had stomach cancer.\r \rPhysical Exam:\rAFVSS\rNAD, pleasant and conversive\rnon-labored breathing\rsoft, non-tender, non-distended\r3-way catheter in place, draining clear yellow urine\rWWP\rgrossly non-focal\r \rBrief Hospital Course:\rMr. ___ was admitted to Dr. ___ service after \rbipolar transurethral resection of prostate. No concerning \rintraoperative events occurred; please see dictated operative \rnote for details. He patient received ___ antibiotic \rprophylaxis. The patient's postoperative course was \runcomplicated. He received intravenous antibiotics and \rcontinuous bladder irrigation overnight. On POD1 the CBI was \rdiscontinued and Foley catheter was kept in place with plans for \rfollow up the following week in clinic for vodiding trial. His \rurine was clear and and without clots. He remained afebrile \rthroughout his hospital stay.  At discharge, the patient had \rpain well controlled with oral pain medications, was tolerating \rregular diet, ambulating without assistance.  He was given \rpyridium and oral pain medications on discharge and a course of \rantibiotics along with explicit instructions to follow up in \rclinic with Dr. ___.\r \rMedications on Admission:\r Lisinopril 20 mg daily, hydrochlorothiazide 12.5\rdaily, Flomax 0.4 mg b.i.d.  \r \rDischarge Medications:\r1. bacitracin zinc 500 unit/gram Ointment Sig: One (1) Appl \rTopical TID (3 times a day) as needed for penile irritation: \rapply to tip of penis for pain relief.\rDisp:*1 tube* Refills:*0*\r2. docusate sodium 100 mg Capsule Sig: One (1) Capsule PO BID (2 \rtimes a day) as needed for constipation.\rDisp:*60 Capsule(s)* Refills:*0*\r3. acetaminophen 325 mg Tablet Sig: ___ Tablets PO Q6H (every 6 \rhours) as needed for pain, fever>100.\rDisp:*60 Tablet(s)* Refills:*0*\r4. Cipro 500 mg Tablet Sig: One (1) Tablet PO twice a day for 10 \rdays: to be taken until catheter removed.\rDisp:*20 Tablet(s)* Refills:*0*\r5. oxycodone 5 mg Tablet Sig: One (1) Tablet PO every ___ hours \ras needed for pain: for pain not relieved with tylenol or \ribuprofen.\rDisp:*20 Tablet(s)* Refills:*0*\r \rDischarge Disposition:\rHome\r \rDischarge Diagnosis:\rProstate cancer, obstructive symptoms\r \rDischarge Condition:\rStable, Good\rA/Ox3\rFunctionally independent\r \rDischarge Instructions:\rINSTRUCTIONS:\r-Do not lift anything heavier than a phone book (10 pounds) or \rdrive until you are seen by your Urologist in follow-up\r-You may continue to periodically see small amounts of blood in \ryour urine--this is normal and will gradually improve\rMEDICATIONS:\r      -Resume all of your pre-admission medications, except HOLD \raspirin until you see your urologist in followup AND your foley \rhas been removed (if not already done)\r      -Complete a course of antibiotics (Ciprofloxacin)\r      -You will be discharged home with a medication called \rPYRIDIUM that will help with the \"burning\" pain you may \rexperience when voiding. This medication may turn your urine\rbright orange.\r      -Colace has been prescribed to avoid post surgical \rconstipation and constipation related to narcotic pain \rmedication. Discontinue if loose stool or diarrhea develops. \rColace is a stool softener, NOT a laxative\r-Do not eat constipating foods for ___ weeks, drink plenty of \rfluids to keep hydrated\r-No vigorous physical activity or sports for 4 weeks or until \rotherwise advised\r-Tylenol should be your first line pain medication, a narcotic \rpain medication has been prescribed for breakthrough pain >4. \rReplace Tylenol with narcotic pain medication.\r-Max daily Tylenol (acetaminophen) dose is 4 grams from ALL \rsources, note that narcotic pain medication also contains \rTylenol\r-Do not drive or drink alcohol while taking narcotics and do not \roperate dangerous machinery. Also, if the Foley catheter and Leg \rBag are in place--Do NOT drive (you may be a passenger).\r \rFollowup Instructions:\r___\r"
  },
  "7f9a68651e621861": {
    "filename": "Data.txt",
    "text": "Name:  ___             Unit No:   ___\r \rAdmission Date:  ___              Discharge Date:   ___\r \rDate of Birth:  ___             Sex:   M\r \rService: UROLOGY\r \rAllergies: \rNo Known Allergies / Adverse Drug Reactions\r \rAttending: ___.\r \rChief Complaint:\rProstate cancer, obstructive symptoms\r \rMajor Surgical or Invasive Procedure:\rTURP, bipolar\r \rHistory of Present Illness:\r___, who was seen in preparation today for his upcoming \rTUR\rprostate scheduled for ___.  His TUR prostate is part of his\rongoing treatment program set up for his stage T3A and B\radenocarcinoma of the prostate, associated with high residual\rurine volumes in the 400s.  He has been on Lupron therapy since\r___ and his residual urine volume today is 234 mL.  Indeed\rrectal exam reveals a tumor outside the capsule.  A history and\rphysical was done and I went over the operation with the patient\rand his wife including the fact that part of his obstructive\rproblem is lack of dynamic voiding due to scarring and\rinfiltration of the tumor into the bladder neck area.  \rTherefore,\rremoving the obstruction may not completely free up his voiding\rsuch that he may still have an elevated residual urine volume,\rbut it should be better than it is today.  In addition, I will\rleave a small amount of extra tissue at the apex to assure\ragainst incontinence as the entire prostatic area may be \rsomewhat\rrigid and removing all of the prostatic tissue could result in\rincontinence.  Putting all this together, the operation will be\rdone carefully to open it up as much as possible without any\rincontinence problems.\r \rPast Medical History:\r- history of low-grade colitis diagnosed on colonoscopy at\r___ in ___, started on Canasa suppository\rand was on them for about a month, but has not used them in over\r___ years.  He saw occasional trace blood in the stool, but\rnothing regularly.  He has not had a colonoscopy since ___\r- hypertension.\r \rSocial History:\r___\rFamily History:\rFather had coronary disease and his mother had\r___ disease.  Paternal uncle had stomach cancer and his\rmaternal grandfather had stomach cancer.\r \rPhysical Exam:\rAFVSS\rNAD, pleasant and conversive\rnon-labored breathing\rsoft, non-tender, non-distended\r3-way catheter in place, draining clear yellow urine\rWWP\rgrossly non-focal\r \rBrief Hospital Course:\rMr. ___ was admitted to Dr. ___ service after \rbipolar transurethral resection of prostate. No concerning \rintraoperative events occurred; please see dictated operative \rnote for details. He patient received ___ antibiotic \rprophylaxis. The patient's postoperative course was \runcomplicated. He received intravenous antibiotics and \rcontinuous bladder irrigation overnight. On POD1 the CBI was \rdiscontinued and Foley catheter was kept in place with plans for \rfollow up the following week in clinic for vodiding trial. His \rurine was clear and and without clots. He remained afebrile \rthroughout his hospital stay.  At discharge, the patient had \rpain well controlled with oral pain medications, was tolerating \rregular diet, ambulating without assistance.  He was given \rpyridium and oral pain medications on discharge and a course of \rantibiotics along with explicit instructions to follow up in \rclinic with Dr. ___.\r \rMedications on Admission:\r Lisinopril 20 mg daily, hydrochlorothiazide 12.5\rdaily, Flomax 0.4 mg b.i.d.  \r \rDischarge Medications:\r1. bacitracin zinc 500 unit/gram Ointment Sig: One (1) Appl \rTopical TID (3 times a day) as needed for penile irritation: \rapply to tip of penis for pain relief.\rDisp:*1 tube* Refills:*0*\r2. docusate sodium 100 mg Capsule Sig: One (1) Capsule PO BID (2 \rtimes a day) as needed for constipation.\rDisp:*60 Capsule(s)* Refills:*0*\r3. acetaminophen 325 mg Tablet Sig: ___ Tablets PO Q6H (every 6 \rhours) as needed for pain, fever>100.\rDisp:*60 Tablet(s)* Refills:*0*\r4. Cipro 500 mg Tablet Sig: One (1) Tablet PO twice a day for 10 \rdays: to be taken until catheter removed.\rDisp:*20 Tablet(s)* Refills:*0*\r5. oxycodone 5 mg Tablet Sig: One (1) Tablet PO every ___ hours \ras needed for pain: for pain not relieved with tylenol or \ribuprofen.\rDisp:*20 Tablet(s)* Refills:*0*\r \rDischarge Disposition:\rHome\r \rDischarge Diagnosis:\rProstate cancer, obstructive symptoms\r \rDischarge Condition:\rStable, Good\rA/Ox3\rFunctionally independent\r \rDischarge Instructions:\rINSTRUCTIONS:\r-Do not lift anything heavier than a phone book (10 pounds) or \rdrive until you are seen by your Urologist in follow-up\r-You may continue to periodically see small amounts of blood in \ryour urine--this is normal and will gradually improve\rMEDICATIONS:\r      -Resume all of your pre-admission medications, except HOLD \raspirin until you see your urologist in followup AND your foley \rhas been removed (if not already done)\r      -Complete a course of antibiotics (Ciprofloxacin)\r      -You will be discharged home with a medication called \rPYRIDIUM that will help with the \"burning\" pain you may \rexperience when voiding. This medication may turn your urine\rbright orange.\r      -Colace has been prescribed to avoid post surgical \rconstipation and constipation related to narcotic pain \rmedication. Discontinue if loose stool or diarrhea develops. \rColace is a stool softener, NOT a laxative\r-Do not eat constipating foods for ___ weeks, drink plenty of \rfluids to keep hydrated\r-No vigorous physical activity or sports for 4 weeks or until \rotherwise advised\r-Tylenol should be your first line pain medication, a narcotic \rpain medication has been prescribed for breakthrough pain >4. \rReplace Tylenol with narcotic pain medication.\r-Max daily Tylenol (acetaminophen) dose is 4 grams from ALL \rsources, note that narcotic pain medication also contains \rTylenol\r-Do not drive or drink alcohol while taking narcotics and do not \roperate dangerous machinery. Also, if the Foley catheter and Leg \rBag are in place--Do NOT drive (you may be a passenger).\r \rFollowup Instructions:\r___\r"
  },
  "e814030955319068": {
    "filename": "Data.txt",
    "text": "Name:  ___             Unit No:   ___\r \rAdmission Date:  ___              Discharge Date:   ___\r \rDate of Birth:  ___             Sex:   M\r \rService: UROLOGY\r \rAllergies: \rNo Known Allergies / Adverse Drug Reactions\r \rAttending: ___.\r \rChief Complaint:\rProstate cancer, obstructive symptoms\r \rMajor Surgical or Invasive Procedure:\rTURP, bipolar\r \rHistory of Present Illness:\r___, who was seen in preparation today for his upcoming \rTUR\rprostate scheduled for ___.  His TUR prostate is part of his\rongoing treatment program set up for his stage T3A and B\radenocarcinoma of the prostate, associated with high residual\rurine volumes in the 400s.  He has been on Lupron therapy since\r___ and his residual urine volume today is 234 mL.  Indeed\rrectal exam reveals a tumor outside the capsule.  A history and\rphysical was done and I went over the operation with the patient\rand his wife including the fact that part of his obstructive\rproblem is lack of dynamic voiding due to scarring and\rinfiltration of the tumor into the bladder neck area.  \rTherefore,\rremoving the obstruction may not completely free up his voiding\rsuch that he may still have an elevated residual urine volume,\rbut it should be better than it is today.  In addition, I will\rleave a small amount of extra tissue at the apex to assure\ragainst incontinence as the entire prostatic area may be \rsomewhat\rrigid and removing all of the prostatic tissue could result in\rincontinence.  Putting all this together, the operation will be\rdone carefully to open it up as much as possible without any\rincontinence problems.\r \rPast Medical History:\r- history of low-grade colitis diagnosed on colonoscopy at\r___ in ___, started on Canasa suppository\rand was on them for about a month, but has not used them in over\r___ years.  He saw occasional trace blood in the stool, but\rnothing regularly.  He has not had a colonoscopy since ___\r- hypertension.\r \rSocial History:\r___\rFamily History:\rFather had coronary disease and his mother had\r___ disease.  Paternal uncle had stomach cancer and his\rmaternal grandfather had stomach cancer.\r \rPhysical Exam:\rAFVSS\rNAD, pleasant and conversive\rnon-labored breathing\rsoft, non-tender, non-distended\r3-way catheter in place, draining clear yellow urine\rWWP\rgrossly non-focal\r \rBrief Hospital Course:\rMr. ___ was admitted to Dr. ___ service after \rbipolar transurethral resection of prostate. No concerning \rintraoperative events occurred; please see dictated operative \rnote for details. He patient received ___ antibiotic \rprophylaxis. The patient's postoperative course was \runcomplicated. He received intravenous antibiotics and \rcontinuous bladder irrigation overnight. On POD1 the CBI was \rdiscontinued and Foley catheter was kept in place with plans for \rfollow up the following week in clinic for vodiding trial. His \rurine was clear and and without clots. He remained afebrile \rthroughout his hospital stay.  At discharge, the patient had \rpain well controlled with oral pain medications, was tolerating \rregular diet, ambulating without assistance.  He was given \rpyridium and oral pain medications on discharge and a course of \rantibiotics along with explicit instructions to follow up in \rclinic with Dr. ___.\r \rMedications on Admission:\r Lisinopril 20 mg daily, hydrochlorothiazide 12.5\rdaily, Flomax 0.4 mg b.i.d.  \r \rDischarge Medications:\r1. bacitracin zinc 500 unit/gram Ointment Sig: One (1) Appl \rTopical TID (3 times a day) as needed for penile irritation: \rapply to tip of penis for pain relief.\rDisp:*1 tube* Refills:*0*\r2. docusate sodium 100 mg Capsule Sig: One (1) Capsule PO BID (2 \rtimes a day) as needed for constipation.\rDisp:*60 Capsule(s)* Refills:*0*\r3. acetaminophen 325 mg Tablet Sig: ___ Tablets PO Q6H (every 6 \rhours) as needed for pain, fever>100.\rDisp:*60 Tablet(s)* Refills:*0*\r4. Cipro 500 mg Tablet Sig: One (1) Tablet PO twice a day for 10 \rdays: to be taken until catheter removed.\rDisp:*20 Tablet(s)* Refills:*0*\r5. oxycodone 5 mg Tablet Sig: One (1) Tablet PO every ___ hours \ras needed for pain: for pain not relieved with tylenol or \ribuprofen.\rDisp:*20 Tablet(s)* Refills:*0*\r \rDischarge Disposition:\rHome\r \rDischarge Diagnosis:\rProstate cancer, obstructive symptoms\r \rDischarge Condition:\rStable, Good\rA/Ox3\rFunctionally independent\r \rDischarge Instructions:\rINSTRUCTIONS:\r-Do not lift anything heavier than a phone book (10 pounds) or \rdrive until you are seen by your Urologist in follow-up\r-You may continue to periodically see small amounts of blood in \ryour urine--this is normal and will gradually improve\rMEDICATIONS:\r      -Resume all of your pre-admission medications, except HOLD \raspirin until you see your urologist in followup AND your foley \rhas been removed (if not already done)\r      -Complete a course of antibiotics (Ciprofloxacin)\r      -You will be discharged home with a medication called \rPYRIDIUM that will help with the \"burning\" pain you may \rexperience when voiding. This medication may turn your urine\rbright orange.\r      -Colace has been prescribed to avoid post surgical \rconstipation and constipation related to narcotic pain \rmedication. Discontinue if loose stool or diarrhea develops. \rColace is a stool softener, NOT a laxative\r-Do not eat constipating foods for ___ weeks, drink plenty of \rfluids to keep hydrated\r-No vigorous physical activity or sports for 4 weeks or until \rotherwise advised\r-Tylenol should be your first line pain medication, a narcotic \rpain medication has been prescribed for breakthrough pain >4. \rReplace Tylenol with narcotic pain medication.\r-Max daily Tylenol (acetaminophen) dose is 4 grams from ALL \rsources, note that narcotic pain medication also contains \rTylenol\r-Do not drive or drink alcohol while taking narcotics and do not \roperate dangerous machinery. Also, if the Foley catheter and Leg \rBag are in place--Do NOT drive (you may be a passenger).\r \rFollowup Instructions:\r___\r"
  },
  "a2081d329e4ed257": {
    "filename": "Data.txt",
    "text": "Name:  ___             Unit No:   ___\r \rAdmission Date:  ___              Discharge Date:   ___\r \rDate of Birth:  ___             Sex:   M\r \rService: UROLOGY\r \rAllergies: \rNo Known Allergies / Adverse Drug Reactions\r \rAttending: ___.\r \rChief Complaint:\rProstate cancer, obstructive symptoms\r \rMajor Surgical or Invasive Procedure:\rTURP, bipolar\r \rHistory of Present Illness:\r___, who was seen in preparation today for his upcoming \rTUR\rprostate scheduled for ___.  His TUR prostate is part of his\rongoing treatment program set up for his stage T3A and B\radenocarcinoma of the prostate, associated with high residual\rurine volumes in the 400s.  He has been on Lupron therapy since\r___ and his residual urine volume today is 234 mL.  Indeed\rrectal exam reveals a tumor outside the capsule.  A history and\rphysical was done and I went over the operation with the patient\rand his wife including the fact that part of his obstructive\rproblem is lack of dynamic voiding due to scarring and\rinfiltration of the tumor into the bladder neck area.  \rTherefore,\rremoving the obstruction may not completely free up his voiding\rsuch that he may still have an elevated residual urine volume,\rbut it should be better than it is today.  In addition, I will\rleave a small amount of extra tissue at the apex to assure\ragainst incontinence as the entire prostatic area may be \rsomewhat\rrigid and removing all of the prostatic tissue could result in\rincontinence.  Putting all this together, the operation will be\rdone carefully to open it up as much as possible without any\rincontinence problems.\r \rPast Medical History:\r- history of low-grade colitis diagnosed on colonoscopy at\r___ in ___, started on Canasa suppository\rand was on them for about a month, but has not used them in over\r___ years.  He saw occasional trace blood in the stool, but\rnothing regularly.  He has not had a colonoscopy since ___\r- hypertension.\r \rSocial History:\r___\rFamily History:\rFather had coronary disease and his mother had\r___ disease.  Paternal uncle had stomach cancer and his\rmaternal grandfather had stomach cancer.\r \rPhysical Exam:\rAFVSS\rNAD, pleasant and conversive\rnon-labored breathing\rsoft, non-tender, non-distended\r3-way catheter in place, draining clear yellow urine\rWWP\rgrossly non-focal\r \rBrief Hospital Course:\rMr. ___ was admitted to Dr. ___ service after \rbipolar transurethral resection of prostate. No concerning \rintraoperative events occurred; please see dictated operative \rnote for details. He patient received ___ antibiotic \rprophylaxis. The patient's postoperative course was \runcomplicated. He received intravenous antibiotics and \rcontinuous bladder irrigation overnight. On POD1 the CBI was \rdiscontinued and Foley catheter was kept in place with plans for \rfollow up the following week in clinic for vodiding trial. His \rurine was clear and and without clots. He remained afebrile \rthroughout his hospital stay.  At discharge, the patient had \rpain well controlled with oral pain medications, was tolerating \rregular diet, ambulating without assistance.  He was given \rpyridium and oral pain medications on discharge and a course of \rantibiotics along with explicit instructions to follow up in \rclinic with Dr. ___.\r \rMedications on Admission:\r Lisinopril 20 mg daily, hydrochlorothiazide 12.5\rdaily, Flomax 0.4 mg b.i.d.  \r \rDischarge Medications:\r1. bacitracin zinc 500 unit/gram Ointment Sig: One (1) Appl \rTopical TID (3 times a day) as needed for penile irritation: \rapply to tip of penis for pain relief.\rDisp:*1 tube* Refills:*0*\r2. docusate sodium 100 mg Capsule Sig: One (1) Capsule PO BID (2 \rtimes a day) as needed for constipation.\rDisp:*60 Capsule(s)* Refills:*0*\r3. acetaminophen 325 mg Tablet Sig: ___ Tablets PO Q6H (every 6 \rhours) as needed for pain, fever>100.\rDisp:*60 Tablet(s)* Refills:*0*\r4. Cipro 500 mg Tablet Sig: One (1) Tablet PO twice a day for 10 \rdays: to be taken until catheter removed.\rDisp:*20 Tablet(s)* Refills:*0*\r5. oxycodone 5 mg Tablet Sig: One (1) Tablet PO every ___ hours \ras needed for pain: for pain not relieved with tylenol or \ribuprofen.\rDisp:*20 Tablet(s)* Refills:*0*\r \rDischarge Disposition:\rHome\r \rDischarge Diagnosis:\rProstate cancer, obstructive symptoms\r \rDischarge Condition:\rStable, Good\rA/Ox3\rFunctionally independent\r \rDischarge Instructions:\rINSTRUCTIONS:\r-Do not lift anything heavier than a phone book (10 pounds) or \rdrive until you are seen by your Urologist in follow-up\r-You may continue to periodically see small amounts of blood in \ryour urine--this is normal and will gradually improve\rMEDICATIONS:\r      -Resume all of your pre-admission medications, except HOLD \raspirin until you see your urologist in followup AND your foley \rhas been removed (if not already done)\r      -Complete a course of antibiotics (Ciprofloxacin)\r      -You will be discharged home with a medication called \rPYRIDIUM that will help with the \"burning\" pain you may \rexperience when voiding. This medication may turn your urine\rbright orange.\r      -Colace has been prescribed to avoid post surgical \rconstipation and constipation related to narcotic pain \rmedication. Discontinue if loose stool or diarrhea develops. \rColace is a stool softener, NOT a laxative\r-Do not eat constipating foods for ___ weeks, drink plenty of \rfluids to keep hydrated\r-No vigorous physical activity or sports for 4 weeks or until \rotherwise advised\r-Tylenol should be your first line pain medication, a narcotic \rpain medication has been prescribed for breakthrough pain >4. \rReplace Tylenol with narcotic pain medication.\r-Max daily Tylenol (acetaminophen) dose is 4 grams from ALL \rsources, note that narcotic pain medication also contains \rTylenol\r-Do not drive or drink alcohol while taking narcotics and do not \roperate dangerous machinery. Also, if the Foley catheter and Leg \rBag are in place--Do NOT drive (you may be a passenger).\r \rFollowup Instructions:\r___\r"
  },
  "9867ffd81b3d7c08": {
    "filename": "Data.txt",
    "text": "Name:  ___             Unit No:   ___\r \rAdmission Date:  ___              Discharge Date:   ___\r \rDate of Birth:  ___             Sex:   M\r \rService: UROLOGY\r \rAllergies: \rNo Known Allergies / Adverse Drug Reactions\r \rAttending: ___.\r \rChief Complaint:\rProstate cancer, obstructive symptoms\r \rMajor Surgical or Invasive Procedure:\rTURP, bipolar\r \rHistory of Present Illness:\r___, who was seen in preparation today for his upcoming \rTUR\rprostate scheduled for ___.  His TUR prostate is part of his\rongoing treatment program set up for his stage T3A and B\radenocarcinoma of the prostate, associated with high residual\rurine volumes in the 400s.  He has been on Lupron therapy since\r___ and his residual urine volume today is 234 mL.  Indeed\rrectal exam reveals a tumor outside the capsule.  A history and\rphysical was done and I went over the operation with the patient\rand his wife including the fact that part of his obstructive\rproblem is lack of dynamic voiding due to scarring and\rinfiltration of the tumor into the bladder neck area.  \rTherefore,\rremoving the obstruction may not completely free up his voiding\rsuch that he may still have an elevated residual urine volume,\rbut it should be better than it is today.  In addition, I will\rleave a small amount of extra tissue at the apex to assure\ragainst incontinence as the entire prostatic area may be \rsomewhat\rrigid and removing all of the prostatic tissue could result in\rincontinence.  Putting all this together, the operation will be\rdone carefully to open it up as much as possible without any\rincontinence problems.\r \rPast Medical History:\r- history of low-grade colitis diagnosed on colonoscopy at\r___ in ___, started on Canasa suppository\rand was on them for about a month, but has not used them in over\r___ years.  He saw occasional trace blood in the stool, but\rnothing regularly.  He has not had a colonoscopy since ___\r- hypertension.\r \rSocial History:\r___\rFamily History:\rFather had coronary disease and his mother had\r___ disease.  Paternal uncle had stomach cancer and his\rmaternal grandfather had stomach cancer.\r \rPhysical Exam:\rAFVSS\rNAD, pleasant and conversive\rnon-labored breathing\rsoft, non-tender, non-distended\r3-way catheter in place, draining clear yellow urine\rWWP\rgrossly non-focal\r \rBrief Hospital Course:\rMr. ___ was admitted to Dr. ___ service after \rbipolar transurethral resection of prostate. No concerning \rintraoperative events occurred; please see dictated operative \rnote for details. He patient received ___ antibiotic \rprophylaxis. The patient's postoperative course was \runcomplicated. He received intravenous antibiotics and \rcontinuous bladder irrigation overnight. On POD1 the CBI was \rdiscontinued and Foley catheter was kept in place with plans for \rfollow up the following week in clinic for vodiding trial. His \rurine was clear and and without clots. He remained afebrile \rthroughout his hospital stay.  At discharge, the patient had \rpain well controlled with oral pain medications, was tolerating \rregular diet, ambulating without assistance.  He was given \rpyridium and oral pain medications on discharge and a course of \rantibiotics along with explicit instructions to follow up in \rclinic with Dr. ___.\r \rMedications on Admission:\r Lisinopril 20 mg daily, hydrochlorothiazide 12.5\rdaily, Flomax 0.4 mg b.i.d.  \r \rDischarge Medications:\r1. bacitracin zinc 500 unit/gram Ointment Sig: One (1) Appl \rTopical TID (3 times a day) as needed for penile irritation: \rapply to tip of penis for pain relief.\rDisp:*1 tube* Refills:*0*\r2. docusate sodium 100 mg Capsule Sig: One (1) Capsule PO BID (2 \rtimes a day) as needed for constipation.\rDisp:*60 Capsule(s)* Refills:*0*\r3. acetaminophen 325 mg Tablet Sig: ___ Tablets PO Q6H (every 6 \rhours) as needed for pain, fever>100.\rDisp:*60 Tablet(s)* Refills:*0*\r4. Cipro 500 mg Tablet Sig: One (1) Tablet PO twice a day for 10 \rdays: to be taken until catheter removed.\rDisp:*20 Tablet(s)* Refills:*0*\r5. oxycodone 5 mg Tablet Sig: One (1) Tablet PO every ___ hours \ras needed for pain: for pain not relieved with tylenol or \ribuprofen.\rDisp:*20 Tablet(s)* Refills:*0*\r \rDischarge Disposition:\rHome\r \rDischarge Diagnosis:\rProstate cancer, obstructive symptoms\r \rDischarge Condition:\rStable, Good\rA/Ox3\rFunctionally independent\r \rDischarge Instructions:\rINSTRUCTIONS:\r-Do not lift anything heavier than a phone book (10 pounds) or \rdrive until you are seen by your Urologist in follow-up\r-You may continue to periodically see small amounts of blood in \ryour urine--this is normal and will gradually improve\rMEDICATIONS:\r      -Resume all of your pre-admission medications, except HOLD \raspirin until you see your urologist in followup AND your foley \rhas been removed (if not already done)\r      -Complete a course of antibiotics (Ciprofloxacin)\r      -You will be discharged home with a medication called \rPYRIDIUM that will help with the \"burning\" pain you may \rexperience when voiding. This medication may turn your urine\rbright orange.\r      -Colace has been prescribed to avoid post surgical \rconstipation and constipation related to narcotic pain \rmedication. Discontinue if loose stool or diarrhea develops. \rColace is a stool softener, NOT a laxative\r-Do not eat constipating foods for ___ weeks, drink plenty of \rfluids to keep hydrated\r-No vigorous physical activity or sports for 4 weeks or until \rotherwise advised\r-Tylenol should be your first line pain medication, a narcotic \rpain medication has been prescribed for breakthrough pain >4. \rReplace Tylenol with narcotic pain medication.\r-Max daily Tylenol (acetaminophen) dose is 4 grams from ALL \rsources, note that narcotic pain medication also contains \rTylenol\r-Do not drive or drink alcohol while taking narcotics and do not \roperate dangerous machinery. Also, if the Foley catheter and Leg \rBag are in place--Do NOT drive (you may be a passenger).\r \rFollowup Instructions:\r___\r"
  },
  "a3e916ae1fce9bf7": {
    "filename": "Data.txt",
    "text": "Name:  ___             Unit No:   ___\r \rAdmission Date:  ___              Discharge Date:   ___\r \rDate of Birth:  ___             Sex:   M\r \rService: UROLOGY\r \rAllergies: \rNo Known Allergies / Adverse Drug Reactions\r \rAttending: ___.\r \rChief Complaint:\rProstate cancer, obstructive symptoms\r \rMajor Surgical or Invasive Procedure:\rTURP, bipolar\r \rHistory of Present Illness:\r___, who was seen in preparation today for his upcoming \rTUR\rprostate scheduled for ___.  His TUR prostate is part of his\rongoing treatment program set up for his stage T3A and B\radenocarcinoma of the prostate, associated with high residual\rurine volumes in the 400s.  He has been on Lupron therapy since\r___ and his residual urine volume today is 234 mL.  Indeed\rrectal exam reveals a tumor outside the capsule.  A history and\rphysical was done and I went over the operation with the patient\rand his wife including the fact that part of his obstructive\rproblem is lack of dynamic voiding due to scarring and\rinfiltration of the tumor into the bladder neck area.  \rTherefore,\rremoving the obstruction may not completely free up his voiding\rsuch that he may still have an elevated residual urine volume,\rbut it should be better than it is today.  In addition, I will\rleave a small amount of extra tissue at the apex to assure\ragainst incontinence as the entire prostatic area may be \rsomewhat\rrigid and removing all of the prostatic tissue could result in\rincontinence.  Putting all this together, the operation will be\rdone carefully to open it up as much as possible without any\rincontinence problems.\r \rPast Medical History:\r- history of low-grade colitis diagnosed on colonoscopy at\r___ in ___, started on Canasa suppository\rand was on them for about a month, but has not used them in over\r___ years.  He saw occasional trace blood in the stool, but\rnothing regularly.  He has not had a colonoscopy since ___\r- hypertension.\r \rSocial History:\r___\rFamily History:\rFather had coronary disease and his mother had\r___ disease.  Paternal uncle had stomach cancer and his\rmaternal grandfather had stomach cancer.\r \rPhysical Exam:\rAFVSS\rNAD, pleasant and conversive\rnon-labored breathing\rsoft, non-tender, non-distended\r3-way catheter in place, draining clear yellow urine\rWWP\rgrossly non-focal\r \rBrief Hospital Course:\rMr. ___ was admitted to Dr. ___ service after \rbipolar transurethral resection of prostate. No concerning \rintraoperative events occurred; please see dictated operative \rnote for details. He patient received ___ antibiotic \rprophylaxis. The patient's postoperative course was \runcomplicated. He received intravenous antibiotics and \rcontinuous bladder irrigation overnight. On POD1 the CBI was \rdiscontinued and Foley catheter was kept in place with plans for \rfollow up the following week in clinic for vodiding trial. His \rurine was clear and and without clots. He remained afebrile \rthroughout his hospital stay.  At discharge, the patient had \rpain well controlled with oral pain medications, was tolerating \rregular diet, ambulating without assistance.  He was given \rpyridium and oral pain medications on discharge and a course of \rantibiotics along with explicit instructions to follow up in \rclinic with Dr. ___.\r \rMedications on Admission:\r Lisinopril 20 mg daily, hydrochlorothiazide 12.5\rdaily, Flomax 0.4 mg b.i.d.  \r \rDischarge Medications:\r1. bacitracin zinc 500 unit/gram Ointment Sig: One (1) Appl \rTopical TID (3 times a day) as needed for penile irritation: \rapply to tip of penis for pain relief.\rDisp:*1 tube* Refills:*0*\r2. docusate sodium 100 mg Capsule Sig: One (1) Capsule PO BID (2 \rtimes a day) as needed for constipation.\rDisp:*60 Capsule(s)* Refills:*0*\r3. acetaminophen 325 mg Tablet Sig: ___ Tablets PO Q6H (every 6 \rhours) as needed for pain, fever>100.\rDisp:*60 Tablet(s)* Refills:*0*\r4. Cipro 500 mg Tablet Sig: One (1) Tablet PO twice a day for 10 \rdays: to be taken until catheter removed.\rDisp:*20 Tablet(s)* Refills:*0*\r5. oxycodone 5 mg Tablet Sig: One (1) Tablet PO every ___ hours \ras needed for pain: for pain not relieved with tylenol or \ribuprofen.\rDisp:*20 Tablet(s)* Refills:*0*\r \rDischarge Disposition:\rHome\r \rDischarge Diagnosis:\rProstate cancer, obstructive symptoms\r \rDischarge Condition:\rStable, Good\rA/Ox3\rFunctionally independent\r \rDischarge Instructions:\rINSTRUCTIONS:\r-Do not lift anything heavier than a phone book (10 pounds) or \rdrive until you are seen by your Urologist in follow-up\r-You may continue to periodically see small amounts of blood in \ryour urine--this is normal and will gradually improve\rMEDICATIONS:\r      -Resume all of your pre-admission medications, except HOLD \raspirin until you see your urologist in followup AND your foley \rhas been removed (if not already done)\r      -Complete a course of antibiotics (Ciprofloxacin)\r      -You will be discharged home with a medication called \rPYRIDIUM that will help with the \"burning\" pain you may \rexperience when voiding. This medication may turn your urine\rbright orange.\r      -Colace has been prescribed to avoid post surgical \rconstipation and constipation related to narcotic pain \rmedication. Discontinue if loose stool or diarrhea develops. \rColace is a stool softener, NOT a laxative\r-Do not eat constipating foods for ___ weeks, drink plenty of \rfluids to keep hydrated\r-No vigorous physical activity or sports for 4 weeks or until \rotherwise advised\r-Tylenol should be your first line pain medication, a narcotic \rpain medication has been prescribed for breakthrough pain >4. \rReplace Tylenol with narcotic pain medication.\r-Max daily Tylenol (acetaminophen) dose is 4 grams from ALL \rsources, note that narcotic pain medication also contains \rTylenol\r-Do not drive or drink alcohol while taking narcotics and do not \roperate dangerous machinery. Also, if the Foley catheter and Leg \rBag are in place--Do NOT drive (you may be a passenger).\r \rFollowup Instructions:\r___\r"
  },
  "fe1da1f635de6c85": {
    "filename": "Data.txt",
    "text": "Name:  ___             Unit No:   ___\r \rAdmission Date:  ___              Discharge Date:   ___\r \rDate of Birth:  ___             Sex:   M\r \rService: UROLOGY\r \rAllergies: \rNo Known Allergies / Adverse Drug Reactions\r \rAttending: ___.\r \rChief Complaint:\rProstate cancer, obstructive symptoms\r \rMajor Surgical or Invasive Procedure:\rTURP, bipolar\r \rHistory of Present Illness:\r___, who was seen in preparation today for his upcoming \rTUR\rprostate scheduled for ___.  His TUR prostate is part of his\rongoing treatment program set up for his stage T3A and B\radenocarcinoma of the prostate, associated with high residual\rurine volumes in the 400s.  He has been on Lupron therapy since\r___ and his residual urine volume today is 234 mL.  Indeed\rrectal exam reveals a tumor outside the capsule.  A history and\rphysical was done and I went over the operation with the patient\rand his wife including the fact that part of his obstructive\rproblem is lack of dynamic voiding due to scarring and\rinfiltration of the tumor into the bladder neck area.  \rTherefore,\rremoving the obstruction may not completely free up his voiding\rsuch that he may still have an elevated residual urine volume,\rbut it should be better than it is today.  In addition, I will\rleave a small amount of extra tissue at the apex to assure\ragainst incontinence as the entire prostatic area may be \rsomewhat\rrigid and removing all of the prostatic tissue could result in\rincontinence.  Putting all this together, the operation will be\rdone carefully to open it up as much as possible without any\rincontinence problems.\r \rPast Medical History:\r- history of low-grade colitis diagnosed on colonoscopy at\r___ in ___, started on Canasa suppository\rand was on them for about a month, but has not used them in over\r___ years.  He saw occasional trace blood in the stool, but\rnothing regularly.  He has not had a colonoscopy since ___\r- hypertension.\r \rSocial History:\r___\rFamily History:\rFather had coronary disease and his mother had\r___ disease.  Paternal uncle had stomach cancer and his\rmaternal grandfather had stomach cancer.\r \rPhysical Exam:\rAFVSS\rNAD, pleasant and conversive\rnon-labored breathing\rsoft, non-tender, non-distended\r3-way catheter in place, draining clear yellow urine\rWWP\rgrossly non-focal\r \rBrief Hospital Course:\rMr. ___ was admitted to Dr. ___ service after \rbipolar transurethral resection of prostate. No concerning \rintraoperative events occurred; please see dictated operative \rnote for details. He patient received ___ antibiotic \rprophylaxis. The patient's postoperative course was \runcomplicated. He received intravenous antibiotics and \rcontinuous bladder irrigation overnight. On POD1 the CBI was \rdiscontinued and Foley catheter was kept in place with plans for \rfollow up the following week in clinic for vodiding trial. His \rurine was clear and and without clots. He remained afebrile \rthroughout his hospital stay.  At discharge, the patient had \rpain well controlled with oral pain medications, was tolerating \rregular diet, ambulating without assistance.  He was given \rpyridium and oral pain medications on discharge and a course of \rantibiotics along with explicit instructions to follow up in \rclinic with Dr. ___.\r \rMedications on Admission:\r Lisinopril 20 mg daily, hydrochlorothiazide 12.5\rdaily, Flomax 0.4 mg b.i.d.  \r \rDischarge Medications:\r1. bacitracin zinc 500 unit/gram Ointment Sig: One (1) Appl \rTopical TID (3 times a day) as needed for penile irritation: \rapply to tip of penis for pain relief.\rDisp:*1 tube* Refills:*0*\r2. docusate sodium 100 mg Capsule Sig: One (1) Capsule PO BID (2 \rtimes a day) as needed for constipation.\rDisp:*60 Capsule(s)* Refills:*0*\r3. acetaminophen 325 mg Tablet Sig: ___ Tablets PO Q6H (every 6 \rhours) as needed for pain, fever>100.\rDisp:*60 Tablet(s)* Refills:*0*\r4. Cipro 500 mg Tablet Sig: One (1) Tablet PO twice a day for 10 \rdays: to be taken until catheter removed.\rDisp:*20 Tablet(s)* Refills:*0*\r5. oxycodone 5 mg Tablet Sig: One (1) Tablet PO every ___ hours \ras needed for pain: for pain not relieved with tylenol or \ribuprofen.\rDisp:*20 Tablet(s)* Refills:*0*\r \rDischarge Disposition:\rHome\r \rDischarge Diagnosis:\rProstate cancer, obstructive symptoms\r \rDischarge Condition:\rStable, Good\rA/Ox3\rFunctionally independent\r \rDischarge Instructions:\rINSTRUCTIONS:\r-Do not lift anything heavier than a phone book (10 pounds) or \rdrive until you are seen by your Urologist in follow-up\r-You may continue to periodically see small amounts of blood in \ryour urine--this is normal and will gradually improve\rMEDICATIONS:\r      -Resume all of your pre-admission medications, except HOLD \raspirin until you see your urologist in followup AND your foley \rhas been removed (if not already done)\r      -Complete a course of antibiotics (Ciprofloxacin)\r      -You will be discharged home with a medication called \rPYRIDIUM that will help with the \"burning\" pain you may \rexperience when voiding. This medication may turn your urine\rbright orange.\r      -Colace has been prescribed to avoid post surgical \rconstipation and constipation related to narcotic pain \rmedication. Discontinue if loose stool or diarrhea develops. \rColace is a stool softener, NOT a laxative\r-Do not eat constipating foods for ___ weeks, drink plenty of \rfluids to keep hydrated\r-No vigorous physical activity or sports for 4 weeks or until \rotherwise advised\r-Tylenol should be your first line pain medication, a narcotic \rpain medication has been prescribed for breakthrough pain >4. \rReplace Tylenol with narcotic pain medication.\r-Max daily Tylenol (acetaminophen) dose is 4 grams from ALL \rsources, note that narcotic pain medication also contains \rTylenol\r-Do not drive or drink alcohol while taking narcotics and do not \roperate dangerous machinery. Also, if the Foley catheter and Leg \rBag are in place--Do NOT drive (you may be a passenger).\r \rFollowup Instructions:\r___\r"
  },
  "935b26fa74f871e7": {
    "filename": "Data.txt",
    "text": "Name:  ___             Unit No:   ___\r \rAdmission Date:  ___              Discharge Date:   ___\r \rDate of Birth:  ___             Sex:   M\r \rService: UROLOGY\r \rAllergies: \rNo Known Allergies / Adverse Drug Reactions\r \rAttending: ___.\r \rChief Complaint:\rProstate cancer, obstructive symptoms\r \rMajor Surgical or Invasive Procedure:\rTURP, bipolar\r \rHistory of Present Illness:\r___, who was seen in preparation today for his upcoming \rTUR\rprostate scheduled for ___.  His TUR prostate is part of his\rongoing treatment program set up for his stage T3A and B\radenocarcinoma of the prostate, associated with high residual\rurine volumes in the 400s.  He has been on Lupron therapy since\r___ and his residual urine volume today is 234 mL.  Indeed\rrectal exam reveals a tumor outside the capsule.  A history and\rphysical was done and I went over the operation with the patient\rand his wife including the fact that part of his obstructive\rproblem is lack of dynamic voiding due to scarring and\rinfiltration of the tumor into the bladder neck area.  \rTherefore,\rremoving the obstruction may not completely free up his voiding\rsuch that he may still have an elevated residual urine volume,\rbut it should be better than it is today.  In addition, I will\rleave a small amount of extra tissue at the apex to assure\ragainst incontinence as the entire prostatic area may be \rsomewhat\rrigid and removing all of the prostatic tissue could result in\rincontinence.  Putting all this together, the operation will be\rdone carefully to open it up as much as possible without any\rincontinence problems.\r \rPast Medical History:\r- history of low-grade colitis diagnosed on colonoscopy at\r___ in ___, started on Canasa suppository\rand was on them for about a month, but has not used them in over\r___ years.  He saw occasional trace blood in the stool, but\rnothing regularly.  He has not had a colonoscopy since ___\r- hypertension.\r \rSocial History:\r___\rFamily History:\rFather had coronary disease and his mother had\r___ disease.  Paternal uncle had stomach cancer and his\rmaternal grandfather had stomach cancer.\r \rPhysical Exam:\rAFVSS\rNAD, pleasant and conversive\rnon-labored breathing\rsoft, non-tender, non-distended\r3-way catheter in place, draining clear yellow urine\rWWP\rgrossly non-focal\r \rBrief Hospital Course:\rMr. ___ was admitted to Dr. ___ service after \rbipolar transurethral resection of prostate. No concerning \rintraoperative events occurred; please see dictated operative \rnote for details. He patient received ___ antibiotic \rprophylaxis. The patient's postoperative course was \runcomplicated. He received intravenous antibiotics and \rcontinuous bladder irrigation overnight. On POD1 the CBI was \rdiscontinued and Foley catheter was kept in place with plans for \rfollow up the following week in clinic for vodiding trial. His \rurine was clear and and without clots. He remained afebrile \rthroughout his hospital stay.  At discharge, the patient had \rpain well controlled with oral pain medications, was tolerating \rregular diet, ambulating without assistance.  He was given \rpyridium and oral pain medications on discharge and a course of \rantibiotics along with explicit instructions to follow up in \rclinic with Dr. ___.\r \rMedications on Admission:\r Lisinopril 20 mg daily, hydrochlorothiazide 12.5\rdaily, Flomax 0.4 mg b.i.d.  \r \rDischarge Medications:\r1. bacitracin zinc 500 unit/gram Ointment Sig: One (1) Appl \rTopical TID (3 times a day) as needed for penile irritation: \rapply to tip of penis for pain relief.\rDisp:*1 tube* Refills:*0*\r2. docusate sodium 100 mg Capsule Sig: One (1) Capsule PO BID (2 \rtimes a day) as needed for constipation.\rDisp:*60 Capsule(s)* Refills:*0*\r3. acetaminophen 325 mg Tablet Sig: ___ Tablets PO Q6H (every 6 \rhours) as needed for pain, fever>100.\rDisp:*60 Tablet(s)* Refills:*0*\r4. Cipro 500 mg Tablet Sig: One (1) Tablet PO twice a day for 10 \rdays: to be taken until catheter removed.\rDisp:*20 Tablet(s)* Refills:*0*\r5. oxycodone 5 mg Tablet Sig: One (1) Tablet PO every ___ hours \ras needed for pain: for pain not relieved with tylenol or \ribuprofen.\rDisp:*20 Tablet(s)* Refills:*0*\r \rDischarge Disposition:\rHome\r \rDischarge Diagnosis:\rProstate cancer, obstructive symptoms\r \rDischarge Condition:\rStable, Good\rA/Ox3\rFunctionally independent\r \rDischarge Instructions:\rINSTRUCTIONS:\r-Do not lift anything heavier than a phone book (10 pounds) or \rdrive until you are seen by your Urologist in follow-up\r-You may continue to periodically see small amounts of blood in \ryour urine--this is normal and will gradually improve\rMEDICATIONS:\r      -Resume all of your pre-admission medications, except HOLD \raspirin until you see your urologist in followup AND your foley \rhas been removed (if not already done)\r      -Complete a course of antibiotics (Ciprofloxacin)\r      -You will be discharged home with a medication called \rPYRIDIUM that will help with the \"burning\" pain you may \rexperience when voiding. This medication may turn your urine\rbright orange.\r      -Colace has been prescribed to avoid post surgical \rconstipation and constipation related to narcotic pain \rmedication. Discontinue if loose stool or diarrhea develops. \rColace is a stool softener, NOT a laxative\r-Do not eat constipating foods for ___ weeks, drink plenty of \rfluids to keep hydrated\r-No vigorous physical activity or sports for 4 weeks or until \rotherwise advised\r-Tylenol should be your first line pain medication, a narcotic \rpain medication has been prescribed for breakthrough pain >4. \rReplace Tylenol with narcotic pain medication.\r-Max daily Tylenol (acetaminophen) dose is 4 grams from ALL \rsources, note that narcotic pain medication also contains \rTylenol\r-Do not drive or drink alcohol while taking narcotics and do not \roperate dangerous machinery. Also, if the Foley catheter and Leg \rBag are in place--Do NOT drive (you may be a passenger).\r \rFollowup Instructions:\r___\r"
  },
  "372ac2fb5acb1479": {
    "filename": "Data.txt",
    "text": "Name:  ___             Unit No:   ___\r \rAdmission Date:  ___              Discharge Date:   ___\r \rDate of Birth:  ___             Sex:   M\r \rService: UROLOGY\r \rAllergies: \rNo Known Allergies / Adverse Drug Reactions\r \rAttending: ___.\r \rChief Complaint:\rProstate cancer, obstructive symptoms\r \rMajor Surgical or Invasive Procedure:\rTURP, bipolar\r \rHistory of Present Illness:\r___, who was seen in preparation today for his upcoming \rTUR\rprostate scheduled for ___.  His TUR prostate is part of his\rongoing treatment program set up for his stage T3A and B\radenocarcinoma of the prostate, associated with high residual\rurine volumes in the 400s.  He has been on Lupron therapy since\r___ and his residual urine volume today is 234 mL.  Indeed\rrectal exam reveals a tumor outside the capsule.  A history and\rphysical was done and I went over the operation with the patient\rand his wife including the fact that part of his obstructive\rproblem is lack of dynamic voiding due to scarring and\rinfiltration of the tumor into the bladder neck area.  \rTherefore,\rremoving the obstruction may not completely free up his voiding\rsuch that he may still have an elevated residual urine volume,\rbut it should be better than it is today.  In addition, I will\rleave a small amount of extra tissue at the apex to assure\ragainst incontinence as the entire prostatic area may be \rsomewhat\rrigid and removing all of the prostatic tissue could result in\rincontinence.  Putting all this together, the operation will be\rdone carefully to open it up as much as possible without any\rincontinence problems.\r \rPast Medical History:\r- history of low-grade colitis diagnosed on colonoscopy at\r___ in ___, started on Canasa suppository\rand was on them for about a month, but has not used them in over\r___ years.  He saw occasional trace blood in the stool, but\rnothing regularly.  He has not had a colonoscopy since ___\r- hypertension.\r \rSocial History:\r___\rFamily History:\rFather had coronary disease and his mother had\r___ disease.  Paternal uncle had stomach cancer and his\rmaternal grandfather had stomach cancer.\r \rPhysical Exam:\rAFVSS\rNAD, pleasant and conversive\rnon-labored breathing\rsoft, non-tender, non-distended\r3-way catheter in place, draining clear yellow urine\rWWP\rgrossly non-focal\r \rBrief Hospital Course:\rMr. ___ was admitted to Dr. ___ service after \rbipolar transurethral resection of prostate. No concerning \rintraoperative events occurred; please see dictated operative \rnote for details. He patient received ___ antibiotic \rprophylaxis. The patient's postoperative course was \runcomplicated. He received intravenous antibiotics and \rcontinuous bladder irrigation overnight. On POD1 the CBI was \rdiscontinued and Foley catheter was kept in place with plans for \rfollow up the following week in clinic for vodiding trial. His \rurine was clear and and without clots. He remained afebrile \rthroughout his hospital stay.  At discharge, the patient had \rpain well controlled with oral pain medications, was tolerating \rregular diet, ambulating without assistance.  He was given \rpyridium and oral pain medications on discharge and a course of \rantibiotics along with explicit instructions to follow up in \rclinic with Dr. ___.\r \rMedications on Admission:\r Lisinopril 20 mg daily, hydrochlorothiazide 12.5\rdaily, Flomax 0.4 mg b.i.d.  \r \rDischarge Medications:\r1. bacitracin zinc 500 unit/gram Ointment Sig: One (1) Appl \rTopical TID (3 times a day) as needed for penile irritation: \rapply to tip of penis for pain relief.\rDisp:*1 tube* Refills:*0*\r2. docusate sodium 100 mg Capsule Sig: One (1) Capsule PO BID (2 \rtimes a day) as needed for constipation.\rDisp:*60 Capsule(s)* Refills:*0*\r3. acetaminophen 325 mg Tablet Sig: ___ Tablets PO Q6H (every 6 \rhours) as needed for pain, fever>100.\rDisp:*60 Tablet(s)* Refills:*0*\r4. Cipro 500 mg Tablet Sig: One (1) Tablet PO twice a day for 10 \rdays: to be taken until catheter removed.\rDisp:*20 Tablet(s)* Refills:*0*\r5. oxycodone 5 mg Tablet Sig: One (1) Tablet PO every ___ hours \ras needed for pain: for pain not relieved with tylenol or \ribuprofen.\rDisp:*20 Tablet(s)* Refills:*0*\r \rDischarge Disposition:\rHome\r \rDischarge Diagnosis:\rProstate cancer, obstructive symptoms\r \rDischarge Condition:\rStable, Good\rA/Ox3\rFunctionally independent\r \rDischarge Instructions:\rINSTRUCTIONS:\r-Do not lift anything heavier than a phone book (10 pounds) or \rdrive until you are seen by your Urologist in follow-up\r-You may continue to periodically see small amounts of blood in \ryour urine--this is normal and will gradually improve\rMEDICATIONS:\r      -Resume all of your pre-admission medications, except HOLD \raspirin until you see your urologist in followup AND your foley \rhas been removed (if not already done)\r      -Complete a course of antibiotics (Ciprofloxacin)\r      -You will be discharged home with a medication called \rPYRIDIUM that will help with the \"burning\" pain you may \rexperience when voiding. This medication may turn your urine\rbright orange.\r      -Colace has been prescribed to avoid post surgical \rconstipation and constipation related to narcotic pain \rmedication. Discontinue if loose stool or diarrhea develops. \rColace is a stool softener, NOT a laxative\r-Do not eat constipating foods for ___ weeks, drink plenty of \rfluids to keep hydrated\r-No vigorous physical activity or sports for 4 weeks or until \rotherwise advised\r-Tylenol should be your first line pain medication, a narcotic \rpain medication has been prescribed for breakthrough pain >4. \rReplace Tylenol with narcotic pain medication.\r-Max daily Tylenol (acetaminophen) dose is 4 grams from ALL \rsources, note that narcotic pain medication also contains \rTylenol\r-Do not drive or drink alcohol while taking narcotics and do not \roperate dangerous machinery. Also, if the Foley catheter and Leg \rBag are in place--Do NOT drive (you may be a passenger).\r \rFollowup Instructions:\r___\r"
  },
  "2c77487ba6068190": {
    "filename": "Data.txt",
    "text": "Name:  ___             Unit No:   ___\r \rAdmission Date:  ___              Discharge Date:   ___\r \rDate of Birth:  ___             Sex:   M\r \rService: UROLOGY\r \rAllergies: \rNo Known Allergies / Adverse Drug Reactions\r \rAttending: ___.\r \rChief Complaint:\rProstate cancer, obstructive symptoms\r \rMajor Surgical or Invasive Procedure:\rTURP, bipolar\r \rHistory of Present Illness:\r___, who was seen in preparation today for his upcoming \rTUR\rprostate scheduled for ___.  His TUR prostate is part of his\rongoing treatment program set up for his stage T3A and B\radenocarcinoma of the prostate, associated with high residual\rurine volumes in the 400s.  He has been on Lupron therapy since\r___ and his residual urine volume today is 234 mL.  Indeed\rrectal exam reveals a tumor outside the capsule.  A history and\rphysical was done and I went over the operation with the patient\rand his wife including the fact that part of his obstructive\rproblem is lack of dynamic voiding due to scarring and\rinfiltration of the tumor into the bladder neck area.  \rTherefore,\rremoving the obstruction may not completely free up his voiding\rsuch that he may still have an elevated residual urine volume,\rbut it should be better than it is today.  In addition, I will\rleave a small amount of extra tissue at the apex to assure\ragainst incontinence as the entire prostatic area may be \rsomewhat\rrigid and removing all of the prostatic tissue could result in\rincontinence.  Putting all this together, the operation will be\rdone carefully to open it up as much as possible without any\rincontinence problems.\r \rPast Medical History:\r- history of low-grade colitis diagnosed on colonoscopy at\r___ in ___, started on Canasa suppository\rand was on them for about a month, but has not used them in over\r___ years.  He saw occasional trace blood in the stool, but\rnothing regularly.  He has not had a colonoscopy since ___\r- hypertension.\r \rSocial History:\r___\rFamily History:\rFather had coronary disease and his mother had\r___ disease.  Paternal uncle had stomach cancer and his\rmaternal grandfather had stomach cancer.\r \rPhysical Exam:\rAFVSS\rNAD, pleasant and conversive\rnon-labored breathing\rsoft, non-tender, non-distended\r3-way catheter in place, draining clear yellow urine\rWWP\rgrossly non-focal\r \rBrief Hospital Course:\rMr. ___ was admitted to Dr. ___ service after \rbipolar transurethral resection of prostate. No concerning \rintraoperative events occurred; please see dictated operative \rnote for details. He patient received ___ antibiotic \rprophylaxis. The patient's postoperative course was \runcomplicated. He received intravenous antibiotics and \rcontinuous bladder irrigation overnight. On POD1 the CBI was \rdiscontinued and Foley catheter was kept in place with plans for \rfollow up the following week in clinic for vodiding trial. His \rurine was clear and and without clots. He remained afebrile \rthroughout his hospital stay.  At discharge, the patient had \rpain well controlled with oral pain medications, was tolerating \rregular diet, ambulating without assistance.  He was given \rpyridium and oral pain medications on discharge and a course of \rantibiotics along with explicit instructions to follow up in \rclinic with Dr. ___.\r \rMedications on Admission:\r Lisinopril 20 mg daily, hydrochlorothiazide 12.5\rdaily, Flomax 0.4 mg b.i.d.  \r \rDischarge Medications:\r1. bacitracin zinc 500 unit/gram Ointment Sig: One (1) Appl \rTopical TID (3 times a day) as needed for penile irritation: \rapply to tip of penis for pain relief.\rDisp:*1 tube* Refills:*0*\r2. docusate sodium 100 mg Capsule Sig: One (1) Capsule PO BID (2 \rtimes a day) as needed for constipation.\rDisp:*60 Capsule(s)* Refills:*0*\r3. acetaminophen 325 mg Tablet Sig: ___ Tablets PO Q6H (every 6 \rhours) as needed for pain, fever>100.\rDisp:*60 Tablet(s)* Refills:*0*\r4. Cipro 500 mg Tablet Sig: One (1) Tablet PO twice a day for 10 \rdays: to be taken until catheter removed.\rDisp:*20 Tablet(s)* Refills:*0*\r5. oxycodone 5 mg Tablet Sig: One (1) Tablet PO every ___ hours \ras needed for pain: for pain not relieved with tylenol or \ribuprofen.\rDisp:*20 Tablet(s)* Refills:*0*\r \rDischarge Disposition:\rHome\r \rDischarge Diagnosis:\rProstate cancer, obstructive symptoms\r \rDischarge Condition:\rStable, Good\rA/Ox3\rFunctionally independent\r \rDischarge Instructions:\rINSTRUCTIONS:\r-Do not lift anything heavier than a phone book (10 pounds) or \rdrive until you are seen by your Urologist in follow-up\r-You may continue to periodically see small amounts of blood in \ryour urine--this is normal and will gradually improve\rMEDICATIONS:\r      -Resume all of your pre-admission medications, except HOLD \raspirin until you see your urologist in followup AND your foley \rhas been removed (if not already done)\r      -Complete a course of antibiotics (Ciprofloxacin)\r      -You will be discharged home with a medication called \rPYRIDIUM that will help with the \"burning\" pain you may \rexperience when voiding. This medication may turn your urine\rbright orange.\r      -Colace has been prescribed to avoid post surgical \rconstipation and constipation related to narcotic pain \rmedication. Discontinue if loose stool or diarrhea develops. \rColace is a stool softener, NOT a laxative\r-Do not eat constipating foods for ___ weeks, drink plenty of \rfluids to keep hydrated\r-No vigorous physical activity or sports for 4 weeks or until \rotherwise advised\r-Tylenol should be your first line pain medication, a narcotic \rpain medication has been prescribed for breakthrough pain >4. \rReplace Tylenol with narcotic pain medication.\r-Max daily Tylenol (acetaminophen) dose is 4 grams from ALL \rsources, note that narcotic pain medication also contains \rTylenol\r-Do not drive or drink alcohol while taking narcotics and do not \roperate dangerous machinery. Also, if the Foley catheter and Leg \rBag are in place--Do NOT drive (you may be a passenger).\r \rFollowup Instructions:\r___\r"
  },
  "428a168be5076ab0": {
    "filename": "Data.txt",
    "text": "Name:  ___             Unit No:   ___\r \rAdmission Date:  ___              Discharge Date:   ___\r \rDate of Birth:  ___             Sex:   M\r \rService: UROLOGY\r \rAllergies: \rNo Known Allergies / Adverse Drug Reactions\r \rAttending: ___.\r \rChief Complaint:\rProstate cancer, obstructive symptoms\r \rMajor Surgical or Invasive Procedure:\rTURP, bipolar\r \rHistory of Present Illness:\r___, who was seen in preparation today for his upcoming \rTUR\rprostate scheduled for ___.  His TUR prostate is part of his\rongoing treatment program set up for his stage T3A and B\radenocarcinoma of the prostate, associated with high residual\rurine volumes in the 400s.  He has been on Lupron therapy since\r___ and his residual urine volume today is 234 mL.  Indeed\rrectal exam reveals a tumor outside the capsule.  A history and\rphysical was done and I went over the operation with the patient\rand his wife including the fact that part of his obstructive\rproblem is lack of dynamic voiding due to scarring and\rinfiltration of the tumor into the bladder neck area.  \rTherefore,\rremoving the obstruction may not completely free up his voiding\rsuch that he may still have an elevated residual urine volume,\rbut it should be better than it is today.  In addition, I will\rleave a small amount of extra tissue at the apex to assure\ragainst incontinence as the entire prostatic area may be \rsomewhat\rrigid and removing all of the prostatic tissue could result in\rincontinence.  Putting all this together, the operation will be\rdone carefully to open it up as much as possible without any\rincontinence problems.\r \rPast Medical History:\r- history of low-grade colitis diagnosed on colonoscopy at\r___ in ___, started on Canasa suppository\rand was on them for about a month, but has not used them in over\r___ years.  He saw occasional trace blood in the stool, but\rnothing regularly.  He has not had a colonoscopy since ___\r- hypertension.\r \rSocial History:\r___\rFamily History:\rFather had coronary disease and his mother had\r___ disease.  Paternal uncle had stomach cancer and his\rmaternal grandfather had stomach cancer.\r \rPhysical Exam:\rAFVSS\rNAD, pleasant and conversive\rnon-labored breathing\rsoft, non-tender, non-distended\r3-way catheter in place, draining clear yellow urine\rWWP\rgrossly non-focal\r \rBrief Hospital Course:\rMr. ___ was admitted to Dr. ___ service after \rbipolar transurethral resection of prostate. No concerning \rintraoperative events occurred; please see dictated operative \rnote for details. He patient received ___ antibiotic \rprophylaxis. The patient's postoperative course was \runcomplicated. He received intravenous antibiotics and \rcontinuous bladder irrigation overnight. On POD1 the CBI was \rdiscontinued and Foley catheter was kept in place with plans for \rfollow up the following week in clinic for vodiding trial. His \rurine was clear and and without clots. He remained afebrile \rthroughout his hospital stay.  At discharge, the patient had \rpain well controlled with oral pain medications, was tolerating \rregular diet, ambulating without assistance.  He was given \rpyridium and oral pain medications on discharge and a course of \rantibiotics along with explicit instructions to follow up in \rclinic with Dr. ___.\r \rMedications on Admission:\r Lisinopril 20 mg daily, hydrochlorothiazide 12.5\rdaily, Flomax 0.4 mg b.i.d.  \r \rDischarge Medications:\r1. bacitracin zinc 500 unit/gram Ointment Sig: One (1) Appl \rTopical TID (3 times a day) as needed for penile irritation: \rapply to tip of penis for pain relief.\rDisp:*1 tube* Refills:*0*\r2. docusate sodium 100 mg Capsule Sig: One (1) Capsule PO BID (2 \rtimes a day) as needed for constipation.\rDisp:*60 Capsule(s)* Refills:*0*\r3. acetaminophen 325 mg Tablet Sig: ___ Tablets PO Q6H (every 6 \rhours) as needed for pain, fever>100.\rDisp:*60 Tablet(s)* Refills:*0*\r4. Cipro 500 mg Tablet Sig: One (1) Tablet PO twice a day for 10 \rdays: to be taken until catheter removed.\rDisp:*20 Tablet(s)* Refills:*0*\r5. oxycodone 5 mg Tablet Sig: One (1) Tablet PO every ___ hours \ras needed for pain: for pain not relieved with tylenol or \ribuprofen.\rDisp:*20 Tablet(s)* Refills:*0*\r \rDischarge Disposition:\rHome\r \rDischarge Diagnosis:\rProstate cancer, obstructive symptoms\r \rDischarge Condition:\rStable, Good\rA/Ox3\rFunctionally independent\r \rDischarge Instructions:\rINSTRUCTIONS:\r-Do not lift anything heavier than a phone book (10 pounds) or \rdrive until you are seen by your Urologist in follow-up\r-You may continue to periodically see small amounts of blood in \ryour urine--this is normal and will gradually improve\rMEDICATIONS:\r      -Resume all of your pre-admission medications, except HOLD \raspirin until you see your urologist in followup AND your foley \rhas been removed (if not already done)\r      -Complete a course of antibiotics (Ciprofloxacin)\r      -You will be discharged home with a medication called \rPYRIDIUM that will help with the \"burning\" pain you may \rexperience when voiding. This medication may turn your urine\rbright orange.\r      -Colace has been prescribed to avoid post surgical \rconstipation and constipation related to narcotic pain \rmedication. Discontinue if loose stool or diarrhea develops. \rColace is a stool softener, NOT a laxative\r-Do not eat constipating foods for ___ weeks, drink plenty of \rfluids to keep hydrated\r-No vigorous physical activity or sports for 4 weeks or until \rotherwise advised\r-Tylenol should be your first line pain medication, a narcotic \rpain medication has been prescribed for breakthrough pain >4. \rReplace Tylenol with narcotic pain medication.\r-Max daily Tylenol (acetaminophen) dose is 4 grams from ALL \rsources, note that narcotic pain medication also contains \rTylenol\r-Do not drive or drink alcohol while taking narcotics and do not \roperate dangerous machinery. Also, if the Foley catheter and Leg \rBag are in place--Do NOT drive (you may be a passenger).\r \rFollowup Instructions:\r___\r"
  },
  "0e2b5c0a75f28e02": {
    "filename": "Data.txt",
    "text": "Name:  ___             Unit No:   ___\r \rAdmission Date:  ___              Discharge Date:   ___\r \rDate of Birth:  ___             Sex:   M\r \rService: UROLOGY\r \rAllergies: \rNo Known Allergies / Adverse Drug Reactions\r \rAttending: ___.\r \rChief Complaint:\rProstate cancer, obstructive symptoms\r \rMajor Surgical or Invasive Procedure:\rTURP, bipolar\r \rHistory of Present Illness:\r___, who was seen in preparation today for his upcoming \rTUR\rprostate scheduled for ___.  His TUR prostate is part of his\rongoing treatment program set up for his stage T3A and B\radenocarcinoma of the prostate, associated with high residual\rurine volumes in the 400s.  He has been on Lupron therapy since\r___ and his residual urine volume today is 234 mL.  Indeed\rrectal exam reveals a tumor outside the capsule.  A history and\rphysical was done and I went over the operation with the patient\rand his wife including the fact that part of his obstructive\rproblem is lack of dynamic voiding due to scarring and\rinfiltration of the tumor into the bladder neck area.  \rTherefore,\rremoving the obstruction may not completely free up his voiding\rsuch that he may still have an elevated residual urine volume,\rbut it should be better than it is today.  In addition, I will\rleave a small amount of extra tissue at the apex to assure\ragainst incontinence as the entire prostatic area may be \rsomewhat\rrigid and removing all of the prostatic tissue could result in\rincontinence.  Putting all this together, the operation will be\rdone carefully to open it up as much as possible without any\rincontinence problems.\r \rPast Medical History:\r- history of low-grade colitis diagnosed on colonoscopy at\r___ in ___, started on Canasa suppository\rand was on them for about a month, but has not used them in over\r___ years.  He saw occasional trace blood in the stool, but\rnothing regularly.  He has not had a colonoscopy since ___\r- hypertension.\r \rSocial History:\r___\rFamily History:\rFather had coronary disease and his mother had\r___ disease.  Paternal uncle had stomach cancer and his\rmaternal grandfather had stomach cancer.\r \rPhysical Exam:\rAFVSS\rNAD, pleasant and conversive\rnon-labored breathing\rsoft, non-tender, non-distended\r3-way catheter in place, draining clear yellow urine\rWWP\rgrossly non-focal\r \rBrief Hospital Course:\rMr. ___ was admitted to Dr. ___ service after \rbipolar transurethral resection of prostate. No concerning \rintraoperative events occurred; please see dictated operative \rnote for details. He patient received ___ antibiotic \rprophylaxis. The patient's postoperative course was \runcomplicated. He received intravenous antibiotics and \rcontinuous bladder irrigation overnight. On POD1 the CBI was \rdiscontinued and Foley catheter was kept in place with plans for \rfollow up the following week in clinic for vodiding trial. His \rurine was clear and and without clots. He remained afebrile \rthroughout his hospital stay.  At discharge, the patient had \rpain well controlled with oral pain medications, was tolerating \rregular diet, ambulating without assistance.  He was given \rpyridium and oral pain medications on discharge and a course of \rantibiotics along with explicit instructions to follow up in \rclinic with Dr. ___.\r \rMedications on Admission:\r Lisinopril 20 mg daily, hydrochlorothiazide 12.5\rdaily, Flomax 0.4 mg b.i.d.  \r \rDischarge Medications:\r1. bacitracin zinc 500 unit/gram Ointment Sig: One (1) Appl \rTopical TID (3 times a day) as needed for penile irritation: \rapply to tip of penis for pain relief.\rDisp:*1 tube* Refills:*0*\r2. docusate sodium 100 mg Capsule Sig: One (1) Capsule PO BID (2 \rtimes a day) as needed for constipation.\rDisp:*60 Capsule(s)* Refills:*0*\r3. acetaminophen 325 mg Tablet Sig: ___ Tablets PO Q6H (every 6 \rhours) as needed for pain, fever>100.\rDisp:*60 Tablet(s)* Refills:*0*\r4. Cipro 500 mg Tablet Sig: One (1) Tablet PO twice a day for 10 \rdays: to be taken until catheter removed.\rDisp:*20 Tablet(s)* Refills:*0*\r5. oxycodone 5 mg Tablet Sig: One (1) Tablet PO every ___ hours \ras needed for pain: for pain not relieved with tylenol or \ribuprofen.\rDisp:*20 Tablet(s)* Refills:*0*\r \rDischarge Disposition:\rHome\r \rDischarge Diagnosis:\rProstate cancer, obstructive symptoms\r \rDischarge Condition:\rStable, Good\rA/Ox3\rFunctionally independent\r \rDischarge Instructions:\rINSTRUCTIONS:\r-Do not lift anything heavier than a phone book (10 pounds) or \rdrive until you are seen by your Urologist in follow-up\r-You may continue to periodically see small amounts of blood in \ryour urine--this is normal and will gradually improve\rMEDICATIONS:\r      -Resume all of your pre-admission medications, except HOLD \raspirin until you see your urologist in followup AND your foley \rhas been removed (if not already done)\r      -Complete a course of antibiotics (Ciprofloxacin)\r      -You will be discharged home with a medication called \rPYRIDIUM that will help with the \"burning\" pain you may \rexperience when voiding. This medication may turn your urine\rbright orange.\r      -Colace has been prescribed to avoid post surgical \rconstipation and constipation related to narcotic pain \rmedication. Discontinue if loose stool or diarrhea develops. \rColace is a stool softener, NOT a laxative\r-Do not eat constipating foods for ___ weeks, drink plenty of \rfluids to keep hydrated\r-No vigorous physical activity or sports for 4 weeks or until \rotherwise advised\r-Tylenol should be your first line pain medication, a narcotic \rpain medication has been prescribed for breakthrough pain >4. \rReplace Tylenol with narcotic pain medication.\r-Max daily Tylenol (acetaminophen) dose is 4 grams from ALL \rsources, note that narcotic pain medication also contains \rTylenol\r-Do not drive or drink alcohol while taking narcotics and do not \roperate dangerous machinery. Also, if the Foley catheter and Leg \rBag are in place--Do NOT drive (you may be a passenger).\r \rFollowup Instructions:\r___\r"
  },
  "Data.txt": {
    "doc_id": "Data.txt",
    "filename": "Data.txt",
    "text": "Name:  ___             Unit No:   ___\r \rAdmission Date:  ___              Discharge Date:   ___\r \rDate of Birth:  ___             Sex:   M\r \rService: UROLOGY\r \rAllergies: \rNo Known Allergies / Adverse Drug Reactions\r \rAttending: ___.\r \rChief Complaint:\rProstate cancer, obstructive symptoms\r \rMajor Surgical or Invasive Procedure:\rTURP, bipolar\r \rHistory of Present Illness:\r___, who was seen in preparation today for his upcoming \rTUR\rprostate scheduled for ___.  His TUR prostate is part of his\rongoing treatment program set up for his stage T3A and B\radenocarcinoma of the prostate, associated with high residual\rurine volumes in the 400s.  He has been on Lupron therapy since\r___ and his residual urine volume today is 234 mL.  Indeed\rrectal exam reveals a tumor outside the capsule.  A history and\rphysical was done and I went over the operation with the patient\rand his wife including the fact that part of his obstructive\rproblem is lack of dynamic voiding due to scarring and\rinfiltration of the tumor into the bladder neck area.  \rTherefore,\rremoving the obstruction may not completely free up his voiding\rsuch that he may still have an elevated residual urine volume,\rbut it should be better than it is today.  In addition, I will\rleave a small amount of extra tissue at the apex to assure\ragainst incontinence as the entire prostatic area may be \rsomewhat\rrigid and removing all of the prostatic tissue could result in\rincontinence.  Putting all this together, the operation will be\rdone carefully to open it up as much as possible without any\rincontinence problems.\r \rPast Medical History:\r- history of low-grade colitis diagnosed on colonoscopy at\r___ in ___, started on Canasa suppository\rand was on them for about a month, but has not used them in over\r___ years.  He saw occasional trace blood in the stool, but\rnothing regularly.  He has not had a colonoscopy since ___\r- hypertension.\r \rSocial History:\r___\rFamily History:\rFather had coronary disease and his mother had\r___ disease.  Paternal uncle had stomach cancer and his\rmaternal grandfather had stomach cancer.\r \rPhysical Exam:\rAFVSS\rNAD, pleasant and conversive\rnon-labored breathing\rsoft, non-tender, non-distended\r3-way catheter in place, draining clear yellow urine\rWWP\rgrossly non-focal\r \rBrief Hospital Course:\rMr. ___ was admitted to Dr. ___ service after \rbipolar transurethral resection of prostate. No concerning \rintraoperative events occurred; please see dictated operative \rnote for details. He patient received ___ antibiotic \rprophylaxis. The patient's postoperative course was \runcomplicated. He received intravenous antibiotics and \rcontinuous bladder irrigation overnight. On POD1 the CBI was \rdiscontinued and Foley catheter was kept in place with plans for \rfollow up the following week in clinic for vodiding trial. His \rurine was clear and and without clots. He remained afebrile \rthroughout his hospital stay.  At discharge, the patient had \rpain well controlled with oral pain medications, was tolerating \rregular diet, ambulating without assistance.  He was given \rpyridium and oral pain medications on discharge and a course of \rantibiotics along with explicit instructions to follow up in \rclinic with Dr. ___.\r \rMedications on Admission:\r Lisinopril 20 mg daily, hydrochlorothiazide 12.5\rdaily, Flomax 0.4 mg b.i.d.  \r \rDischarge Medications:\r1. bacitracin zinc 500 unit/gram Ointment Sig: One (1) Appl \rTopical TID (3 times a day) as needed for penile irritation: \rapply to tip of penis for pain relief.\rDisp:*1 tube* Refills:*0*\r2. docusate sodium 100 mg Capsule Sig: One (1) Capsule PO BID (2 \rtimes a day) as needed for constipation.\rDisp:*60 Capsule(s)* Refills:*0*\r3. acetaminophen 325 mg Tablet Sig: ___ Tablets PO Q6H (every 6 \rhours) as needed for pain, fever>100.\rDisp:*60 Tablet(s)* Refills:*0*\r4. Cipro 500 mg Tablet Sig: One (1) Tablet PO twice a day for 10 \rdays: to be taken until catheter removed.\rDisp:*20 Tablet(s)* Refills:*0*\r5. oxycodone 5 mg Tablet Sig: One (1) Tablet PO every ___ hours \ras needed for pain: for pain not relieved with tylenol or \ribuprofen.\rDisp:*20 Tablet(s)* Refills:*0*\r \rDischarge Disposition:\rHome\r \rDischarge Diagnosis:\rProstate cancer, obstructive symptoms\r \rDischarge Condition:\rStable, Good\rA/Ox3\rFunctionally independent\r \rDischarge Instructions:\rINSTRUCTIONS:\r-Do not lift anything heavier than a phone book (10 pounds) or \rdrive until you are seen by your Urologist in follow-up\r-You may continue to periodically see small amounts of blood in \ryour urine--this is normal and will gradually improve\rMEDICATIONS:\r      -Resume all of your pre-admission medications, except HOLD \raspirin until you see your urologist in followup AND your foley \rhas been removed (if not already done)\r      -Complete a course of antibiotics (Ciprofloxacin)\r      -You will be discharged home with a medication called \rPYRIDIUM that will help with the \"burning\" pain you may \rexperience when voiding. This medication may turn your urine\rbright orange.\r      -Colace has been prescribed to avoid post surgical \rconstipation and constipation related to narcotic pain \rmedication. Discontinue if loose stool or diarrhea develops. \rColace is a stool softener, NOT a laxative\r-Do not eat constipating foods for ___ weeks, drink plenty of \rfluids to keep hydrated\r-No vigorous physical activity or sports for 4 weeks or until \rotherwise advised\r-Tylenol should be your first line pain medication, a narcotic \rpain medication has been prescribed for breakthrough pain >4. \rReplace Tylenol with narcotic pain medication.\r-Max daily Tylenol (acetaminophen) dose is 4 grams from ALL \rsources, note that narcotic pain medication also contains \rTylenol\r-Do not drive or drink alcohol while taking narcotics and do not \roperate dangerous machinery. Also, if the Foley catheter and Leg \rBag are in place--Do NOT drive (you may be a passenger).\r \rFollowup Instructions:\r___\r",
    "preview": "Name: ___ Unit No: ___ Admission Date: ___ Discharge Date: ___ Date of Birth: ___ Sex: M Service: UROLOGY Allergies: No ..."
  },
  "Annotate Path.docx": "PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u00002oWf\u0001\u0000\u0000\u0005\u0000\u0000\u0013\u0000\b\u0002[Content_Types].xml \u0004\u0002(\u0000\u0002\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000j0\u0010E\u0476J(\u0262e\u001bh\u00014NDB81$14 {\b1\u069al\t\u0011w%\u0017=^i7+-\u007fd\u0019&0A6l4\u0019L6\u00010#\u00d2S\nO\u0015X\u0000*V$:\u0019\u000fB~\u0019^K\u0012\u0683\r\u0007/PI~7$\u0011\fiJ&B0ZDutOJK(H\u000exG\r\u001fL+\u0003v\u000f\u0015dc\u0011\u04fbW>*\\XR\u0016m\u000ep\u0012Z}\u0016HwnMVn\u007f-\u0014\")/\u000fZwB`\u0018\u00134\u0012\t\u0001sDXj\u0014;A*\u029dc\u059d\u0010\u00004\u001c[S9> {V4pW&A\u0014\u0003|d?\u0000\u0000\u0000\u0003\u0000PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000\u001e\u001a\u0000\u0000\u0000N\u0002\u0000\u0000\u000b\u0000\b\u0002_rels/.rels \u0004\u0002(\u0000\u0002\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000j0\f@\u047dQ\u0018N/c\u0018\u0007\b[IL\u0013j<\u0002]aG\u04d3zsFu]\u001aU\r\t^[x\u00001xp\ff#I)\u0283Y\u0015\u001a\u0006\u0013*D\u000bi\")c$qU~31jH[{\u0007=E\u001d\u0019~\nf?3-\u07b2]T\ua4f82j),\u001al0/%b\n\u001az\u0149,\t\t/|f\\\u0012Z\u0019?6!Y_o\u001b]A\u0001\u0000\u0000\u0003\u0000PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000UU\u001f\u0004\u0000\u0000\u0011\u0000\u0000\u0011\u0000\u0000\u0000word/document.xml\u0518o8\u0010O!{k@H\u00aa@YU:\u05b1-\t\u001d\u000bJ!f<\u3658\u007fz\u0359SR3gw;r\u001d\u0289H2_^D\r\tf\u04d9{4}\bR\u001b\u0007\u0010\\{Ifnj\u0011$9\u05b7yFbkn\u0211n3B^\u0004#oT\u0012j\rX\r\u000e%\nA\u0002\u01c8X\u0019zdx\u0017C&\u000eE}\u007f\u0005\bv{}Tp1*D\u05aa\u001eh|\u0015\b&\u05d1\\x\u001d\uf4e6\u05d1>);Ny\u000bI9Ln\u02b1\u06a1\u001c\u0001&{Xf\u000e\u001c-\u0006g\u0015\u0016TG\u0203b\u0014\",HZq#\u007f[Zyu\u0012\rS\u000b\u0010}5LVV\r]-j\nK5(\u0003?\nLv!\u0006i\u000b)?r@v^z\u0003S{mU\b\u001cb~\u0013\u0556\u007fLF\u0003i\u0011\u0010\u0013l-\u0004\u001f\u0015_\u0013z\u0003O\u000b{\u0401\u001f\u00115\fDm9j9uT,';:\u001bX\u0003\u03cd9\u0001$E\b?h/+~\u0489Ipm\u0006XwIS\u0013\u0003\u000bAK\u001c\u0010\u0003\u0004e\u02dc6\u9007$rcYB\u001ei\u064f\u045e%{o/O\u0017?-B\u01ccyNJi\u01c5/\f,u \u0003*\u0002\t\u0007\u067e&}i\u001a[f\u001bI\u0612\u0012\"}K\u0018\u0012+\u000494Y/Q\\(|B\u001d\r\u05e3h\u0019L`4\u000bg\u0305}.p\r\u0016\u0017\u0619u\u0018wJ\u000f3@Gez\u02bei\u0014\u0006[Fw6.ZlrSX>\u0003%|#f\u00036\u0014im\u0018/zeJ\u05ae\u001busOI;1\tX\u0542ml0s8\u82c6\u0006AV\t}TV\u001c$\u001c#-)c\u0006nK\ue3e8\u001fl\u0010'C\u001b%h9\u0017+`)\u0007\u001c\u0014\u007fO;;\u0012\u001d\"s!1\u0462P:?3%eQ~w\u0007K\u0011&&+\u0003\u0002?\u001e=>@*Dh\u0007(i(7OKH\u0004P?J\u001dUp\u0007V\u001e\u078d\fts_)z?\u001eY\u00cd\u019bDQr'L\u0015p\u0012Rs\bcD~3=M)N(eW\u076d\u0010\u693b+Lm\u001146kD~?cq\f\u0001+E\u0016fD\u033f\u0001\u0000\u0000\u0003\u0000PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000\u001d\u0005\u0001\u0000\u0000\u0003\u0000\u0000\u001c\u0000\b\u0001word/_rels/document.xml.rels \u0004\u0001(\u0000\u0001\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000j0\u0010\uf17e{-;mC\ts)\\[\u0001d{CcMZ}EJ\u0012\u0006\u04c33bgz\u0015;5\u0002$\u0005uoZ\u0001\u001f\u0005'ijA\u0001#zw7T\u0090bhXq\u000e\u001d\u0404:-)HAVEH%w\f\u022f2\u066e\u0016v#b\u001c?\u0676i\n_mhF\u0005H\u00146!S\u0016IIB\u0016\b\b4*\u0002\u001c\\}\u0016u.l|!8[s\u0010\u02d8\u0010\u0014f\u0002pf6\u001c\nY\t\u065ax\t'\u0010~\u001f\u0000\u0000\u0000\u0003\u0000PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000R\u0006\u0000\u0000 \u0000\u0000\u0015\u0000\u0000\u0000word/theme/theme1.xmlY[\u001b7\u0014~/?yw<3\u0012-6Mv\u0764Qk35AwcBO})\u0014\u0487\u0006\u0587R\u001ah/1\u000b\tJgdk\u06e6kX\u001c}:Xs1\u0001'qL]r\u001d)$9w&\u0003\f\u0012Byow\"B1\u0002R>a\u03c9H/|*!DS\u02319e1\u0014S7&uu[\u0018\u0001\t\u069b9\"pT:{kc\"%)aJ52$4v\u0017_!a\u0004##t_8@.@qS\u07fbR\b\u0011Q![\\.\u0017-|-\u3360;;Mo_\u0003\u014d;\u0467\u0001p:+\u0378^r;~-Gnk\u01aenk7\r\u0006e5NQ`5({\fv}\u001ft\u001b\u0006^\u000e9\u05e0dn;V@\\\u00bb\u001e\u0002U/EW&X=&\u0012\u000b\u0005NXh\u000e\u0012O\u0005`yJ\u0001)L(\u076ey2\ud82a\udfbfh\b)R|\u00002sMjuJzG}\u0663\u001f>\u000e#a\n,wcO\u0157v</~7\u00a0\u0553g??yg\u007f|\u0005g\f?1\u0006:\u0005i,\u0017h\u0000\u001d8 .K\u0004*\u0019\u000bz,\"\u0003}c\u0005\t\u0006\u0234]&\u04c5\rA0bK-Ql\u0000\u000f(%\u0003\u02ack*[a\u0672\rm\u1597T=\u001cF\u0220yH\u0010%H\u00005F\u0017\bY>\u0630\u00012\\0\u0018@l5\u0011>6\u0010c\u95d5a`@M\bH7 D0p)`le\fcRFC\u0011H\u001e08\u0017!\"\u0014gsM2^2oY~@Vd\u0002/l}Hi\u00199a\u0004\u0019'Q\u0019\u0001_\u0010\u0016\u0015V\u0012!-\u0000Jwp\u001d\u0001F\u0336%\u00105!)H}1XFh#D)!\u0004|`\u0530yAZ$Ud5h\u01aaj'ZI\u00157\u0016bn!\ni\u0005VY$J\u00192c&7-^taR\u0526cc}ZoE\b+x]1\u007f/\u01e4\u033dWA/-#\u0013\u000b\b\u0012c\"` \u0006t+E\f\u0017\"j;iUnnn\r's*o\u001e[S\u0601ST\n]\f)\u1dff\u0019er\u000bS\u0002h.*}ES/\ua60b:\u688e:(]\u0005Gk+|\u6610C\"h\ub887\u02fd?NB+4t\u0006.dP?\u0003F\u0147XD\u0011L4!\ua403rY8nn5@\u00017x\u04b7R\u0000\r6H\u0013Yo]\\nVY\u0004\u02d0(MfhXH\u05dd!Wv.,\u0016\u0016\u001d\u02bd\"\u000f'\u0000\u0545x\u0018p!=S~=wOW\u0019\\oY^Wq=\u001fO\u001b$Jf(a$\u000fsupAObF&|Vn \u0002r5\u0002f\n\u04de3?cJ}\\e*H\u00a4LEnW,)b\u0004yP\u0018\u000b\u0000\u001bHRpZ[J}_e'\u001cMEEO\u0454c\u0012kU.%hv\n\u0252\u0746PAS\u0006a.6\u059caV\n\u008a[*\u07ca\u01bbbBF0?Q<\r:4U|1\u01e1rk\u0017R\u0003YqS\u04de?!_bU}Us]wN?\u0010J\u050a\fjZkR;\u01c24&4\u0388>\rV\u001d\u0010Rv^k{2GZ]\u00125Ud\tt:\u0017`py\u0006\u000f5\u0013kF\u04edu~\u000f7\u000e<w4\u001fJ(lOV[{\u077f>^\u06974S]\u0007\u05f5~so\u0001yk\u055aU\u001boLBI\u0003N4\u001bFIZCk\u001f4Vg<'\u07b89r%8Obm\u043d\u007f\u0000\u0000\u0000\u0003\u0000PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000yZ\u0016\u0004\u0000\u00001\f\u0000\u0000\u0011\u0000\u0000\u0000word/settings.xmlVn6\u0010}/\u007f0\\G\u0017r*\"\u0016,LIM\u0017x{hw\u00173sf4<\u001c\u0017FGX*\"\u000b\u0002oy)*7sS6FJ#^!*8{\u00077a*5\u0011PprmnRW\u00163D9\fix\u001b!kq)X4)\b%GAx={iO1fBZT5)q\"[v!l\u0019f%PjK\u001a\u060f\u0001u${gF>\f{!c[3\u0001\u0014%V\n6QW C\u00151\u0015_RAx\u0018i\bW\u0004I_.9|<!e<\u0251\f\r\u001f+\u6120j/&\u000egOTetn|\u00134\"uTdX\u0018\u0013N`TSN|Y\u04e6G\u0003\u001bP.\ub32a;\u0014\u0012nffeBB9 \u0011sd3.\ud8ef\udd5b\u0005\u0006F7!h6Xp^4z\u00014:H\u0003c\u001aL\u001d%\b\n\u0627\u001b\u00186g1\u0015QK\u0013*r-\u001apzF(r$*5yJ`[\t\u03af\u0012\u007f\n1)\u0014\u0011vh\u000e\u001b\u0010\u00117P]\nZI\u07beE&f\u000f>H!ILs}8s\r/xU\u0000\u001d?Q\nd\f\u001ay:48H\u0426wJfw\"Y\u0013)|\u0015h\u0752\u0012\u0012\u0010\u001aC>cT=Ny[\u0006g8'n)\u0016l?V|kRnE\b}t\rd\u0012>*5L6L!$^g6!wYrZC\nc,5_\u04adGX!VHFks\u01a3%\u000e/0\f1|m\u0003\u0014Cfx\u0007\u0626\"\u0175]5g0{>\u001d,\u000f)\u06a6C\u00125K\u0018}$0gWm(\u000ec\u0004jyY>\r\u0667\u001ada#\uda8b\udf98\u030dt\u001a5Mb\u0013=J6[\u001d\u001ahx3>\u0014\"E\u001df\u001fPi\f`ol\u0016;[<\u06266\u001dl%\u01b6#\u0002apKc\u0005b\u0001\u007ferWCI`\u0003+\u007fa(8\r\\\u000eZHf0N+Q>,ou\u0010%\u00e9T=/^\"\u001es.(.\u06fb,`\u0015\u018b$0el\u0011\u0007Yo\u007f\u000e\u0737\u007f\u0000\u0000\u0000\u0003\u0000PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000\u0003\u0000\u0000\u0015\u0000\u0000\u0012\u0000\u0000\u0000word/numbering.xml\u0317n6\u0010\u000b\u001d\u0004i\u000f\u0016\u000e\u001c'\u000e\\A5W\b \u001en2}>V^Cvj\u0003I6{cjI\u03a7/w;\u039c\rQJpkuHdJzp5w\u001dmH1,=7?\u01a2K`\u0003\fm,\u0318<FH'\u0019X_s(\\'#Z\u0444T)\n<+r%\u00135p`\u05b8d\u05cf*`\u000bPae\u0007C&\u0006\u037b`\u0004\b0p0jlV\u001dP4\n\u0004YuHq\u007fx8R%\u0191.i>9N{eN\u0004,OF\u001c\"\u0002p\r]RF\u001e\u07b4`*Gd\u0004Q-`\fq\u0012\u0016\rE.Bjmq\u0015_\u000fm\u0004an\u000bAdg6M]\u0015A&\u0005'\u0094!E\u0018(hV\u0007>\u0006Y\u0003|O\rg\u037em\u06bf\u000fk8\u0000_;\u03aa\u033fO\u001eo\"\u0688>)\u07b3\u0244\t>x4G=O\u0003\b:iBz~,\u001a\u01bcfn\u02e1=mpb9 \u07f3\u0006L\b\u0016\u0010Aa\u0007\u001b~\u04a9Ia\u001d!\u001b\r\u03b0nMS\u0011W=\u000bAC\u0001c2ieaMZ\u001f|}Q?)Y\u0007\u001a=x([=\r`\u0546?.Bdd8J\u0393q-K\u0006\u0019}\u001dpS\u0001\u0017\u000e\u001dK+/V^cK{\u000b] ^jpb>\u00179\bVn\u0012\"B*;Y5w+C{Eb)B\u001b\f*\bB\u0017\u0015^0C\u007f!\u001b\u009e9idv\u0675j9kv|y\u0007Za\u001b@aMcE\u078dy~Cc\u0013Wq>vrY0FLK|\u000f\\_I3\u022a\u079e@}L;pgAI\u017ai,j7zxh+N(\u001c/{\f\u0003N&\u0000pJV\u0018a%\u0005T(\u00113/\u001dg+#G8ae(Qg=Rl\u001b\u0016tTj\u07fe9T\u000fmG\r\u0013:D\u0006\u000f\u0004\u001al`>\u044e.qE;9.\nGvB\u001d7Fs\"\u001d7\u0017i48t\u000f\u007fmk\rWvqZE<Y46\u000b\u02ec\u01aaI\u001b\u0000\u0000\u0003\u0000PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000\u0006S\u000b\u0010\u0000\u0000\b\u0000\u0000\u000f\u0000\u0000\u0000word/styles.xml]rF\u0012}\u07ea\u0007v\u001f\u001c\"E]*J\u0292kmG1\u0010\u0018@\u000b\u07f9\u0001\u001c1 zb\u0014\u05d6,\u0012`\u0019\u04d8n\\\u01df-+\u03cb8K/\u000f\u0006?\u001c\u001d\u0004<\r(N/\u000f\u077c:;\b\u0011K_\u001e<\u001f\u001f/)E \u0000b\u0011^\u001eryqxXs`\u000f\u0652b,\u0017\u0014_\u0005\u001fVWaX2I\\>\u001d\u001e\u001f\u001d\u000f\fL\u0005%\u243f\u0542?y\"\u0010\u02e2B{2B^\u0014\u0017[8a\u0006#\u0000<+Y8\u0018#\u0005%\u0007G\"Y\u0003\u0000\u00018p\u0018g\u0006PX8q\u00198qdu\u0002V(a\u000fG[XETFs\u001c\\\u0461e%b8Kp#\u000bQ;X\u000f6&\rI\r\u001c.\u008bii\"W\u0006\u00b1\u0002\u0005,\u0017?#a1\u001ff F'!(\u000b\u0019[%e!\u6df9j?7YZ\u0016\u0005+8\u0013\u0015.bi\u0011\u001f=\u0015\"f;C\u37b0(Wq\u0014\u001f\u001c\u0016\u001fx_\u0018c0\\NmlKXz_m/\u0013s\u05a6h&`t\\\"o\nA<\u0016\u03ff+\u001f\u001f\u007fZn\u007fS\\0Vb6\u0018\u001f\u001e$\f\u01e7g\u0557+%[iD\u00015!`L\u0004;\u0011&:\u0002|A\u001a&qy\u0012\u001b,\u0017QlE.\"Z?Lq\u007fK_o#\raJXyQRDo|)\u061b2'i_u\u0015d?L|6>\nXZ\u00146c]\np_\r\u027e\u001a\u001a\ufae1}5\u0014s6\u00148f\u0000.\u001c\u001a8\u000eq\u001cZB8q(\u0001pt4\u00cf8\u000e7EYB\u0647\u000eoo}}J}\u0006\u001dpww?\u000fww\u001dz\u0015\u00172K*eYf%\u000f\u49377\u001aK\u0005iI$\u0007I\u0000#9\u0011F\u000bCHL\u001cl\u0016{8O$[E#\u0004\u0339H\u001c#9!tl:P\t\u0006j1%%'iD<|\u0015\"IP\u001dZs)\u0017,\u0333]\u0018Y|\u0010\u0017J\u0004W$DXh\\La\r\u0014L@\f\u0014Lj\f\u001aH\u00194\u00013hDj\f\u001a\u0478\u00194q3h..\u0013\u0015Y\u01e0{:5F25>gy \u03701c\u06f9\u02a2V#Q\ub54bZv\u000f\u0006\u001aj<\"yxD\u0002K\uc8d8&\t;|fUHD;aJOh=l-8/d\fKtVI\u0011\u05bd\u07f15V\u007fYmG%\u0019H^\u000b4a\u04d2\"-{t%I#:Igl\u001f+J:Ib9gEr\r#[>\u06c4)\roo_-X\u0004t3ww\u001f?\u0004wRr`h\u0000\u0016d\u00124\u001d|-h_\u0013\u0014uLpHYD$q\u001aC\u0015\u07bf4cyDvs}?J\u0249\u0010'l\u0513\u000e\u0002m(\u000flH\u5c6c\u000bQ\u0004*\u001b\u0016<\u001f>e\u0001IeUjO\u00136O\u0011\u0014 `7\u001f\u0006\u001c^'(b%To<\u00ed\ud860\udff7\u007fg$gn\u0000+@\u0011\u0000\u02460KV<bGx\nx\t]F\u0011\u0014\u07bf8\"#CQ1hP`T\u001c(0R\u0002\u07e1cM\u0002\u007f\u0006#\u0002X`T~Fz'cQ\u00023\u0005Fg\n\u03c6o\u0002>I0)\u01829\u000bD|r?\u0011AM=#(j<'aTM\u0000)k\td[Q\u001buMbQ\"\u0292$\u02c8jk\u0013\u073cwmz\u0012w\u0017n\u0013\u0016yD<w\u001cV\u0013XvU7:=?2j\r3>iY%\u001bf\u001bl\u001ayD#\u0562(|b<n<z\u00f8zx=\u0630<h\t\u001c\\\u03d27,O;Z6:Z*nX\r\u001f\u001a\u001d\u007f\u001c|m^T\u001b76He\u000by\u0446Ta(\u0016@vimM<n{(\u00189Q:\r&k,\uc620\u06ab\u0000q_M;E_Wo\\pP{1qJ\u000b\u001e4\f_\u06882q\u001cn\u0010\u001bs\u0000rCtDNsTHrtMnA\rVV\u001e\u0017O(>\u046a,\ry:@\u000b\u0015Bc@\t\u0015{\t\u0015\n!B\u0010h\t\u0018N\u001e'Th#T#T\u0016*@\u000b\u0015B\n!B\u0010hz^B(hB\bP!\u0004ZjC\u001e'Th#T#T\u0016*@\u000b\u0015B\n!B\u0010hB\bPP!\nZ\u0010\u0002-T\b\u0016~_\u001e'Th#T#T\u0016*@\u000b\u0015B\n!B\u0010hB\bPP!\nZ\u0010\u0002-T\b\u0016XC\u001e'Th#T#T\u0016*@\u000b\u0015B\n!B\u0010hB\bPP!\nZ\u0010\u0002-T\b\u00126\u0001c+\u04e96\u0530;T+7Vg\u0011!h|pn 43Uv\\Vq-\u0011\u000b\\?c|y\u0016B]3\u0005\u08ee2jsy\u0012$y6O-s\u0016}mKp\u001a\u001c\u0005]\u0014q:\u0002ma2\u001e8\u06e2e\u000e-F[p\"e\b\u0007-\u001e['\f'\u001di\\_\n\u0010B8u#%\nP\u0018]Is#te\u03cd\u0415F7\u0002O'\fX7\u0014a7\u001fPfXFR\r\u0011\u00060TC(o!\u001f00b\bX\u001bj\u0000O5\u001aBQ\rOeX!\u0002j\t\tO5\u001aBQ\r'wX!\u0002j\u001a\"xQ\r`PTC(?A\u001a\"`\bX!\u0017\u0000\u019fj\bM5jZUQ6F1l&a!l\u0019\u20b3e-Y\u059e\u0652-A*q\u0652M\u001b+{n4\u0011P|:a\u013a\feKMT\u000b\u054d\u001a-9eKT\u3ca5Vq\u0652j\\D5.[j?8\u0011eKT\u3ca5Vq\u0652j\\D5.[j\u001a-5Q\u001a-R\u02d6T\u3ca5&qR\u0013\u0578lj\\\u001a-R\u02d6ZeKnqR\u0013\u0578lj\\D5.[rR\u02d6ZeKT\u3ca5$&x\u0005d2{_;VK_\u049c\u0017YG\u0001~@\u001dW\u0012[-E(~_1o@\u001eW\u001b`\r^J\u001a\u02de\u0004f0Yu\\-*\u001dMZ\u0000\u0017R-L8_hSb\u0106!U3skW~c\u0138>\u01cbjxx|n\u0086Y'\u047e&\b~x5w\u0011\u00182ggF~k\u04c7I\u0752\u03b4\u047a\u001ce9&o3a^gNn\u05d9\u000b~\u074cN7\u050fU\u0004<`J\u0014\u0001tu\u0011U\u0017e6k8\u001f9v:\tA4sy\u05b2\u053f\u00103Y7o{U;s!v/{\renqw^\u0550;k\u0013UmcLbq\u000bw3S\u000f=E\u0247Sb]_\u0011'N0mx\u0011J%//v\u0001\u0004l\u000f,\u0007/\u0007F\u000f8]@bA\\v\b\u001dbkWOo8uz\u0019[\u001ao8.\u001a\f\b{\u027f\u007fB\u0178\u072bO.#;7\u007f\u0017\u001aT<=\u0018l\u0016\u0017;hf\rAjym_p\u0014vw)-}V\u0002.\b;\u001dDS->O=J/{\u001a}c\u001aJI_gKO\u0013>r\u0011{\u0007G}[zi\t}A8\u0001\u000e7;^l2\u000f8\ubb720I#\u0447U!f\"\u007f\u077fZv/`\u0010V@k\u0501+\u0019\u000fw0wP\u007f\u0014Mp(=&\u9e9e\u007fT.\f\"!\u0011\u00e6.JU\u0000S<D|.FDlak\u0005<$+b\u5108\u0015S\u001e~4D\u0383wx\u0018\u0013`Jt\u007f\tuW2\u8893S\"J\u0300Pi$\u028f3\"\u0012Y/gwS1.J\u0389(1#Bu2~AXMC)5a\rE\u0019jg@\u0018:],_>UUC!\\\u013c_\u000bc}D_Uzsj\u02c99\u06b3kNk\u0006\u001b\u001a-Ws;jY\ubd7a\twP(\u0002k\u0015)@\u011c\u0016C\u06eeg.qcg!I@nP\"@7\u000b8>3ek\nl3RhR!\tLf<\u03eel\u0017]j\u0017hen9:F\u0006*8uS\"{\u001dfWMrlza{\u000f\u00e1\u0018\u0019!cuK^36.A/>l<4x\u0004D;x\u0019\u0436.\u0012\"'X^E\uabfe.~W\bO2r!o\u001f\u007fx\u0527\u0773,^_A}\u65a4\f\u0311zB~neilz.o'}Z\u0006\u0005~}O\u0007\u001b\"/N1rjN\u0000\u007f7JVPQr[5U\\%\u0601Idu\u0588V\u0007\u0000\u0000\u0003\u0000PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000&Ho\u0001\u0000\u0000-\u0004\u0000\u0000\u0014\u0000\u0000\u0000word/webSettings.xmln \u0014\u0000%{{:5Kc5Y\u0016,K=\u0000\u00a9%\u0002\u0001\\uO?xcwS\u000e7_J:&'aJ\u00120\u001c4|}\u0006$q\u0019\u0014\u001a\u0001\u001cY.uV\u0003\u000f\u007f$(e(u\u0004\u0010+0a@\u000f]\u001ap\u0015r-\u0007:N\u0019i\u0019{E!9<#i0\u0267\u0016T\u0010\u0478RV\u0577h5ZQY\\XVGO3ihr\u0005i-:,0,B(m\"i?`|\u00058\u0019ACf\u05d13;;Rt\u0015\u0001\u012e\u00171~8\u0011\u07b1\u01dd\u0388\\Y\\y)\u00168\u000bo&\u06f4\u0019<xg\u001bU\u00adLJ\u001a8~\u0126\ta\u07ccmiB \"_\u0007Vh,\u000e,L)^B^</\u0000\u0000\u0000\u0003\u0000PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000\n\u0019my\u0002\u0000\u0000L\n\u0000\u0000\u0012\u0000\u0000\u0000word/fontTable.xmln0\u0010@\u0005\u000f\u0016K8A4@/=)z)\"EwH\u0249\\9C\u0016lQC\u00134owRD\u001bfk4j\u007f<=^\b,Q%\u0011ZEg\u0010|pWZY0_\\E\\[\u0313\u0004h$K06X4D\u0012n.\r|\u0005$OIa9\u0014]U\u0007M\u05d2)\u0013\u0004\u00127pm\u03e1m)\u001b)\u00035K$\u0005\u0015\u0003h\u0415t3(LR\u07d2\u00150\u000e\u0003\u0003]\u0018c1\u0012sx\u0019\u0199pxdzr\u001dGyK\ufc60e\u001d;<\u0012Kj\u00021\u0012a\u0122Gl\u000bLhg0i\u0017^g(JiC\u0002IX\u0011\u0016V\u0017;&5*\u001ah\u06f9vD\\j\rQ\u001aX]\u001bOxdi:8\u0189\u001bHkb9F;0o\u0015\\\u000f\u0452Q\u001b6\u0439!]W\u0631e\u0013\f#`8B=gv\u001czcIka`K\u0006WiII-|&\bu\u0014\u0371U\u0016!F>\u03cfF12\u0006F3/s{6\u0019\r\u001bS4p8\u001bE\rKfN(F\u007fO|EW#]\u0006BVC\u001bSci\ryz/\b)\br \u000fj>z?,w=*$C#\u007f5\u0017\u0000\u0000\u0000\u0003\u0000PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000p{\u0001\u0000\u0000\t\u0003\u0000\u0000\u0011\u0000\b\u0001docProps/core.xml \u0004\u0001(\u0000\u0001\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000QO0\u0010M\u000eK\u001d]!\u0010I\u0012\u0018o=M[\u0018v\u001b\u001b.\u0012]w^dv\u02b3\b\n%\f\"\u0014d\u000b\"GuTr)\tSTE&a:fQ\u001a\u0013`\u0003$m\u00141\u0196 v\t\u001ber|jXS[(\u001c\u001cQ\\\tSDgI:I}0Y-\u0019\frb2 :0PW~ph[\u0015\u001dX\u0014\u0160\u0018\u0568KP+\u0006(M8p\u0019\t>/`9\u0012\u001f3\u0003)Q\u0005+\u001dd\u5edcT)\ub396CY(\u00ede\u001e`\u001167\u000e<Q~\u001b\u0001po(?\u4f00fP7.nln+oza4\u001cd&x<\u88da\u007f\u0011\u0003_qWl\u0005\u001a7\u0006\u0000\u0000\u0003\u0000PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000\u001djp\u0001\u0000\u0000\u0002\u0000\u0000\u0010\u0000\b\u0001docProps/app.xml \u0004\u0001(\u0000\u0001\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000RN0\u0010#\u000fQS@T\u001bW\bq%5\u06727c[[\u047fg@\bO;\u06b0L\u0010e\u0017yV:mS/lg1\tq\u00161_\u0013x\u000ecH\u001acF\u00126y_1\u0016esj[.t\"\u0011\f\rsu%8&vV\u0014\f?\u0012ZjG|P\\\u007fEZ\u001d<qF$+:`#\u000bKTC z\u0004,\u001a=7\u0014\"|\u0001l`\u04ca d\u0005e\u0001l\u0002{HYep){:q`+@\u0011(wA\u0003'){m\u0007\u001fCAh\ud5f9\u0011V\n\u001b\nka\"\u0002!`:/,\u0271\"+wk79SBiI\u0003\u0122\";z`zy\r;\u007f\u001b^\u0017qa\u001c\u001e\u007f\f\u0004\u0000\u0000\u0003\u0000PK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u00002oWf\u0001\u0000\u0000\u0005\u0000\u0000\u0013\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000[Content_Types].xmlPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000\u001e\u001a\u0000\u0000\u0000N\u0002\u0000\u0000\u000b\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0003\u0000\u0000_rels/.relsPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000UU\u001f\u0004\u0000\u0000\u0011\u0000\u0000\u0011\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0006\u0000\u0000word/document.xmlPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000\u001d\u0005\u0001\u0000\u0000\u0003\u0000\u0000\u001c\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\r\u000b\u0000\u0000word/_rels/document.xml.relsPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000R\u0006\u0000\u0000 \u0000\u0000\u0015\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000T\r\u0000\u0000word/theme/theme1.xmlPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000yZ\u0016\u0004\u0000\u00001\f\u0000\u0000\u0011\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000[\u0014\u0000\u0000word/settings.xmlPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000\u0003\u0000\u0000\u0015\u0000\u0000\u0012\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0018\u0000\u0000word/numbering.xmlPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000\u0006S\u000b\u0010\u0000\u0000\b\u0000\u0000\u000f\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u001c\u0000\u0000word/styles.xmlPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000&Ho\u0001\u0000\u0000-\u0004\u0000\u0000\u0014\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000,\u0000\u0000word/webSettings.xmlPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000\n\u0019my\u0002\u0000\u0000L\n\u0000\u0000\u0012\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000.\u0000\u0000word/fontTable.xmlPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000p{\u0001\u0000\u0000\t\u0003\u0000\u0000\u0011\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u000041\u0000\u0000docProps/core.xmlPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000\u001djp\u0001\u0000\u0000\u0002\u0000\u0000\u0010\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u00003\u0000\u0000docProps/app.xmlPK\u0005\u0006\u0000\u0000\u0000\u0000\f\u0000\f\u0000\u0001\u0003\u0000\u00006\u0000\u0000\u0000\u0000",
  "cancer.report4.txt": {
    "doc_id": "cancer.report4.txt",
    "filename": "cancer.report4.txt",
    "text": "Followup status post hospital discharge for matched unrelated donor stem cell transplant for mantle cell lymphoma, day +37. Mr. name is a 69-year-old gentleman with a past medical history significant for mantle cell lymphoma diagnosed in xxx who was recently discharged from the hospital status post his matched unrelated donor stem cell transplant. He completed 7 cycles of hyper-CVAD based chemotherapy still with persistent disease. He subsequently had 2 cycles with bortezomib and bendamustine based chemotherapy. His bone marrow biopsy prior to admission for his transplant showed complete remission. During his transplant course, he did develop fluid versus pneumonia. He was treated like a pneumonia, but he did have a thoracentesis done to tap the fluid. His breathing did improve after the thoracentesis. He formed small welts at the site of the procedure, which resolved on its own. He also developed a rash requiring prednisone. The rash has since resolved. \nToday, the patient states that he is feeling well. He denies any fever, chills, nausea, vomiting, chest pain, shortness of breath, cough or cold symptoms. He is eating and drinking well. He denies any abdominal pain, diarrhea, constipation, lower extremity edema, bleeding and bruising. \nRemaining 10-point review of systems negative. \nSignificant for hypothyroidism secondary to thyroidectomy over 30 years ago, mantle cell lymphoma status post second cycle of hyper-CVAD based chemotherapy followed by 2 cycles of bendamustine, bortezomib protection based therapy; peripheral neuropathy secondary to vincristine and bortezomib, vitamin B core antibody positivity. \nSignificant for thyroidectomy over 30 years ago, inguinal hernia surgery xxx and lymph node biopsy xxx. \nSignificant for heart disease. A brother who had an MI at age of 58, another brother who had heart disease and diabetes mellitus; sister who died of a stroke at the age of 85 and another sister who had some form of leukemia. His son died of colorectal cancer. \nThe patient is not married, lives alone, although his daughter will be staying with him post-transplant. He quit smoking several years prior. \nAcyclovir 400 mg 1 tablet 3 times daily, Baraclude 0.5 mg daily, dapsone 100 mg daily, gabapentin 200 mg 3 times daily, Synthroid 150 mcg daily, Ativan 0.5 mg 1-2 tablets every 6 hours as needed for nausea, vomiting and anxiety; Noxafil 200 mg 3 times daily, omeprazole 20 mg daily, Levaquin 500 mg daily, prednisone 2 tablets daily, Compazine 10 mg every 6 hours as needed for nausea, Rapamune 1 mg daily and Ambien 10 mg as needed at bedtime. \n\nThis is an elderly male who appears in no obvious distress. \nWeight 68.5 kg, temperature 36.6, blood pressure 151/76, respirations 20, pulse 93. \nSclerae anicteric. Oropharynx is pink. No mucositis or thrush. Head, normocephalic, atraumatic. \nSupple. Trachea midline. \nClear to auscultation bilaterally. No crackles, rhonchi or wheezing. \nRegular rate and rhythm, normal S1, S2, no murmurs, rubs or gallops. \nSoft, nontender, nondistended, normoactive. \nNo clubbing, cyanosis or edema noted. \nNo rash noted. \nCranial nerves II-XII grossly normal. \nSodium 142, potassium 3.2, chloride 108, carbon dioxide 27, BUN 15, creatinine 1.08, calcium 8.3, total protein 5.5, albumin 3.4, T-bili 0.5, direct bilirubin 0.1, alk phos 83, AST 16, ALT 18, magnesium 1.5. WBC 2.4, hemoglobin 8.3, platelets 48,000, ANC 1.5. \nThis is a 69-year-old gentleman with a past medical history significant for mantle cell lymphoma who is status post MUD allogenic stem cell transplant, day +37 today. \n1. Graft: The patient is well engrafted, off growth factors and transfusion independent. \n2. GVHD: There was a question if the rash that he developed was GVHD. He is on a prednisone taper. He is currently on 20 mg daily. This will be tapered potentially on Friday if his rash remains stable. \n3. Disease status: The patient had his day 30 bone marrow biopsy. Bone marrow biopsy showed no signs of disease. His chimerism is still pending. \n4. Infectious disease: The patient with no signs of acute infection. We will stop his Levaquin as he is no longer neutropenic. We will continue on prophylactic acyclovir, dapsone and Noxafil. \n5. Fluid, electrolytes and nutrition: The patient has low potassium and magnesium level today. I will start him on potassium 20 mEq daily and magnesium 500 mg q.12 hours. We will monitor his electrolytes closely. \n6. Hypothyroidism: The patient will continue on his Synthroid 150 mcg daily. \n7. Hepatic: The patient has a history of hepatitis B. He will continue on his Baraclude daily. \n8. Insomnia: The patient will continue on his Ambien 10 mg at bedtime as needed. \n9. Neuropathy: The patient will continue on his gabapentin 200 mg 3 times daily. His neuropathy is well controlled on this dose. \n||||END_OF_RECORD \n",
    "preview": "Followup status post hospital discharge for matched unrelated donor stem cell transplant for mantle cell lymphoma, day +..."
  },
  "cancer.report2.txt": {
    "doc_id": "cancer.report2.txt",
    "filename": "cancer.report2.txt",
    "text": "cough History of Present Illness: Age yo m with a pmh of Rt sided empyema s/p decortication in date, NHL in date in remission, p/w a 2 week h/o productive \ncough. He is otherwise very healthy, and was mowing the lawn at home until this morning. He then took a nap, and woke up around 2 pm with some mild b/l lower chest wall pain, which prompted him to come in. He states that his cough has also been worsening slightly over the past few days, with yellowish phlegm intermittently. He denies recent fevers, chills, SOB, abd pain, diarrhea or other sx. Pain was in the epigastric/ b/l lower chest wall region, dull in nature, slightly worse with cough. EKG was NSR, CXR showed possible developing LLL infiltrate, though read as negative. CURBS 65 of 2 for BUN of 40 and \nAge>65, O2 sats >94% on RA, afebrile. No recent ospitalizations. \nDrug Allergies/ADR from Pharmacy: ceftriaxone, Lipitor, lisinopril, Penicillins, Statins-Hmg-Coa Reductase Inhibitors, No Known Food Allergies \nPast Medical History: Essential hypertension \nAtrial fibrillation: not on coumadin \nChronic kidney disease: baseline S Cr of 1.3 \nPulmonary: Rt sided empyema s/p decortication in date \nDiabetes: A1c 6.6 \nHyperlipidemia \nHematology: NH lymphoma in date, in remission \nPsychiatry: Mild cognitive impairment \nGERD / PUD \nTIA \nPast Surgical History: Other surgeries: Rt lower lid BCC removal in date \nPulmonary other: Partial rt lower lobectomy in date \nFamily History: No Reported Family History \nSocial History: Tobacco use: former smoker; PPD: date; Length of use: 30; \nPack years: 30; Quit?: several years ag \nAlcohol use: yes \nDrug use: no \nLiving environment: home \nOccupation: Retired engineer \nADLs: independent \nFAMILY HISTORY/SOCIAL HISTORY \nPROBLEM LIST/DISCHARGE DIAGNOSES \nProblem name: 1; Pneumonia \nPatient presented with 2 weeks of productive cough concerning for atypical community acquired pneumonia vs bronchitis. Patient has history of empyema s/p decortication, and partial right lobectomy. Had CURB 65 of 2 on admission. Was afebrile with no leukocytosis. Chest X-ray showed no obvious consolidation. \nPatient was treated with Levaquin 750 mg IV q48h for possible CAP vs bronchitis with improvement in symptoms. Patient, and family insisted on being discharged home. Antibiotics was transition to azithromycin 500 mg PO daily for a total of \n5 days. \n3 Days zithromax \n2; Acute renal insufficiency \nPatient was found to have AK with BUN/Cr 41/1.59 on admission likely due to prerenal azotemia. Baseline Cr 1.2-1.3. This improved with IVF hydration, and holding of HCTZ. BUN/Cr 31/1.23 upon discharge. \n3; Hypertension \nWell controlled. HCTZ was held in the hospital due to name. This was resumed upon discharge after name improved. \n4; Hyperlipidemia \nContinued on Gemfibrozil. \nHospital Course: see above. \nDISCHARGE DAY PHYSICAL EXAM \nName 11:47 11:30 09:30 \nTemp 36.40 \nTemp Site Oral \nPulse 56 61 \nPulse Site 1 Monitor Monitor \nBP 100/59 \nBP Site \nBP Position \nRR 20 \nPulse Ox 96 \nO2 Delivery Device Room Air Room Air \nPhysical Exam Systems: GENERAL: No apparent distress \nEYES / ENT: Pupils equal, round, and react to light; Extraocular movements intact; Conjunctivae non-ictereric; Moist oral mucosa, no lesions; Neck supple Decreased breath sounds bilaterally. No crackles, wheezes, or accessory muscles use. \nRegular rate rhythm; No murmurs, rubs, gallops \nNo rash, jaundice, ecchymosis or ulcers \nNormoactive bowel sounds; Non-tender, no masses, not distended, no rebound, no guarding \nNo clubbing or cyanosis; No limitation of range of motion; No \njoint swelling, tenderness, effusions; No pedal edema; Pedal pulses: 2+ distal pulses bilaterally \nAlert oriented x 3; No gross deficits; Cranial nerves intact \nNormal mood and affect \nLABORATORY/STUDIES \nMetabolics Common: xxx xxx \nName Units Range 10:43 16:43 \nNA mmol/L 135-145 140 139 \nK mmol/l 3.5-5.3 4.0 4.1 \nCL mmol/L 97-110 107 105 \nCO2 mmol/L 24-32 23* 26 \nAnion Gap date 10 8 \nGlu mg/dL 70-99 99 106* \nBUN mg/dL date 31* 41* \nCreat mg/dL 0.60-1.30 1.23 1.59* \nGFR >60 55* 41* \nCA mg/dL 8.7-10.7 9.5 9.9 \nMag mg/dL 1.6-2.4 2.1 \nPhos mg/dL 2.5-4.5 2.6 \nCBC/Diff: xxx xxx \nName Units Range 10:43 16:43 \nWBC th/mm3 4.3-10.3 7.7 8.0 \nRBC mil/mm3 4.40-6.00 4.15* 4.39* \nHGB g/dL 14.0-18.0 12.7* 13.2* \nHCT % 42.0-52.0 37.9* 40.4* \nMCV fl 82.0-101.0 91.5 91.9 \nPLT th/mm3 140-440 244 261 \nNE % 43.0-72.0 67.7 \nLY % 18.0-43.0 19.4 \nMO % 4.0-12.0 8.2 \nEO % 0.0-8.0 4.2 \nBA % 0.0-2.0 0.5 \nCardiac Enzymes: xxx xxx \nName Units Range 10:43 23:30 16:43 \nTroponin I ng/mL 0.01-0.04 0.02 0.03 0.02 \nRadiology: xxx 5:05:00 PM \nChest, PA and Lateral \nMR#: Social ACCT#: Telephone \nPatient: name, name \nxxx \nM \nRequested by: name, name \nname for Study: ?PNA \nExam Date/Time: xxx 17:05 \nExam Type: Chest, PA and Lateral \nEXAMINATION/TECHNIQUE: \nChest radiographs, upright PA and lateral views. \n\nUN-?PNA , CP \n\nChest CT dated xxx \n\nThere is flattening of the right hemidiaphragm is unchanged. Also unchanged is partial resection of the right posterior sixth rib. No focal consolidation, pleural effusion or pneumothorax is seen. The pulmonary vasculature is normal. The cardiomediastinal silhouette is unremarkable. No displaced fracture. \n\nNo acute cardiopulmonary disease. \nLO, name \nDISCHARGE MEDICATIONS/ALLERGIES \nFinalized Medications at Discharge: xxx 4:11:00 PM \n\nAllergies: \nceftriaxone: Severe \nLipitor: Severe \nlisinopril \nPenicillins \nStatins-Hmg-Coa Reductase Inhibitors \nPROBLEMS/REASON FOR ADMISSION: \nDiagnosis/Problem During This Admission: BronchitisChest Pain \nWhy You Were Admitted: Admit with cough. Improved. Sent home on antibiotics. \nProcedures Performed During This Hospitalization: Chest xray - no Pneumonia. \n||||END_OF_RECORD \n",
    "preview": "cough History of Present Illness: Age yo m with a pmh of Rt sided empyema s/p decortication in date, NHL in date in remi..."
  },
  "cancer.report3.txt": {
    "doc_id": "cancer.report3.txt",
    "filename": "cancer.report3.txt",
    "text": "Interim maintenance chemotherapy. This is a 4-year-old male with a history of a T-cell lymphoblastic lymphoma (diagnosed xxx), who presents for scheduled chemotherapy according to the COGA5971 protocol, regimen B1. His \nlast admission was date to date. He has not had any recent fevers or illnesses. Mom has noted mild rhinorrhea recently. He is to have two cavities filled by the dentist and this will need to be done at an inpatient setting at xxx in location during the week of \nNo fevers, no mouth sores. Positive rhinorrhea. No \narthralgias. No chest pain, no nausea, vomiting, diarrhea, no weight changes, no changes in urine output, no headache, and no rash. \nAcute lymphoblastic lymphoma diagnosed xxx, now \nstatus post consolidation chemotherapy with high-dose methotrexate and intrathecal methotrexate, status post placement of a right subclavian line xxx. History of malrotation with midgut volvulus and incidental appendectomy at time of repair. History of a dystonic reaction to Reglan. \nHistory of rigors and difficulty breathing with IVIG. History of methotrexate clearance delay xxx. \nNormal growth, but language delay and sensory \nintegration disorder. name is on IEP at school for speech and OT. \nAt home Pepcid 10 mg p.o. b.i.d., Zofran 4 mg p.o. q.8 h. \np.r.n. nausea, Bactrim 40/200 5 mL b.i.d. every Monday, Tuesday and Wednesday. \nname had a dystonic reaction to Reglan in the past. When not given Benadryl pretreatment he has rigors and difficulty breathing with IVIG. Otherwise, no known drug or food allergies. Full diet with no restrictions. \nUp-to-date including seasonal flu and H1N1 vaccines. \nPaternal uncle with leukemia at age of 30. \nLives split time with mom and dad. In pre-kindergarten at \nthe name name. No recent travel. \nTemperature 37.1, heart rate 73, \nrespiratory rate 24, blood pressure 102/42, SAO2 98% on room air, weight 19.3 kg. General: The patient is alert and playful, in no apparent distress. HEENT: Pupils equal, reactive to light and accommodation. Extraocular motions intact. Nares patent. Oropharynx clear, no lesions. \nSupple, no lymphadenopathy. HEART: Regular rate and rhythm, no murmur, rubs or gallops. LUNGS: Clear to auscultation bilaterally, no wheezes or crackles. ABDOMEN: Soft, nontender, nondistended, no hepatosplenomegaly or palpable masses, positive bowel sounds in all 4 quadrants. GU: Normal male genitalia. EXTREMITIES: Warm, well perfused, no clubbing, cyanosis, edema. NEURO: Alert and oriented, no focal deficits. SKIN: No rashes or petechiae. \nCBC: White blood cell 6.1, hemoglobin 10.8, hematocrit 30.4 and platelets 293, segs 58, lymphs 17, sodium 140, potassium 4.5, chloride 104, bicarbonate 28, BUN 8, creatinine 0.41, \nglucose 95, calcium 10.1, total protein 6.1, albumin 4.5, T-bili 0.5, alkaline phosphatase 146, AST 33, ALT 23, and LDH 231. \n\n1. Heme-Onc: name was admitted for interim maintenance chemotherapy for his T-cell lymphoblastic lymphoma. He is following protocol COG85971, regimen B1. He was initiated on aggressive hydration and high-dose methotrexate was started once urine parameters were met. Intrathecal methotrexate was given on xxx. This was followed by leucovorin \nrescue hour 42, and leucovorin was given per protocol at hours 42, 48 and 54, and every 6 hours until the methotrexate level was found to be less than 0.1. He was receiving D5 quarter normal saline with 30 mEq of bicarbonate at 155 mL an hour until his methotrexate level was less than 0.1 micromoles. name first methotrexate level at 24 hours was 71.4. At 42 hours, his methotrexate level was 0.982. At 60 hours, his methotrexate level was 0.203. At 72 hours, the methotrexate level was less than 0.1, and name was stable for discharge. His CBC was normal and was normal during his stay. \n2. Renal: name was prehydrated with aggressive IV fluids and achieved urine parameters with spec gravity less than 1.010 and a pH between 7 and 8. He stayed within these parameters throughout his hospital stay. His BUN \nand creatinine were closely monitored in order to ensure clearance of methotrexate. They remained stable throughout his whole stay with BUN being less than 2 and his creatinine ranging from 0.31 to 0.4. His electrolytes were stable throughout his stay, and he did not need any repletion. \n3. GI: name was given Zofran 9 mg IV daily and had no nausea or vomiting throughout his stay. Liver function tests were within normal limits on admission. \n4. Infectious disease: name has been afebrile throughout the course of the admission. He had some mild rhinorrhea. name was restarted on his \nBactrim prophylaxis at discharge. This had been stopped due to \nadministration of methotrexate. He will continue the methotrexate every Monday, Tuesday, and Wednesday. \n5. Cardiovascular: name blood pressures were mildly elevated during admission to a max of 139/89. This is felt to be secondary to aggressive IV fluid hydration. His heart rate was normal throughout his entire hospital course. He had a port in place for cardiovascular access, which \nwas used to administer IV fluids, medications and blood draws. He did not complain of any palpitations or chest pain and he remained stable from a cardiac standpoint. \n6. Neuro: The patient did not require any pain medication throughout the course of the admission. \nT-cell lymphoblastic lymphoma. \nNone. \nPepcid 10 mg p.o. b.i.d., Zofran 4 mg p.o. q.8 h. \np.r.n. nausea, Bactrim 40/200 5 mL p.o. b.i.d. every Monday, Tuesday and Wednesday. \n\n1. The patient should follow up in the Hematology Oncology Clinic on xxx at 9:00 a.m. \n2. The patient should take all medications as prescribed. \n3. The patient should call the Hematology/Oncology clinic or return to the Emergency Department if he experiences fevers, shortness of breath, or if the parents have any other concerns. \nReviewed \nname name, MD xxx 17:41 \n||||END_OF_RECORD \n",
    "preview": "Interim maintenance chemotherapy. This is a 4-year-old male with a history of a T-cell lymphoblastic lymphoma (diagnosed..."
  },
  "manual_text.txt": {
    "doc_id": "manual_text.txt",
    "filename": "manual_text.txt",
    "text": "The patient is here for a routine followup visit for his lymphoma and to receive his maintenance rituximab. \n1. Recurrent follicular cell lymphoma. His most recent relapse was in the large bowel. Routine surveillance colonoscopy with numerous biopsies showed polyps as well as a nodular mucosal area in the proximal ascending colon and in the cecum. Multiple biopsies revealed a low-grade B-cell lymphoma. Removal of one of the polyps revealed a tubular adenoma. \nA. He initially presented with a mass in the large bowel in the early 1990s associated with diarrhea and iron-deficiency anemia. Biopsy of the mass was said to reveal large cell lymphoma and he was given chemotherapy at that time. He had a recurrence in date and was re-treated. \nB. In date, he had another recurrence with diffuse lymphadenopathy and weight loss. At that time, a lymph node biopsy was done and showed a low-grade follicular lymphoma. \nC. Bone marrow aspirate and biopsy in xxx done because of pancytopenia revealed a hypocellular marrow with normal trilineage hematopoiesis. Lymphoma in the marrow was noted as well. The cells in the marrow were CD5, CD20 and PAX5 positive. Cyclin D1 was negative as well as BCL6. BCL2 was positive. Flow revealed lymphoma cells which comprised 17% of the nucleated cells. FMC7 and CD10 were negative. Cytogenetics revealed a trisomy-12 with deletion of 13Q and TP53. There may have been an MDS-related clone of 20Q minus. \n2. Pancytopenia present since date. This was multifactorial secondary to MDS as well as lymphomatous involvement of the bone marrow. \n3. Asthma. \n4. Chronic renal insufficiency. \n5. Monoclonal gammopathy with 2 IgG monoclonal bands which were IgG kappa and IgG lambda, probably related to his underlying lymphoma. \n6. Increased PSA, followed by Urology. \nThe patient received 4 weekly infusions of rituximab 375 mg/m2, completed in xxx. In xxx, he was started on maintenance Rituxan 375 mg/m2 every other month which he will receive for 2 years. \n\n1. Four cycles of fludarabine ending in date. \n2. Three cycles of fludarabine in date. \n3. Fludarabine in date. \n4. Six cycles of CHOP in date. \nAlbuterol inhaler, aspirin, fish oil, multivitamins, vitamin C, and vitamin D. \nname name returns for followup of his low-grade lymphoma. Unfortunately, for the last several weeks, he has had an upper respiratory tract infection associated with a cough productive of yellow sputum. He denies any fevers, night sweats or chills. He has had associated wheezing and dyspnea on exertion. He is slowly improving. \nOtherwise, he denies any new medications or hospitalizations. \nThe patient denies any current fevers, night sweats, chills, headache or visual blurring. He continues to have a productive cough and dyspnea on exertion. He denies any PND, orthopnea or peripheral edema. He denies any abdominal pain, nausea or vomiting. His appetite is good. He denies any diarrhea, constipation or GI bleeding. He denies any dysuria. He denies any increased bruising. He denies any heat or cold or known glucose intolerance. He denies any significant musculoskeletal pain or skin rash. \nNegative for lymphoma. \nThe patient's performance status is ECOG 0-1. He has been feeling poorly because of his upper respiratory tract infection which he is slowly recovering from. Usually, he is very active. He has a significant other and they do ballroom dancing. He lives independently and does all activities of daily living. \n\nThe patient is afebrile, blood pressure 151/93, pulse 83 and regular, and his weight is 87.6 kilograms which is stable. \nNo scleral icterus. Pharynx without lesions. \nSupple, no adenopathy, no supraclavicular or axillary adenopathy. \nClear without wheezes, rales or rhonchi. \nRegular rhythm, no murmur heard. \nSoft, no hepatosplenomegaly, no abdominal masses, no inguinal adenopathy. \nNo peripheral edema, petechiae or ecchymosis. \nNo rashes. \nThe patient is alert and oriented. Strength is intact and gait normal. \nCBC revealed a white blood cell count of 6200 which is a little bit higher than he usually runs with 75.5 polys, 7.5 lymphs, 14.7 monos, 1.6 eos, 0.7 basophils, a platelet count of 166,000 which also has improved and a hemoglobin of 13.6 with hematocrit of 40.1 which has fallen slightly. MCV is 94.1. BUN is 17, creatinine is 1.12. AST is slightly elevated at 44 and ALT is elevated at 64. These had not been elevated in the past. \nname name is a 78-year-old male with: \n1. Recurrent follicular cell lymphoma for which the patient is receiving Rituxan. Most recently, it was found on surveillance colonoscopy. He was asymptomatic. He has tolerated the Rituxan without difficulty. He is due today for another maintenance dose. \n2. Large cell lymphoma which was his original lymphoma if the pathology is to be believed and this was in date. He is status post 6 cycles of CHOP chemotherapy. \n3. Asthma which is under reasonable control. \n4. Viral upper respiratory tract infection which he is slowly recovering from. \n\n1. I will hold the rituximab infusion today because of his upper respiratory tract infection and he will return in 2 weeks for this. He will return again in 2 months for another maintenance cycle of rituximab. \n2. I will see him in followup in 4 months and again write for the orders. All the orders have been written. He receives 375 mg/m2 intravenously after premedication with lorazepam, hydrocortisone, famotidine, Benadryl and acetaminophen. He tolerates the drug without difficulty. \n||||END_OF_RECORD \n",
    "preview": "The patient is here for a routine followup visit for his lymphoma and to receive his maintenance rituximab. 1. Recurrent..."
  },
  "cancer.report1.txt": {
    "doc_id": "cancer.report1.txt",
    "filename": "cancer.report1.txt",
    "text": "The patient is here for a routine followup visit for his lymphoma and to receive his maintenance rituximab. \n1. Recurrent follicular cell lymphoma. His most recent relapse was in the large bowel. Routine surveillance colonoscopy with numerous biopsies showed polyps as well as a nodular mucosal area in the proximal ascending colon and in the cecum. Multiple biopsies revealed a low-grade B-cell lymphoma. Removal of one of the polyps revealed a tubular adenoma. \nA. He initially presented with a mass in the large bowel in the early 1990s associated with diarrhea and iron-deficiency anemia. Biopsy of the mass was said to reveal large cell lymphoma and he was given chemotherapy at that time. He had a recurrence in date and was re-treated. \nB. In date, he had another recurrence with diffuse lymphadenopathy and weight loss. At that time, a lymph node biopsy was done and showed a low-grade follicular lymphoma. \nC. Bone marrow aspirate and biopsy in xxx done because of pancytopenia revealed a hypocellular marrow with normal trilineage hematopoiesis. Lymphoma in the marrow was noted as well. The cells in the marrow were CD5, CD20 and PAX5 positive. Cyclin D1 was negative as well as BCL6. BCL2 was positive. Flow revealed lymphoma cells which comprised 17% of the nucleated cells. FMC7 and CD10 were negative. Cytogenetics revealed a trisomy-12 with deletion of 13Q and TP53. There may have been an MDS-related clone of 20Q minus. \n2. Pancytopenia present since date. This was multifactorial secondary to MDS as well as lymphomatous involvement of the bone marrow. \n3. Asthma. \n4. Chronic renal insufficiency. \n5. Monoclonal gammopathy with 2 IgG monoclonal bands which were IgG kappa and IgG lambda, probably related to his underlying lymphoma. \n6. Increased PSA, followed by Urology. \nThe patient received 4 weekly infusions of rituximab 375 mg/m2, completed in xxx. In xxx, he was started on maintenance Rituxan 375 mg/m2 every other month which he will receive for 2 years. \n\n1. Four cycles of fludarabine ending in date. \n2. Three cycles of fludarabine in date. \n3. Fludarabine in date. \n4. Six cycles of CHOP in date. \nAlbuterol inhaler, aspirin, fish oil, multivitamins, vitamin C, and vitamin D. \nname name returns for followup of his low-grade lymphoma. Unfortunately, for the last several weeks, he has had an upper respiratory tract infection associated with a cough productive of yellow sputum. He denies any fevers, night sweats or chills. He has had associated wheezing and dyspnea on exertion. He is slowly improving. \nOtherwise, he denies any new medications or hospitalizations. \nThe patient denies any current fevers, night sweats, chills, headache or visual blurring. He continues to have a productive cough and dyspnea on exertion. He denies any PND, orthopnea or peripheral edema. He denies any abdominal pain, nausea or vomiting. His appetite is good. He denies any diarrhea, constipation or GI bleeding. He denies any dysuria. He denies any increased bruising. He denies any heat or cold or known glucose intolerance. He denies any significant musculoskeletal pain or skin rash. \nNegative for lymphoma. \nThe patient's performance status is ECOG 0-1. He has been feeling poorly because of his upper respiratory tract infection which he is slowly recovering from. Usually, he is very active. He has a significant other and they do ballroom dancing. He lives independently and does all activities of daily living. \n\nThe patient is afebrile, blood pressure 151/93, pulse 83 and regular, and his weight is 87.6 kilograms which is stable. \nNo scleral icterus. Pharynx without lesions. \nSupple, no adenopathy, no supraclavicular or axillary adenopathy. \nClear without wheezes, rales or rhonchi. \nRegular rhythm, no murmur heard. \nSoft, no hepatosplenomegaly, no abdominal masses, no inguinal adenopathy. \nNo peripheral edema, petechiae or ecchymosis. \nNo rashes. \nThe patient is alert and oriented. Strength is intact and gait normal. \nCBC revealed a white blood cell count of 6200 which is a little bit higher than he usually runs with 75.5 polys, 7.5 lymphs, 14.7 monos, 1.6 eos, 0.7 basophils, a platelet count of 166,000 which also has improved and a hemoglobin of 13.6 with hematocrit of 40.1 which has fallen slightly. MCV is 94.1. BUN is 17, creatinine is 1.12. AST is slightly elevated at 44 and ALT is elevated at 64. These had not been elevated in the past. \nname name is a 78-year-old male with: \n1. Recurrent follicular cell lymphoma for which the patient is receiving Rituxan. Most recently, it was found on surveillance colonoscopy. He was asymptomatic. He has tolerated the Rituxan without difficulty. He is due today for another maintenance dose. \n2. Large cell lymphoma which was his original lymphoma if the pathology is to be believed and this was in date. He is status post 6 cycles of CHOP chemotherapy. \n3. Asthma which is under reasonable control. \n4. Viral upper respiratory tract infection which he is slowly recovering from. \n\n1. I will hold the rituximab infusion today because of his upper respiratory tract infection and he will return in 2 weeks for this. He will return again in 2 months for another maintenance cycle of rituximab. \n2. I will see him in followup in 4 months and again write for the orders. All the orders have been written. He receives 375 mg/m2 intravenously after premedication with lorazepam, hydrocortisone, famotidine, Benadryl and acetaminophen. He tolerates the drug without difficulty. \n||||END_OF_RECORD \n",
    "preview": "The patient is here for a routine followup visit for his lymphoma and to receive his maintenance rituximab. 1. Recurrent..."
  },
  "cancer.report2.txt_annotated.txt": {
    "doc_id": "cancer.report2.txt_annotated.txt",
    "filename": "cancer.report2.txt_annotated.txt",
    "text": "cough History of Present Illness: Age yo m with a pmh of Rt sided empyema s/p decortication in date, NHL in date in remission, p/w a 2 week h/o productive \ncough. He is otherwise very healthy, and was mowing the lawn at home until this morning. He then took a nap, and woke up around 2 pm with some mild b/l lower chest wall pain, which prompted him to come in. He states that his cough has also been worsening slightly over the past few days, with yellowish phlegm intermittently. He denies recent fevers, chills, SOB, abd pain, diarrhea or other sx. Pain was in the epigastric/ b/l lower chest wall region, dull in nature, slightly worse with cough. EKG was NSR, CXR showed possible developing LLL infiltrate, though read as negative. CURBS 65 of 2 for BUN of 40 and \nAge>65, O2 sats >94% on RA, afebrile. No recent ospitalizations. \nDrug Allergies/ADR from Pharmacy: ceftriaxone, Lipitor, lisinopril, Penicillins, Statins-Hmg-Coa Reductase Inhibitors, No Known Food Allergies \nPast Medical History: Essential hypertension \nAtrial fibrillation: not on coumadin \nChronic kidney disease: baseline S Cr of 1.3 \nPulmonary: Rt sided empyema s/p decortication in date \nDiabetes: A1c 6.6 \nHyperlipidemia \nHematology: NH lymphoma in date, in remission \nPsychiatry: Mild cognitive impairment \nGERD / PUD \nTIA \nPast Surgical [Test] History: Other surgeries: Rt lower lid BCC removal in date \nPulmonary other: Partial rt lower lobectomy in date \nFamily History: No Reported Family History \nSocial History: Tobacco use: former smoker; PPD: date; Length of use: 30; \nPack years: 30; Quit?: several years ag \nAlcohol use: yes \nDrug use: no \nLiving environment: home \nOccupation: Retired engineer \nADLs: independent \nFAMILY HISTORY/SOCIAL HISTORY \nPROBLEM LIST/DISCHARGE DIAGNOSES \nProblem name: 1; Pneumonia \nPatient presented with 2 weeks of productive cough concerning for atypical community acquired pneumonia vs bronchitis. Patient has history of empyema s/p decortication, and partial right lobectomy. Had CURB 65 of 2 on admission. Was afebrile with no leukocytosis. Chest X-ray showed no obvious consolidation. \nPatient was treated with Levaquin 750 mg IV q48h for possible CAP vs bronchitis with improvement in symptoms. Patient, and family insisted on being discharged home. Antibiotics was transition to azithromycin 500 mg PO daily for a total of \n5 days. \n3 Days zithromax \n2; Acute renal insufficiency \nPatient was found to have AK with BUN/Cr 41/1.59 on admission likely due to prerenal azotemia. Baseline Cr 1.2-1.3. This improved with IVF hydration, and holding of HCTZ. BUN/Cr 31/1.23 upon discharge. \n3; Hypertension \nWell controlled. HCTZ was held in the hospital due to name. This was resumed upon discharge after name improved. \n4; Hyperlipidemia \nContinued on Gemfibrozil. \nHospital Course: see above. \nDISCHARGE DAY PHYSICAL EXAM \nName 11:47 11:30 09:30 \nTemp 36.40 \nTemp Site Oral \nPulse 56 61 \nPulse Site 1 Monitor Monitor \nBP 100/59 \nBP Site \nBP Position \nRR 20 \nPulse Ox 96 \nO2 Delivery Device Room Air Room Air \nPhysical Exam Systems: GENERAL: No apparent distress \nEYES / ENT: Pupils equal, round, and react to light; Extraocular movements intact; Conjunctivae non-ictereric; Moist oral mucosa, no lesions; Neck supple Decreased [DIAGNOSIS] breath sounds bilaterally. No crackles, wheezes, or accessory muscles use. \nRegular rate rhythm; No murmurs [SYMPTOM], rubs, gallops \nNo rash, jaundice, ecchymosis or ulcers \nNormoactive bowel sounds; Non-tender, no masses, not distended, no rebound, no guarding \nNo clubbing or cyanosis; No limitation of range of motion; No \njoint swelling, tenderness, effusions; No pedal edema; Pedal pulses: 2+ distal pulses bilaterally \nAlert oriented x 3; No gross deficits; Cranial nerves intact \nNormal mood and affect \nLABORATORY/STUDIES \nMetabolics Common: xxx xxx \nName Units Range 10:43 16:43 \nNA mmol/L 135-145 140 139 \nK mmol/l 3.5-5.3 4.0 4.1 \nCL mmol/L 97-110 107 105 \nCO2 mmol/L 24-32 23* 26 \nAnion Gap date 10 8 \nGlu mg/dL 70-99 99 106* \nBUN mg/dL date 31* 41* \nCreat mg/dL 0.60-1.30 1.23 1.59* \nGFR >60 55* 41* \nCA mg/dL 8.7-10.7 9.5 9.9 \nMag mg/dL 1.6-2.4 2.1 \nPhos mg/dL 2.5-4.5 2.6 \nCBC/Diff: xxx xxx \nName Units Range 10:43 16:43 \nWBC th/mm3 4.3-10.3 7.7 8.0 \nRBC mil/mm3 4.40-6.00 4.15* 4.39* \nHGB g/dL 14.0-18.0 12.7* 13.2* \nHCT % 42.0-52.0 37.9* 40.4* \nMCV fl 82.0-101.0 91.5 91.9 \nPLT th/mm3 140-440 244 261 \nNE % 43.0-72.0 67.7 \nLY % 18.0-43.0 19.4 \nMO % 4.0-12.0 8.2 \nEO % 0.0-8.0 4.2 \nBA % 0.0-2.0 0.5 \nCardiac Enzymes: xxx xxx \nName Units Range 10:43 23:30 16:43 \nTroponin I ng/mL 0.01-0.04 0.02 0.03 0.02 \nRadiology: xxx 5:05:00 PM \nChest, PA and Lateral \nMR#: Social ACCT#: Telephone \nPatient: name, name \nxxx \nM \nRequested by: name, name \nname for Study: ?PNA \nExam Date/Time: xxx 17:05 \nExam Type: Chest, PA and Lateral \nEXAMINATION/TECHNIQUE: \nChest radiographs, upright PA and lateral views. \n\nUN-?PNA , CP \n\nChest CT dated xxx \n\nThere is flattening of the right hemidiaphragm is unchanged. Also unchanged is partial resection of the right posterior sixth rib. No focal consolidation, pleural effusion or pneumothorax is seen. The pulmonary vasculature is normal. The cardiomediastinal silhouette is unremarkable. No displaced fracture. \n\nNo acute cardiopulmonary disease. \nLO, name \nDISCHARGE MEDICATIONS/ALLERGIES \nFinalized Medications at Discharge: xxx 4:11:00 PM \n\nAllergies: \nceftriaxone: Severe \nLipitor: Severe \nlisinopril \nPenicillins \nStatins-Hmg-Coa Reductase Inhibitors \nPROBLEMS/REASON FOR ADMISSION: \nDiagnosis/Problem During This Admission: BronchitisChest Pain \nWhy You Were Admitted: Admit with cough. Improved. Sent home on antibiotics. \nProcedures Performed During This Hospitalization: Chest xray - no Pneumonia. \n||||END_OF_RECORD \n",
    "preview": "cough History of Present Illness: Age yo m with a pmh of Rt sided empyema s/p decortication in date, NHL in date in remi..."
  },
  "WOC Raghu_9985112396857338632.docx.docx": {
    "doc_id": "WOC Raghu_9985112396857338632.docx.docx",
    "filename": "WOC Raghu_9985112396857338632.docx.docx",
    "text": "PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000\u0002GOx\u0001\u0000\u0000\u0003\u0006\u0000\u0000\u0013\u0000\b\u0002[Content_Types].xml \u0004\u0002(\u0000\u0002\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000N0\u0010EHC-J\u0732@\b5\u0012*Q>'/$mP\bn\"33rdU\u0002\u001f59\u0019f\u0003VHSc\u0793$Df\u0004S@N\u0010d|}5m\u001d\u0004&d\u0011{4\u0005h\u00162`^K_R\u0017+\u000e\u0006w[\u00134V\u001ed<z-UL7\u0750|:(I4VY92\u000bSLVxP\u15c49$g\u0011te\u012fY\u001c\u0019*\ub7b0.`\u00c1r8`{\u0003R@2e>2]tmFev\u0726\u0016+7-\u0010d\u068af\u000frU\u0010OC(\u0004\u03b9\u0017a\rQ0\u0005)0w\n\u038fZBD|'s6\"s\u000bn\u007f:\u0141\u001d(um\"Z<\u001fT\u0000l\f\u001bpZ?o\u0000\u0000\u0000\u0003\u0000PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000U~\u0005\u0000\u0000\u0000\u0002\u0000\u0000\u000b\u0000\b\u0002_rels/.rels \u0004\u0002(\u0000\u0002\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000MK\u00031\u0010!\u033d;*\"^DMd\u0001C2\u000f(.\u0535\u001e3y3C\u059b\u001d+4xW(A\fyX\u0702JB\u001dWp\u0004b#InJ\u0010\u0014*E\u001db=[J\u000fM%a B\u001d,o0f@=a n\u0015\u0010\u0014oA;N<\u0017v\"\u001fe\u04e8bR1\u0013R\bEF\u0003\u001e7ZnhY\u0210\u0010j\u001fy#1'<\u72a6\u001f7\u001f\r9m.3\udb74\udd13Y\u0003\u0000\u0000\u0003\u0000PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000yw\u0005\u0014\u0000\u0000\u0000\u0000\u0011\u0000\u0000\u0000word/document.xml=r\u06f8[\u04a9\u06a7X]&Y&\u036dLi \u0013by/n%@d$U\u0016H\u0002\r\u0000|X\u0004=\u0013oZJ[nI$t\u000f\u07b4~2ZR:\thH\u07b4\u001eIe\u007fFlAT\u0002\u0010a_F\ue6d6QI\\,\u0758&t]wIgIYG\u0015$I\u0000N*\u000fA\u0012\u001a#@zN'\u0018\n7\u0010XU@\tR\u0005q2;HU\u0005~\u0012 \u00028\rRM UH iUHi*\ucd2828H\b\u000f4^8)\\w\u0013\u007f\u02e2+\u0000\u001c9?\u0003?}\u0004Yq\t\u0014A\u00156,\u0004\u06acB\u07f48\u0017V~\u07beY qh\u0001]C\u001e I\u02f61c7\u001f\u0015Z'&\u0001#\r\u0013\u03cfVaq*4x@\r\"(-#HQ\u06e5F4<\u0001<b\u0016AN~|l\"UcHYR\u0000\u000e~B|\u042c\rr)\u0001\u0015\u0000K4\u0016%\fq\u001bGU\t'\u0015?\rr\u000e&f\r,\u0002j%\u001d`%t+\u7a03md%49A\u0019,J!L7h\nbm\u000e;1A9Y\u0004\u0017v\udb53\udc97<q*\u0004~]\t%bzN\u0004|oB\u001a;\u0000(\u0002@\u0002%6\u0003\u0017\u0018\u0019\u007fX<?Ea\u001e`aI\u0012[\u0004N\u0011\u007f#x#'vn@\u0511L]i`BS->8oZ\u001d=s5\"s'\u000bR|cXO1$BO\u0000\u0017\u0001]'~\bd\u00032.7wxt\u0000*&>\u0014O:+\u001cO1s\u0006`WK\u0018A8tRb0\u0005n\u001e\u0019>?3?&0_0iBC1;XI\u0005bnU\u0001_D\u0001D\u0013v\u001b{w\u001eU\u0019jK\u0012\u000fF\u0001\u001dP\u06d2P\u020c\tG7M\u0002IKr.?\u001f8\u0011Y\u0405\u0003\u0576\u0001l\u0116#\r{\u0014WtI\u000f\f#Q\u0011M|oWNb\n\u0016;rH\u0018j|\u0013^\u00162\u0001k\u0005fNm\u00036\fU5\u0000\u0010\u0006\rMT0Z\u000b}Q\u0014U\u0019E|NtW\rXwCa:S\u05d7@\u0007\b+>\u0012\u001a\u0015\u0018Y\u0000~\u0001S )E\u0003HNbY;`\";m`\u019a~d(@dHY,<s}\u0004/\u0002\u0016VJ\u001f\u0001\u0015&\u0011\u001b:y<^/ bX\u0007y`\u001f\u0003tZGqLB\u009bV\f\\(p%i^R\u0010R0}@]+8e]\u000eAl3\u0010)9,\u001d \u000f\u000etOkF'q\f\b$\u0011h\u0014b\u0002:\u0015\u0005\f\u655aW\u0645\u0005@^~\u07c5xn\u000e\u001e8\u001dD\u001f\u0109BZ\u0001\b48\u0005-\n\u00045\u000eI\u0000Ru<Te\u0010~3\u001f\u000f0\u05ddNsW\u0019!\u0018_Yj_f\\\u0003cu\u0007\u0000\u0013FowCN,\u0017\u0012\f%z@\u000b\u00073sb\ud870\udc9b07iYtu'\rl,\b\u000e}:\u0016\u0017Lu6us\b^9\u0019+\u00bc\t~+4|\u001f*\u0370f\f0W*)\u0002 }?ACY\u001fPB\u0452(\fDVv)\u000eWoK\u0002\u0010\u001e-^\u00058\u007f\u0018?\u000fh\u0000E\u001aoDa>\\!\u0011\u00042U\u00181\u06dbV]\u001a`#r=\u016c\u0005\u001a+\u0002niB,%? \u0015}\u06d6u\u0012F}\u0019\u0010\u0004\u001apwRfK}m\"W%+`\u001b;\u0013\\.U\u001f=Z%Y~~\u0005\u000e'y_)F4\r\u0002g=$\u0b00'\u013a\t~\u000f\u0002LN\u0010L.\u042eq@\uc84f\u0004M\u0420b\u065co\u001bO\u01ad\u0005\u000fE\u001e;\u031e5+}\u0018\u001fnm@\u045cI\u0003\u0011\u000bd/hD\t*2\u000bN\n\t\r!FYE9\bPz&#\u01bau\u0002gCuF\u0003g6a\nu\u001bf\u0376F\u0623\u0002g'\u001b|\u0003g\u000f\u001a8j\u000f\u0003<nRX;$\u001e8e\\\u0004R.>\u007f\u0007\u03a7\u0005\u038d\u04fe\u0016.Y\u0019\u000b?YYr>e\u0011$\u4540Jx%f2\u0005\u02e2\\#[Q\u0017|bXU+;Y\u0013u7klt:b5\u0740&(%j\u07af\nlD:c\u000e\u001e?.\u2ee9\u001d\u0012S\u0013\u0000Vm+gP9/\u000f:qT$N,}%V'y\u077f#\"$&R\u0005\u0018,LX,B\u0014O(X>g4\u0001Y\u07cc\u001c\u0527!3_4\u001e1gj\tV8=\u03d9\fH5\u000b'\\^\n\\aB2Zm\b\t(WCK5F\u0013{\u000fTk)m\u0007\u0007\u06d9fc4QX,\\<as[T3%C\u05b8Q|Wzs.\u0017OOoo&\u000fLk$_o\u0007'Y\u0414VPYU\u0005\u0019\u0352\u001crtw@9:KJcX2gtapAP):.r\u001d\u001eqf\u0004Th7o74]RvY`\u0002uH<\u06ab&e\u000e\u038ab=\u0016c\u0016\u0015\u0013#\"\rf\u001a\u0001vjk\u0003gz\u001b\u001aO`VN\u000fb\t\u001a\u04fd\u0012[\u000e\u0266\u061f\fnyKa\b~H\u0011\u00fc_\u0019A?Gh\u001cS1&zw5<.fJE*\r\f8c\u0002\"MV\u0012\u0016\u0010IX#ed[\t\u000bc\u0013{an,a\u0473jn>aVO7\u0001d,+CWS\f=DMd,2cqQr+_C\tFb\u001cZxwx\u0001Cgb\u001aX\u001f\u01ee|\u001aQ\u0019AcYd1Ey\u0003\u0001\u0002]&)\u0004\u0003\u0002\u000e.\u0016g'\u0004yW<\u001d{>'\u0018\ts\u0007\u001et\u0011y\u0016\u001c=AA]?et\u001bvw\b.\f\u001cs1bx~n\\\u000fYn].IF{\u000b\t\u06926dm*j\rHaM?R:\u9863w8W)=LE\u00044\\\u0378H\u000fs7\u0018+[\u0014k4'cH_B>J{\u0012f'#q\u0002\tg$$N\u0001,z\u0004\u07c2\u0003\u0005\u000f\u0657AvjROSS\u0015;P~p<e\u06a4\u0671C\u0476St\u001e\u020ay~b\u03af~\u79a6D\u02c7>\u0007c\u001dC\\$mdk0B\u0013ZMCL\u0017JK\u0019\u0005'\u0014\u025f\u0013X\u0622hUz\rJW5C\u001c\t+\u001clebb.\u00141YUvCr\ubee0\u84f1\ny.T}0E+P\u04fd\u0013e<RG\u0017\u0001zqM\u0004.\u001e'6eX/LlR\u000b\u001c#6c\u0574,\u0015 Ql\"\u000eiwzWWC\u001bq$+RP+\r\u007f\u0010_22Eap|nl!%N\u001cT<oy.D\f\u0006gyn\rIR\u482bY\u0019OY\u001cdsG\u000ey4'\u0013y|dH\u001dVT!f\u0016\u0397\u000e\u0019/\u001c?o\u03f3\u0007bIq\u001fW\n\u26d9FH\\l\u07f2\u0016A6 57\u001cJ\u001c\u0000DT'~J86h\u022ea|`\u007f&,C\u0011()Mo\u001d_4\u0237Z\u05ad\u001e\u007f0\u001evuA\b3\u0018cu\u078d\u007f\u001es\u0012]\u0454^\u007f\u001cI&!Z}3`o\u0019TP\u0321\u0006\u001e>VVui\u0019x=&cD\u01c3\u037a{|\u0014\u0017W\ucccf\u0007C8F}{39&r!H%2stp\u0001B\u0005Dpf Qr}\u0013[|aC\u001c\u0001C\u073b`^\u007f%Tl!`i\u0012\u0002;\u000eZvz[hPIoY\u001a&<PGi\u0011A\n(|\\}\u0006no[\u0005){b\u001e\n\u001du\u07f7t\u03af$\b#DS\u0001*j\u000b<1+\u0011\u01e0v\uc3f7\u031e m>\ubbdb+;t\u000euc`?#?BVr)\u00006c2\u014dNI\tRub7.A\u000e\u0013dG$J%:\u001200N\u007f4\u001d?>Fb\u000fK.T\u066eW\u056c,l<WO\u0019pn=z2WzlwZH*t]G\bXu\u0010W,(\u000fW3\u001fm\u001e\u000f\u0011+\u00149Q\u0014\u0013\u039dxy#\u034b~H\u06e3\u02d9\u0013?\u001aisGC\\W\u001bX\u0019\u000fCUpuUT\u001e\r\u04098Oy\u00107~\\B~Y@0&uy}\u0007&Ux+n\u0017\u0004Bz/]nt\u0092,hr\u0013P|\u0003\u0005N45\"(O!B\u008dvRSV4T\u00adDa{\u0003N>bi\u0003UV*'h\u02fa<^ 39LzrX8\u0019{s5\u060fPHH~\u0006\u064c\u01fc\nIE\u0012R\u0010B\u0013\u01f5!\u0003\u023b%d\u0139<\u0014:NX\u0011B\u027b#4u\brGw(\t@Se[\u001br\u001al?=JGj{^\u001e\u0002\u0012\u0012#TxX#Z<J3aFN\u04ac=QFb9IZL\u000eu\rk\f\u00053\u001bI\u001eEK\u0014\n9N'8BB\u0092\u0003K%<!{g8Kw1!=v\u0001\f\u001d~+\u0003#x@$XNz/4!F4\u0181K,\u040c\u1df0$7m-<'g>JhA\ta7#\u012a`Db@oH#\u0012DRy\rS\u0494H`mD)\u0002Y\u0638dGI%\ud866\udd6f[\u001b:f4F\u0013\u0014{J8N]m\u07348\\\u0011B\u001cIb\\F\u0017aT<t!\u0001{\"i\u0006r_,8f`})\u001c\u001dA\u001e#4w1!:Lh0\u02ed\u0002\u001b}\u0007\u0002lBw'\u000f\u0005'\u02df\u0017W\u0012(Ku\u000babbw9:@\u0007q\u04cb\"|K\u001aB\".\b\u001ev-h\u001f\u00122__0=\u0014\"M1\u0014\u0013'A'{p\u0019Ha\u05f7`HenBbI\u0003/0Ydtj=U<4Y\u0001YemdA,EzHE[\u001e?I,;\\\u000ef\\\u0389A\u0014\u0004LbP\u000f|\u0002!}\u0015Pcr\fK\u0397\u0014\t#9$K\u05cdI\u0014<k[ \u001aI\"p8Y\u0010<\u001eJU\u0013\u0018k\u0004M?0\u0361?y+sKY]|[KFw(\u000f3w\u00de\u001b\u000fp\u001b;\u0019Hj\u001fUTK\u0007rZsOS\f,\u001b\u02db\u07075\u007f \rK9\u0767C\u0373\u0017phs\u0108\u001d}CE\u000245I{Ut4D\u0197\u0017\u051cZgo\u03dfi>U5\u0015>\u0549{r:(h\u0614U\u03ba\u0011S3Z&~!slu{5l<\u06dc:\u04e4-+\u000f\u0014E\u00d8/>E\u000b\u06dalCokG\u001cqP[\u01b3LG\u0012\u0007Q]K3\"x\u0141w\u0013>\u05d5]`\u000fUeb(|\u00e6\tx\u0478E\u0007Gl\u0002\u0001\u001fbO\u0602pwh\u0007dsG\u0505\nf^\u00183c8Q<\u07da\u007f\u000fzXuoq~lt\u000f6^.mh6\u0013<-Kmgj\u0001!\u0012`bB\u0001{~Yl\u0001]r\u0309\u0003\u001ax\"]8\uf846g\u0010\u03f5U(Znl\u0007wv3\u0001\u001f\u0018\u0001X0u,\u0010\u07ad\u0439\u001d\u0012{'\u0000\u0007\u0004/f~\u06b7nUx!\u000feE\u000e~\u01cf\u008c\u0002\u0000\u0000\u0000\u0003\u0000PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000E\u04cfcW\u0001\u0000\u0000\u0006\u0006\u0000\u0000\u001c\u0000\b\u0001word/_rels/document.xml.rels \u0004\u0001(\u0000\u0001\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000O0\u0018&\u000fK\u001b(*aA\u001c(\u001e<*J\t6\b2\",Ly~y1\u0018->:U\u0012\u001c\bT\u0019WE^&gW(r*FV%84\u001a\f@P\u001f6\u001b\u0017\u0005\u0017RTzo\u0004I\u001d\u0006TX\u0275\u0507\u0016lF\u000b 8\u0011[@\u001dhRd,O\u0006~gpJ{\"\b!;\u0018R[O\u0004F\u0015g03x\u001f\nv[!i*&Fi!i\u0015/\u0005\u0001VsS|28YlKqp%\u0005\u0006Vf!n*z\u0010\u0011%Vku\u001bc\u0012\tm^_btyQ\t~7pI]\tk't*j \u04a6\t{\u000f?\u0001\u0000\u0000\u0003\u0000PK\u0003\u0004\n\u0000\u0000\u0000\u0000\u0000\u0000\u0000!\u0000fY9h:\u0000\u0000:\u0000\u0000\u0016\u0000\u0000\u0000word/media/image1.jpeg\u0000\u0010JFIF\u0000\u0001\u0001\u0001\u0000`\u0000`\u0000\u0000\u0000C\u0000\u0003\u0002\u0002\u0003\u0002\u0002\u0003\u0003\u0003\u0003\u0004\u0003\u0003\u0004\u0005\b\u0005\u0005\u0004\u0004\u0005\n\u0007\u0007\u0006\b\f\n\f\f\u000b\n\u000b\u000b\r\u000e\u0012\u0010\r\u000e\u0011\u000e\u000b\u000b\u0010\u0016\u0010\u0011\u0013\u0014\u0015\u0015\u0015\f\u000f\u0017\u0018\u0016\u0014\u0018\u0012\u0014\u0015\u0014\u0000C\u0001\u0003\u0004\u0004\u0005\u0004\u0005\t\u0005\u0005\t\u0014\r\u000b\r\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0014\u0000\u0011\b\u0000\u0001E\u0003\u0001\"\u0000\u0002\u0011\u0001\u0003\u0011\u0001\u0000\u001f\u0000\u0000\u0001\u0005\u0001\u0001\u0001\u0001\u0001\u0001\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b\t\n\u000b\u0000\u0010\u0000\u0002\u0001\u0003\u0003\u0002\u0004\u0003\u0005\u0005\u0004\u0004\u0000\u0000\u0001}\u0001\u0002\u0003\u0000\u0004\u0011\u0005\u0012!1A\u0006\u0013Qa\u0007\"q\u00142\b#B\u0015R$3br\t\n\u0016\u0017\u0018\u0019\u001a%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz\u0000\u001f\u0001\u0000\u0003\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0000\u0000\u0000\u0000\u0000\u0000\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b\t\n\u000b\u0000\u0011\u0000\u0002\u0001\u0002\u0004\u0004\u0003\u0004\u0007\u0005\u0004\u0004\u0000\u0001\u0002w\u0000\u0001\u0002\u0003\u0011\u0004\u0005!1\u0006\u0012AQ\u0007aq\u0013\"2\b\u0014B\t#3R\u0015br\n\u0016$4%\u0017\u0018\u0019\u001a&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz\u0000\f\u0003\u0001\u0000\u0002\u0011\u0003\u0011\u0000?\u0000\u05ef'\u053f{'|_o'\u0000\u007fFxCz}K\u0000m\u0000M\u0000\u7d1f\u0463\u0000i?P@\u0013}\u007f'k\u0007\u010f\u0010|4f\u007f\u000ejRi\u0797' O\u007f\u001dQ@\u001fqYxsh7\u001bb\u05b4}\t\u007f\u0789\u0000\u001a.?\u001b|O=|G|e{V{GoA\tq-\u0000W@x_gx\u0017\u00007\u001d}esqK~e;\u0003\u05a4p|V }\u07c85\u007f]\n\u007f\"Oc^.\u04bc\u000bsY[\u001d>-+t\u0000t{\u0013mw.\u0000U\u0017k)W\u6644pT\u07c8>,P~-^d>_\\\u0014W)G\rK@YV<\u008a(3\n(2\t>\u0000\u0011\u001fJWz\u05dd\u03ffD|\u0007\u0000`;/\u0012\u87b5\u0015\u007f\r\u0018\u000e\u001d)i\u0007JZ(\u0000(\u0000(\u0000(\u0000(\u0000(\u0000(\u0000(\u0000(\u0000(\u0000(\u0000Z|C\u0000!K\u00006C\u0000!K\u0000|\u001d6\u001a\u000f\u06dd_X\u02b5|\u0000`W\u0016>%\u0017~W<\u001d\u007f)&X\u0000o\u0012\u001f_x\u001a\u0000z1|\u0013\u0017\u007fWY\u04e6M\u0012i7eO_\u0017\u0000~\u03cf?V^\u0011:\u001dt\b\u0017\u028bVF\u0000L\u0000U\u0002\u0000\u007f\u001a\u0000f\u0000\u0004_\u0007h\u02eda\u0003i\u07fd[t\u071fw\u007f\u01ac~\u0012>\u0005o'R\u0016\u076f\u0016K+\u0000}Ej\u0000\u00be6Oj)\u000f\u0011jOQi\u0000\u001ef?T\u001e|\u00043jz\u001f|SCN\".|[YJ7\u0017\u0000\fG::}_\rV{]B/\u0012*\u007f\f\u001b\u0000\u001fj:t=G:\uadd7)kio\u000f\u07d6Wm\u0000\u0002:n3@\u04f5[\uadb60[]\u007fiV%W\u007f?>?n,> \u0000+X\u03e4x\u007fM\ud77b7\u007f\u0000O\u001f\u007f\n\u001c=_\u0006.^EY\u007f#'\u0000\u0000:gjB\n<?,\u0296&\\\n(|\u000f#\u01df\u0011xwW:K*2DwJ\u007f~2cc\u007f\u0000\f\u001c,%:;c?z0WO\u3fc7\u001a-Y4\u0011[Aa^k[S~S>+UV\u0018<9g\n?a?g\">\u0003\u0000\u001dJOZH\u0000\u0007e\u0000R\u0013\u05bf\u0006y\u1fc5\u0001\u00e5- KPu\u0005\u0014Q@\u0005\u0014Q@\u0005\u0014Q@\u0005\u0014Q@\u0005\u0014Q@\u0005\u0014Q@\u0005\u0014Q@\u0005\u0014Q@\u0005\u0014Q@\u0005\u0014Q@\u0005\u0014Q@\u001f.]__\u0010\u007f\u001fuGPk{KHWs+=~x7\r\u0000\u0003\u03cbY_\u0010W\u00128[\u0000U\u0002\u007fY\u007fJ\t.Yx\u000bB7\u0015R^!\u0007\u00166\n_/5\u0000i\u07cand4hk]\u0016\u047f[\u00007o2>>~~5i7g2YCYE\u0000<\u007f&**(\u0002+o'W\u0017'}n\u000f\u001e8h\u001bfTu?\u007f\u001b\u007f\u001f\u000f_\u0000Vr5\u01af\u0019\u0018gOO|x\u007f\u0017O,\u0007Zom\u0015\u0011A\u0004K\f1.D]_<~_d_\u0007.n:uE\u007f&sx\u0000\u007ftQS\u0017V4\u001c\u061a>x4E\u0017A*\u007f;L%n~^}\u075f\u007fjF4og\u007f.G\u0003B\u0014\"~K\u0017^U$\u0015\u0000\nj_\u001c|s\u0016mJ\u007f\b\u001a|\u0013W\u00174\u0007E\ud685\u053bbO\u007f\u0000~\u0010;|\u0013\u001d-\u03de\u007f\u007f&4\nHUy|+]+\u001f\u0474Elb`E^kF|q\u001dkAbuh_7\u000b_zoIc\u0006X\u0527[m>'W\u0014Z\u007fP\u0006^\u000eu\u0000\b?\u0005m_\u0007q<\"}vi\n$>#C\u011a\ueae9\\y^J\u0013K\u066a\u0014W\ubb94!G\u0007r~~\u03ffD|\u0007\u0000`;/\u0012\u87b5\u007f\u001f\u0001\u0000\u000e\u0000Dz%~\u000b_?a\u007f\n\u0003JZA\u0496\n(\n(\n(\n(\n(\n(\n(\n(\n(\n(\n(<\u0017#\u07f2\u0007\u000b}\u000e\u0005VC\nH\udab2\udfd7\u012fFx/Y\u0006O\u0011i4\u0004:_koa,xN,\u0532?Wc6\u007f\u0007\u0012\u0000z/\u000f(b\rWzjO;'\u0003PO\u001f}7\u0006\u000f\nj\u001f!O \u139d>e\u0565_w\u0000\u0001_h:\u000e\u001aK,H--\u0014Q/UZ>\u0017\u04bc\u0013?A`{\b\u0016\u000b[Kt\u00141/5w\u038bg\u0017Z/\u023f$\u0016y\u007f$0i@\u03adXQ<O\u001d\f}Jm\u03a9>t<\u0000+M_/\u0012\u001av\u05d7\ue45b\u0000@Okc\rg\u0000n}nXV{&!?\u27d8fy!Kgg>uomk\u00047\u0017\fE\u0014+\u0000QW?\u0000\b\u0155<Ygnu\u0000}z\u0000=_;\u0000\u6e55,43\u0003\u0013\u007fd\u0000\u000f\u001e\u0017\"o\u0016>\u0000\u007fO7\u0000c_E\u04f1\u04bc\u000fomJ\u0017Ov/WW|\u0013R?Oi`h\u007fv'\u07f7\u01ff]S\u0015sf.7\u007f/\u0007\u0000{gk\u32b1\u007f\u007f>\u007fq}y;\\+K<vU\\\u0003\u001c\r\b\u04c9n3\u0013,]YUQE\u0015T\u065cp]qF\u000fu\u0012w\u0015~\u017d>\u039fu~o\u007f[\u05ffj_U\u001aWTt]\u001au\u000bws$|ZH?\u0007e\u0000R6\u0000=\u007f\u0235\u018fZ\u0000\u0159&\u0017\u0010>\u0012\u001f\u0097Z\u05c7<5ol{\u0019\u000f?\u053b/\u064fn@|<W\u00ba.n\u001b{R~_5\u001e7\u00007\u001f\u000f\u0000E5|K\u0000e/3.O[\fW:RbE.\u0633\u0000\u0549}YZ\u001amV^\\E\u001b<vmuk?\u001f<\u0013}\u000f_\u0003w\u0006\u0173s\u0015/\"\u0000k\u03ce\u007f\u0003|V4[\u001aM\u059azf\u0014M|Q\u0004gU\u071f7\u007f\u0007P\u0003\u0000g>#\u001f\u0011xz\u00edV[bYUotF\u076fXt\u000f\u06e5A3\\|gwv7QX\u0011}'f~z\u007f\u007fw\u0013\u0005\u010d3L\\}LS|q_\u001b}\u0000@\u001eE|\u01e5Q]*\u07cb/\u0005j>\u06e8|/\u0000A%E.\u001ftu*N\u001f\u000e<}o\u000eTT\u001e\u000fd\u0000`\u04b57Z\u0534W[\u0013F\u0000j>eix{w\u001f\r><;wVZ[?5\u053bYb^x|I\u00130\u0017kul[v\u0017lS;\u0011z>\u001es\u0000\nm17>\u001b?\u0011\u001fV\"!e\b^\u001f\u007f_:\u0006?j\u001f\u001c'Ow_\n\u001d>\u001f)\u0005_[Ke;'q-nFeI\u0656\u001f\u076c?Ov\u007fK}\u0015r\u0015L\ufd51~\u07dff\u03db\u0001\u0015\u00147/EM\u00025o\u0011[y\u0000t6=&\u0000e~z7>I4j?4yl,oo{\u00007k\u0003J+\u0647\u0000v\u000fVa<Q-^lH\u0016\u0000Uj\u0011Tq?;\u0687\u0017P\u5f7dT\t|R/+.\u0000\u0000f=+3\u0011xcO n\u007fk\u001a\ue9ea\u0000gi\u0000\u03fcRSmoT\u0001%y\u000f_|8\u058f\u0017~2fFktywmw>\u07fdV\u0007_\u0692\u017f\u00155/*|\t\u001e\u000f.w:Oo\u007fo\u0000=.\u0017o\u0015o\u0017\u007f4\u0000\u06dbDV>\u0005_&%#K*|g_\u0007\u05ff\u00039c\u00c7\u000bG\u001aO_L}3N\u0017\u0660#/\u0000{\rp\n_x0\u0000u\u000f\u0003-+:K*\u0000\u001e_\u0000(\u0000x>\n~_\u0012\u0000f_\u0011jx;V]\"KfDm\u0000{oF\u0000i\u0019k\u001b,~}7\\Ajl{%I\u0016kI\u007f\u0789o\n9C\u0000!K\u0000>\u0004\u0016\u0007\u0013;GW!yr7Mw\"\u0005?<\u0000\u0000V='}c\u0694\u001e\u0013\u043e\u001fx:\u0155|1a[HyD\u0000~~>6o|;\u0165u\u0011\u0000W?7\u09c6g\u0000\u001aO|3kY\u066en]\u007f{s?&?\u0000e\u0015i\fou^+\r6/6{[E>b)0\u0653\u000b\u0016w .\u0367\u06af\rQ\u007f_\u001c~5?\u001b_.3YE\u0000%_W\u0000h\u0003S?\u001fw]>\u0000=[y\u001d~d\u0015#l4*~\u0297\u0014Q_W\u07f2L<>/dM~7\u007fUYaK\u0003KT<|&\u0012.m~\u0000^<uK\u0013dV2\u007foe\u007fqj8R\bQv*R\u0000\u06b8\u05a9\u000b\u0007O\u0005O#^DD~V\u001f\u001a?n|R}\u001f\u045dv?/\u0004-}g|_\u0000_\u007f+Z\u05f7XZo$\u0000\u0000?/\u0395_e\u007f<?tl\u0000\u001d\u00000\n*\ue465j\u001e!\u001eg=\u07d46n\u007fuZW>'\\E\u0014Vu6c'\u0000$C\u0003\u0000)_\u0014\u0000(?\u001ao\u007f\u069f/|\\Kn}|;\u007fY\u0017Z[~\u0000!O\u0001\u007f\u852f?\u001cW\u0017K\u007f\u001aN=K\u000b\\\u0012\u072fgZ\n~\u0245\u0004\u000fUc\u15cbu}Be\ucd1b\u0000\u0016&?7E\u0012\u0007Zv\u0017tL\u0013eW\u0000\u001dz\u0000\u0019KX~#B?\u012d.UtMMml~eDVE6Y\u00008\u07f4\u001e'\u05fcAoz<f%K,\u075em\u0007P\u03ce_e~;\u0000\u000e\u0000H\u001ecL\u000f\u0000\u0000\u0000\u0477\u0015> \u0011\u0000\t?9\u001ej\u001e7LL=}nY<}n\u077f\u0108f|= ]_\u000f[\u000e}k\u0007{O_{@\u001e\u001b\u0000\u00044\u0000\u0015~\u00f0\u001a\u000bsW\u06a5\u057bb\u00005_5o\txC\u01ff%o\u0016p}4;/\u0000\u07fa\u007ff\u0017h[\u00de\u0015\u000f<>\u001dL\u055eTWo\u0552\u0004\u0000\u001eZ\u0000\u0000+aB_\u0016\u001e'WE[Uyj\u007f\u0001w\ud067?4^%\u0001}M%K\u0004Rl&G/W>'>\u0010j\r\u001e#K\u0467K[ozZ\u02ad?nE@~\r\u001a|=;Y\u0011g{i/ug/o-q_\u000b?c\u001f\u0002iW\u001e'_P\u001b&4\u0013m\u0017l.\u0000\r\u0000yU\u0000n56\u0000L\u051b\u0000\u001d\u0260>*c=\u000b7?cfm\u06f6I?\u03b5\u0010\u0000d#w\u0003\u01fa|Y\u000f<?#6\u0019,\u001d;wT_}w~%aoo:<K\u001am-\u07a1pEw*~4Ee\u0000e?>\bu\u007f_M\u001bOK\u000f?\u0002-V\u0016v^Dv/?\u0000[\u0017\u001fSmF\u001dc_\u0001\u0000Qu:-h5\u007f!<miZ\u000f\"\u0012bD\u0552\u0012\u0000UbIg{W\ucbe0~\u0437#\u013e%.cimb\u000bm\u0001\u001fWg6i\u0000+\u000f\u0015q_p/\u0015\u001f\u001b?fm\u0013J\u000fe\u001aw\tv\u0012NKD}t\u0000UZ\t>\u0011\u000f\u001cmew\u0014\u000b\u000bj>)|*%\u0014E\u0012\u0000\u0001eu\u001f\u061b*\u0366$Y\u001d#j$_\ucbdb,\u0609+?\u0001_\u00ed\u0003u=R\u0000:Xm<#F~\u051e\u0017FqxLoO*u\\E-\u0015E\u0014\u0000_R\u0006\u0007#\u001az;l^u\u0000\u001bg=_\u0018\u007f!-\u0007\u02eai<^\u05c9\u0000|Hn\u0000\u0000\u0015ux$\u07f2H\u05bcsM{U\u0016Zo5\u0000[-6P\u0007?\u5137\u0000P\u064d<:\u0012h|j\u037d\u007fV\u0000C\u0000e\u0000\u00157@O\u001b_j\u001e*\u0012_\u0011=A\u0000<-$H_V\u0007d/\u000f=\u0013\u000e\u0017\u0019%m!dX\u0016_e\u000f}\u001fLM--.5\u001bVXSc_^BY\u0000\u007f)\u0011w\u007f[\u0014\u0000QE\u0014\u0001Cz}K\u0000g\u0013sS_\u001f\u0006bg|Q\u001cW\"\u0000z\u001b\u007f\u007fkEiiwou\u0005YunUAvO\u001f\u0005_\u0005\u0000PhIYR$]V3\u007fkoZ_\u001e%}\u0007Fd/\u007f\u057f{\u007f\rx\u0007F\u0010\u001af]BT\u007f-\u007f\u000f\u0000A_\u001a\u0007xr|6yK\u007f\u08b4\u001f\u000fj^*\"}Vv\u0015[\u076b\ubfc6\u0000\u0003|\u0007:\\xk[ZFE\u0411]\u0015>_j\u033f?\u0333z\u0019|,30Y}\\lJ_o/%w\u001d)\u007f{c\u0000K\u0000L/>\u0000Gm\u0012E\u0012DU\u007f\u01d6S\u0015\u001e7\u001d_0j`TT`\u0000Qfkvu\u001e!\\Y\u063f\u0000\u057eHZ%9\u0011;*\u02d2\u000eR?9\u0000k\u0000?3j\u001c\u0019g\u03d7k\u007f\u007f9^!C;3ov\u0000j\u0007B\u0018L<)\uc7cfW<F\"u$})\u0002b]s\u0019\u007f>{\u007fK\u0000?\\okO\u0002|y\u0015\u0012k;{\u0014+\u0017]\u03bf3*F\u000b\u0017Mj}UogIC\u0004\u000b\u001b\u0000\u001eo\u001d|-Cx/\u0018K\u000b6e-\u05d5j\u0000\u078a${7\u007fp8z\u0018.p}(K\u250f:+*|\u0007-\u000f_\u0003qi0[^V\u001bXoh\u0000gr>\u0000|i~W\u0002~&G\u1d34=?Xgn\u0014zq/W\u0677W\u0000$C\u0003\u0000)_\u0001\u007f\u0002}o\u0013<4\t\b-\u0000\u05b5i\u001aW\u0000~%\u0000\u0015\u007f\u000b\b\u001fuY~\u0000\f4WD\u053cU]V\u0016\u0131&\u07f4L\ua38dw\"*W~\u02bf\u001dm?h\u03c1~\u001a-\u001a^]Ajv\u0000,/\"gO_Yk\u0000t'O\u064b\u027e{\u000b\r\u000f\u0017\u0006\u0017pq\u0000V\u0007Qx\u001f\u000b\u000f\u0015x\u0000D4]J+M\u000fO+U/7c4\u0012y~ong\u001d\u000f_U\u001a\\/d=\u0017Sk\n\u0014Ky/F~_Fa\u0013\\\u05c1o<\u0001-6%vgo6\u077e].\u0000w\u0003:+\u0000j\u000f~?\u0006YEyw=\u0016V6RQy\u04bfF37BXO\u0018A{\u000bx\u00bau74[+/tN*;\\J\u00157\u07fe\u0001W\u0313|j\u011f\u000f_\u000b|\t\u001e\u0018\u00166\u001a3]Kp-K?vsxc\u03c8%\u001a\u0000\u001b;\u001d\u001eo\b]-\u0014d$.-]$vnoYh\u0003\u8bca>.?\u001e4P|i\u001deTTA\u4e17X]%f]D]\u001b\u0000y\u052f?j'I\u001b*}*w_\u001dz?V?uj\u0000\u0000\u0001\u000fk_\u001e9\u0014\u001b\u07c1<O[\u0012h6\u0015\u019dh\ud957\udf7c\u000b+Q|+j/\u0017|+\u0007|[un-\u70ed\u02e8f {\u07b2\u0000(\u001a!\u0014;xWPx\u0000r}P\u0011YX9fkWuOfo~~V.YEtJ\u0005-\u5d3aK\u0014~\u001c\u0016<)Qi_\u00062\u0016Gd4=s\u007fhH\u001fb\u001foHe\u000b}v?\u000f\u007fh\u001aj/~\fxM#\u0003vS6]\u06ea+7<7@\u001ek>\u0002xB?\fx'H]#H\u0013\u04e1yeo3a\u0017J>&\u0000\u0010>\u0018~\u053f\u000e~\u001cj>\u001fkgEu;\u076cQ\u0000}v|0>\u001b-\u0019m\u0013\u001a.upKu\u0012I\u0014\u0016,^lo\u02a8~\u0000}!Ex\u00df\u0015x\u0000J\u057ckLI6Z\f6>'m&&wE+\u0017\"}yG\u0000h\u0019|ro\u0004x\r:hZ\u007f`{Ibw_6/V*\u0000\u0002~\u001e,\u0013x\u00ed7LKEuo\u01693E-\u061b}\u0013oC\u0010x\u053e\r=.{Yg{Ff}+o\u007f4[Z\u0000-~l\u0018I\u0006\u001f\u0013\u001am\u059f^%\n\r\u0012ZQnok?\u0018s\u014f\u0001|\u001c\u0785\u000fX]VN\u058a\r<\u04a4wD\u000f\u001bW|G,\u0018ln\"\u2cfb\u04bcC>x!s>'irD}\u0555R\u0000+1E\u0017&Ke[Q]K*Ww%<_kZ5\u001a\u007f\u0012[]\u06f6&u\u00cf\u001d\u0010y{\r\u0006+_\n3+O\u0785\u0013M,V\u007fy\u0001W+\u001ew\u016dO\r\u039b6~~v\u0012E\u0000\u0005\\\u058b\u0002\u00007a.+o[Ur\u0592EO%\u0629\u0000|5}\u000f\u0003XGF\u0689\u000ej\u0000}?\u00df\u00055=~+/'e-g\u000fn_%\u001acc(\u040e\u001e\u0012aW'_\u0013?\u081f\ng\u001d*\u007f\u0000t\u001bo\u0010\ub33eT&\u03fb\u007f\u0000W>'W|:\u00075\u02cd{UN[UOo~\u0006~>2\u053f??:yd]\u0695~\u039f\u0015|\u0011\u15b1X5kX-R)&o\u0735r.i:Py`}\u0003Ey\u01ffV\u059f\u0010|/yu<\u0014\u0016\u056buUwq\n\u000f\u0687\u06a7_\"tT9V)bzr\u0000k>7<u\u000b7TtV=k\u00147]\u0019Z4\r{JN\u0016V\u019f:u'\u001f\u5ae7)R\u001a&\u0015F9R?\u001c_~%M_3\u0011SOv\u03f2}_7w+O\u06775\u001f\u0018|J;\u000b[_4{_\u0000\u0000u\u007f\u0000\uea5e;hYJ$Jx?iR2h~'F$o+V\u0000k-}.+q\u0018^1>rEK\u000f?k)s\u001e\u0011Yz{\u0004\\\u05b2VIW|g_\u000fq;.5/\u000b^\u000b\u000e~\u05e4kq\u0016\u04b6\u0002.\u007f\u0003n\u0018b];*\u00005\u0541\u001a~\u039d)\\u=I\u001f4W\u8fab\u0007?\u001aZf\b]ckW\u0000\u0002Z\t|4\u001b.-O\u001e_tVIJ_\u0015Sj\u0000W+-y}\u0000#?\u0001\u007f\u892f<u]+\ud9b6\udc12\u001b\u0019~ 6SIvZ\u0000W\u007f\u000et\u001f\u0010]<5wcH\u0012-*_2|\u0019ai[MK\u0017\u00d7_yyp/\u0277~_\u0517<3C\u0011ADL+\u001dh_\u0010G\u0571g/|]Ik\u0000]m\u2be7\u0000\u093e\u001b<\u001f\u0000C\u04ad4lE\u0014W\u0000|\u0013D\u0016/JO\u0011Za\u0006\u0000-RWIZ/%\u0000,|K\u0005\u007f7z\u0017$+oyw?oy[n\u0000kmA\u017f7\u0000\u0007/\u0018\u0366gHt\u001bG\u028b_g\u0000Q|\u0000+?\u09bao,?e\ud97c\udfe15;_#\u00da=Vgf\u0012\u0000\u0007ix6\u0000\u007f<5z%uu|>MUb0\u000bPZ^hEo;_Ovb$Ip\"\u028e@\u001a?\u001b?\u000f\u0000\u000bt\u007f\u0006x>\u04e1\r*U`[\u5055\u0000u\u007f_!xk\u000bWt\u001e]\u0000G5`5eq`7\"\u0016\u001bzW?\u0000\fV'h\rT\u02f9e_/\u007f\u077a\u000b~\u0005Gocj C^YDy ke4\u0001_7\u007fmw>\u0001SJt\u0632\u02b6K\u0017K\u0017Ul\u000f\u0016xwp\u001f6\rW\u15ab.=\"Q/+]\u03f7\ueeb5}3o\u065f^(,5-/_\u0515bu\u000f\u000fk\\\u05c8\u0016\u007f\u029eo~\bx\u0003Fku{?\ti\u0012\u04bc\\\u0007o>QI\u2bc8\u007f\u0000~\"xv^\u001fu\u000f%\tb[g\u001a+{w<7\u017e1xS\u000f\u0015|M\u0675/\nxB[+U\"6}W\u000b}\u0633\u05c44K;J\u0017\u001ae\u0015E\u0004U\u0355z-\u001f\u0663w\u0000j\u001e\t,\u00075DwkptKiY\u0000\u047f\f5\u0003/ hrxwZO+2-W\u0002u(5*\u001f\u0019Z\\;M\f+Wx\u000f\b\u0013)M\u0007\u001aR@\u0000DWUj4/c\u1bc7i\u0000\t~\u05b2V\u076b&t\u0012oWO\u0000@\u001f>~\u0000\u066b:<1_W/\u0017Gy*K\u0006+[\u0014k.\u0000E/_DxXg\u000f\u001a\u007f_xg+V\u0016t\u0011\u007f'Y\u007ft;|\u3da91\u0006\u0015\u016d\u00a7Yug\u0000\u0007\u001fW\u0000t;.t\u03f6[&l\u03f9^J~\u035e\u0004<zS\ub697>(N^\u04dblA;\u001d{\u0017\u0014uou\u000f\u0007<5\u0001_\u0016o\u0211T*Y'e9\u001b> 56\\\u04eciZ\u0595w\u0015me(\u0003\u3bc4)\u046e\u001fTx\u001e\u001dZ/{Fbw-?u\u001fN\u007fT_\u0015?g\u000f\u000fiw~\u0017\u0005O\u05adW\u001bem,\u0277\u0000{\u00ef\u0013Mg}o}%l\r\u0000jyn.%\u0000J,Wx\u0010\u0013\u0019Ok\u00137u%\u017a\\\u001f'Tm\u0000\u000f@\u0019\u001b~\u021f\u001c#\u001cZ\\\u001a][\u071d\u001e\"{]Ve\u0aff.d\u0000R\u0010\u007f\rWz\u0000{T>\u0000\u0011E_cm?*(-\u0275\u0775_\t?c\u0000\u000359u?\u0006xB-6SOu=y^k\u0000\u0000\u000f\u0000c\u06d8-\u007fn\u06b6I#[)R\u0016o|\u0000]#;x\u000bzg>#xwKtwJ|\u0535Y|\u07fd\u0341\u077fmw\u0012\u001b\u01daE)MEu6~\u0015o*_\u007f>j|q;x\u001bz_w6\u001ak+\rSAn-\u0000k*7}\u00007/O|\u007f63`W@$3\u04a71u~[;6+\u0000|\u0017_K|?%rwwy\u447d\u064d\u0014\u0001xF}ke\u0000\u06bf\u000f\u001a\u007f\u000b\u0000[\u0000IZO\u0017[E}:\u0000\u06bfo\u0018\u0000\u00017#s;~\u0001|.\u0000\u001f\fY\u007f\u056f_-o\u0000\t\u0000\u0469_\n!k>\r5\u0016j\u0000o\t_?[(\u000b\u0000\u0013y\u0000R>W)\u007f\u00a5~\u001dkrI\u001a3||\u02fd_\u0001_n\u007fj&o\r|?\u007fo'yu6x/\u0007\u0000\u0013x\u001eM+\u001c[+C\u0015\u05a3J3J\u00007K\u0000~<\u007fC|\u0005\u0004\"\u0016\u0015\u0000P\u05ed\ue780<cr\u0000]\u0000cN\u0000qWm/\u0016?\r|\t\u000f\u0015M\u0000\u0012\u0012{K\u0012\u0016_\t\u007f:\u0092\u0013?b\u053f,/\u001fC~\u0002^\u0006f\u0000Nve\u007f\u007f\u0001\u0013oY\u007f\u0014Iw\\.\u0309L|\u0000U?\u0018\u0019xZ\r\u007f\u02ec\u0000}\u0013SwW\u07f07|\u0003\u001f\u0000\u001d\u001f>.\u07c7u-{Eu[{W~[k\u0000|W\u0000=1\u007f\u0092|!}G\u0567F\u029fGoR_)\u0000\u0014\u0001\u0016;_}G\u00bf\f\u02d9t\u0002NmWQ[w\u04bcQD\u0000\ucbd4k_O.<?\\L<5{)\u00daFY~o\u022d+79Ux~\u0007<e\u0000gj\u00124O?/M_\u000e[<#\u0000\tf\u0017f/w\u007f\u0017r=7rj\u0795}\u001f\\\u0016k\u0016k_e~o\u0000v+\u000b\u001dv:;\u001b\u02cb?\u000e>P\u03f5K,\u010b/||\u000f9uWZ-dwnvxT@W$co<Ok\u001b\\\u0016+.}}TR)/\u0779~\u00010\u04fe\u0004u-#wt\u007f\u00134Akj>G\u001e[H?j_\u0673.+\u001f\u06ac:DQ[V}k\\3~ryW_x?'7\u01ffK|\u000e\u011a|_:j\u001e\u0019KobO\u0000'wS|Me\u001c!\u053cChD5k|Yh\u001b\u0015\u0000~E\u000ewe\u0006\u007fM>\u0777v\u03f4E\u007f\u000f|#\u001f|Bc\u0015|Uo4O\u069cvEga\u0013\uce96/\u07f2\u0771\u007f\u0006\u07ff_\u007f\u9e84\u001ay\u0192\u0000V/'q\u0000c\u0015\u0003r+;\u0000-Sk?\b\u0017/\fx>nI\u001b\u0018v\u06f2GHw|h\u0003+_K\u2fcfbO^/\u0697\u0017j\u02e5j~\u0014R\u001as-\u016dDT\u007f]\u0000s7w\u0000\u001a?7\u00af\u0019|G+yw\u008c]LJo_\u007f\u0000\u001e\u0000\u001a\u0000\u0000\r?n\u0006|3\u007f\u0006O5G\u04fc;|\u07f3yg\u007fU\u001f\u001e{\u001f>\r|7/Qu_>#\u001d>t\u04ec?\u0015fWYU>m_>?\u0a7aTI\u001e\u0006X\u03e7Ok+`%'t_U\u0000\\\u0000/\u0017\u07c5ng|Z\u0017\u00f8o'\u000bDt\u007f\"'{kY|[nD\u007f+\u007f\u007f\u001c|Y\t\u001a\u019ad\u001e\"-*[kUEtbo\u007f9@\u001fF~\u001a\u001c\u0013x5}[HMTZSi7ZVJ\u001fg\u0789Z?L\u0000/\u001f\u0014\u007f:\u0000*\u0000\u0012\u0000\n*\u0000(\n(\n(\n(\n(\n(\n(?\u0011\u0000ooK\u01be\u0001\u007f\u0018xO\u00d7#Fy.ZXT\u07fbk\u0775~\u0000\u001e.\u001c\u007f\u00aez\u0019/oY_5gvyv7}\u07d6:^?4\u0001\u0000\u0004|o\u07cb\u001c\u03cc|7}\bx~-N/kwx\u0424Q7\u0377vf.\u001f,?\u00ef\u0015x\u01df\u000e\uf1b5z\u001b}2'}3Oco5>\u056fj(\u0003A<[%\u05abc75_\u0015x{Y\u04a5\u0731l'\u0016rWoeQ\u007f+\u0000f\u0015[7~-W\u0006\u00fa<\u067eKoOd(\u000f7\uf23ao\u03c7W\u05de\u0000M4gn\"Us3lg\u0000HLR^\b]\u0000?\u0002i\u001at5/v|\u07fdy~o\u0014\u0001\bEEO\u000ej:Wrh:\u0013;c?\u0017\u0000\u007f\u001b\u007fc\u007f\u0007>(\u0015\u04fc;Mh\r{In\r\u02b4K.\u067f~EE\u0000~N~\u0000\u05cf?k__\u000e>4h&'\b48\u0011z\u0006h\u001d\u0011E.\u03dbw?]6\u001f\f\u0000i\uf3ffu\u001d\u0006R\u0363J\uda99\udce9\u0014\u0179+\u0012d\u0017\u0001\u000f;?W|JmKRM7K/\u001aWNjDkVT\u0000k?(\t\u001f\u001d\u03c6z|\u019dG\u001a\u0014_A,_\u0576&;??_\u0000\u066bE\r\u06a4\u02e4z:K,\u000e\u007fb\u0016\u0000vgO\u061f7\nWuM#wk<I[\u001ejnV\n|\u001frT\u0001{i\u0015\u0117wPimhu\u010b\u0014Q/_\u001b\u001ao\n~\u007f}'J.u>,V%o\u028d_?o\u0011\u0000\u06ffE_\u001f\r\u0000}\u0015s\u007f\u0263B\u000f\u001d-tm\u0013N\u2e16O$\u0013\u067dsW\u039f\n\u031f\u0014\u000b=6x_}D\u05ee~KYo7g~e]_)>\u0012\u0000JM\u007f\n\u0000o)LYo>\bxE\u0017W\u05c9u{{\u0005[O\u0000<\u0777o\u0014\u000b\u03c7\u000b>.x_|\u008b8\u000f'\u0000\u0002D\u0000-s\u0000Ho\u0016k\u0000]\u2beb?lo5\u0000\u0005>\\7U\u00143ZOg\nS\u0000mU?uo\u0000l\u0016$\u0000=bA\u0003g~\u0006!|Gm\u007f\u001e>\u001e!\u007f\u01edV\u0016\u0000e\ue9ba*\u0000^\u0000)\u0000UqG'\u0000\u0017\u0000R\u0007_\u0007a\u000f\u007f\u0007/j>5e\u0554 *\u0017\u0000.\u0000\u000f~$~2\u04ae4\u0018\u0016\u0000\u8df6\u0000x\u0000\u03777/W\u0000H\u0000\u001f}J\u0000C\u001f/@\u0019\u001f\u0018i\u0000\u0004\u05a4]nH<\r(.S\u007ft\u007f]o\u0015X_?(\u0f1aG)\u0019U&Wye\u000f\u0000/J\u001b<<U\u0000_\u007f-@\u001fBQE\u0014\u0000QE\u0014\u0000QE\u0014\u0000QE\u0014\u0000QE\u0014\u0000QE\u0014\u0000QE\u0014\u0001PK\u0003\u0004\n\u0000\u0000\u0000\u0000\u0000\u0000\u0000!\u0000\u0301H^/\u0000\u0000^/\u0000\u0000\u0015\u0000\u0000\u0000word/media/image2.pngPNG\r\n\u001a\n\u0000\u0000\u0000\rIHDR\u0000\u0000\u0001\u0000\u0000\u0000\b\u0006\u0000\u0000\u0000-\u0000\u0000\u0003\u0000PLTE\u0000\u0000\u0000\u0000\u00003\u0000\u0000f\u0000\u0000\u0000\u0000\u0000\u0000\u0000+\u0000\u0000+3\u0000+f\u0000+\u0000+\u0000+\u0000U\u0000\u0000U3\u0000Uf\u0000U\u0000U\u0000U\u0000\u0000\u00003\u0000f\u0000\u0000\u0000\u0000\u0000\u00003\u0000f\u0000\u0000\u0000\u0000\u0000\u00003\u0000f\u0000\u0559\u0000\u0000\u0000\u0000\u00003\u0000f\u0000\u0000\u00003\u0000\u00003\u000033\u0000f3\u00003\u00003\u00003+\u00003+33+f3+3+3+3U\u00003U33Uf3U3U3U3\u0000333f3333\u0000333f3333\u0000333f3\u0559333\u0000333f333f\u0000\u0000f\u00003f\u0000ff\u0000f\u0000f\u0000f+\u0000f+3f+ff+f+f+fU\u0000fU3fUffUfUfUf\u0000f3ffffff\u0000f3ffffff\u0000f3fff\u0559fff\u0000f3fffff\u0000\u0000\u00003\u0000f\u0000\u0000\u0319\u0000+\u0000+3+f++\u0319+U\u0000U3UfUU\u0319U\u00003f\u0319\u00003f\u0319\u00003f\u0559\u0319\u00003f\u0319\u0000\u0000\u00003\u0000f\u0000\u0000\u0000+\u0000+3+f+++U\u0000U3UfUUU\u0300\u0000\u03003\u0300f\u0300\u0300\u0300\u032a\u0000\u032a3\u032af\u032a\u032a\u032a\u00003f\u0559\u00003f\u0000\u0000\u00003\u0000f\u0000\u0000\u0000+\u0000+3+f+++U\u0000U3UfUUU\u00003f\u00003f\u00003f\u0559\u00003f\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000(\u0000\u0000\u0000\u0006bKGD\u0000\u0000\u0000\u0000\u0000\u0000\tpHYs\u0000\u0000\u000e\u0000\u0000\u000e\u0001+\u000e\u001b\u0000\u0000 \u0000IDATxY:\u0014\u007f=\u001a=oq*:\u0004\u0018v\u000f\u0003S1oW(M\u0012\u0012Hh\r\u0010(@\b!\u5c5b\u0001\u0010B\bC!M\b!,\u0014\niB\b!dPH\u0013B\b!\u000bB\u0010B\bY(\u0014\u0484\u0010BB&\u0010B\u0016\n4!\u0010P~n\u0000'I\u0019hRI\u0236l{\u07fa%F\u001fXPHoj2\u00042\u001cE\u0012\u00102\u00067\u0018m|\f$I\u0014\u0010\u000b#D\u007f\t!>%SM!I\u0012ES8L7D ^\u0010BP\bJ\u0002`8 [\u0014\u0784mB!1tB#\u001e\\\u0018\u0011B@s7&\b\u0010\u06d9|,m|\u0019WM9=\u001agRbH\u001c\u000b&C!Mq\u0478l9r\u45f6\u055f\u001f\u000b_}Z1T}C~#cQBZ\u0002\nO\t@\u0000(nW\n$?J=y\u0004\u0010s3Kd}\u001671-\u001c}\u001co}\nsjR\u00152D\u0711M*\u0004$$\r^\u0002O\u0017\u0002o\u0013_mQ{=\u07fd_s='XBLj\u0002\\\u001bjRioH7\u0717\u0010\u0019\u0017#X6\u001a\u0014arM\u0014/-.\u0014fz\udab7\uddfeY^%\u07d5pD\u0015~w\u0015\u001c>>5\u0006\u001czs\u0018r\r7\u03bbq4\u00112Itwqx.TrT'Q<*k\u0002\u001a[P=+\u04e0VB\u00125S9V^X\u0014^C]h\u0014]\u000e.c5X\r\u00188v[um\u000b.\u0000ssmcuH<\n&Ur.TWJ+jB\u0010h\nn\bsk\u0005zz[kh56F\uecb5\u8f87yhuX\\7^6h{\u0010j\u0006F\u000bK\u001f>\u0001uCKG\u0014!]sW4x/\u0004[MjFYw]n\u0018\u0010SkRVcu\u8d8cyXR_,-d\u0004\r\u001c+nReJ\u0004\u057e.tu_\u0000_\u0000! \u000f\u0012\u0001K=\u0004A>W\u007fz]@<_3z]@`u?\u0003@~\u0012\u0010{{\u0014cca~\u03209I\b,u_\u0006\u020d\u00d0\u000b(\u0016=\u027a\b\u00128&P\u0665kEh\u0005Ja^R\u00007,j*^m&n\b&\u0006\t1\u000fMh!-R\u001d/\u0005JF@74gy\u000f'\u0001qH=2!\u00a6\u0011ntcL(swq*\u001aAZU\u001au_G[&:b]l\n\u007fK71/-ge&\u0015\n\u0006{_?T!E\u001b?\u0016qc]\u033d\u01ee%d)T&of>\u0015!\fD$)\u000f\u0002:t\u000f\u001fuV\ub8dd3\u001dguh+!fNI>\\R_n@^\u02b8$a\u0016s\u06f4+\u001e\u049f\u0792LO\b3\u0609g?deL\u0411K\u00156f=Yk_\u0620%m|s>)84[ i\u069e=\u001f\u07e4;R4FIiCfo{l\u001f\u001fC\u0018O\u019c/};.\\r\u000ey@X&\u039at'UcFO)\t8.C5\n\u06c3iTj0mzv!\u001e;\u0019\t\u0447\"p\u001eP~\u001fNBIU<^\u06ec\u001a\u0011b/_pe\u0011bR\u0018s1c2ZyuIm!=_k_\u0521p%&z)\\4W\u02edU$\u01044dRO3&:\u001chVgBu\u07df{\u000bwl}}p\b<4w\u0007kn:^:\u001bR@\fv}\r\u000f2X16m[=\u001fB,8X52\u001b\u0016\u007fW\tY\u0003\u051c\u000b`\u0524+PSv$&d\u000e,yv?,\u0019\u0006\u00050\nV((2E\"9\u007f\u000f\\m\u000f.nRi)C\"\u000b\u0014\u0404,v>n\u001b\u0019\u000e%n*h\t\u0014S /e\u0010-1\u0151t4(\u001f}e\u007f\u0005\u0004\u0018M\u070cL\u000f\u00162\u001fOGH\u0017\u001f\u0019d&X602=\u06e1!Bs\u001fJbRV\"dmHI\u001aBZV_\u0002Ze\u0704\u0010B\u0234\u0004%\u0010o\u0013|e\u0019O\f\u0016#\u0010B#o\u0013,N`\u04a8&\u0010B&-H\t\b\b&\u0010Bfn~e\u0015fQh\u0017!\u0010yv&X\n\u06ee\b!\u0001(\u0003*\u0013;SM\b!B)\u001fxiUv\u0012AS7!\u00102\u001b~\u0017\u0468!W\u0010B|$>-\u0359hB\b!d6v\u06beh\u001e@\u01adW\u0010B|\u001eJPS\u0012B\u0002OM2zv8?zE\b!\ufa0e##J>)7\u001a4!,\u0004yJ>>;PCx8Z5Vv@G\u001a-4!,\u000biL\u0013vv|u#M\bY\u001e\u016d\u043f\u001dL\u0167t\u0553+SB\u02327D|+\u0011HF\b!\u000b\t\u063dSG%P<\fn\u0000xL\u000eBd\u0011/nB\u0012I0\u0012J>>iJM\bY\u0010VM/e!\n\u0016kl\"e`\f\u001ac\u0001\u01747nBBf\u0015BAzA2%\u000f,T\u0019V\u049f&!~s\bp\t!^X\u0002\u00e8IofW\ne|VOFw$;g*;g.\u0019Kc\u0000`\nC~L%I$Q,\u06b8.f\u007f4\u0001ofC\u05f4i\u0012\u0004J!\u0002\u001fy&Q\\h9MhLw\u0007QX\u0118\u0690 Re\u02a1]/\u0441{\u0017\b\u0014k\t\u000e\u000eb\u000f\u0000{2\ru!d\u0005p\fpv=\u0001\u0004,j5[d\u001bGBxM\u001cw\u0018NZE\u023c\u0014\u007f]k8\b}x\nWd\u001aZs#h\u0002\u001aC\u0011=\bA-\u001bi\u04b1|6Pz.\u0014\u001a4*4\u0018]a\nXq+~:&\u0134@Mq\u0004-hrC\u0011\u001a\u06edX\u0005I\u0018\r~i\u00130tn o\u061a\u0004s\"\u036e\u0019(*Xul\u0013i\u03e8q38\u0014;RB K&2!\u03a74Kwt\b\nyN.d\u0018M\u0751|VS7\u071eCB\u032e+Tu\u0013V1\u0016LH\u0010 \u001bSOW\u00000OH'brDzfblOw\u0018@sw\u0018\u007f\u0015fI\"+\u00d4T$6ge\u0005vTKPo\u001b\nUkM2:BVE\u0456\u001a\u0000\u0018|I6\u000eb\u0005b(\u0017aZ4JVo\u0018/\u0006\u063dG3\u0018\u0000s*B\fGd\u0227T:\u0019mU?\u001a`d7\u0006-X`\u01b1\u001a(P\u0017\u025a0h[|>\b\u00010w`\u01b11\u057bea\u0000&\"\u0002-n}&[aO\u001a2|\u0013'\u035adM\u0018^E*\u0013Yl{_m\u00e2O\u0014\u075e\u0006\f\u0004&@\u0582\u0272\u00141K(&di|2uklW6f\u001a\u000bh$C\u0582%{5\t\u0011>\u001956O\u06b8SsE'M\u0519L\u0000#v\u0006=Qu\u0010`\u06a2b*G\u04b0Tr?l\u001fMD'-6'tCS[%k\u001fN/^l5tdCrw\u000baKb2L7[>J}dwR$\u83ce\u02a5\u0015\t-~jX\u001b]\u001a\f\u032cd\u07901y\n\u0007_3\u007fq+?7t0g\u0139^qw\u00031\u001d(\u0012?V\u07c6e\u0010\u0003\u0003UL\u0628I?*\u001e\u0012&!!{\u0017\u001fw\u06b6O5\u0017\u0002>U{^Tx\u0016\u0000\u0004I0s\u0016\u0007\u00018)]>FO)OT\u001e(\u000565iR/S\u0017Up~Rx8B=\n=\u0013IeR\u0005ts-\u001b\u0005P\u0016J| \u044dh[\\\u001d;q{A'XAo'cl4\u016d@q+Q\u001d\u000fGd[@\u0003@~'\u0001x>\u001as})\u0002Ea\u0437\u00ab_T$x8u?W'S'1zR\\+\u001a9N\u0012i\u0553FKPo\u000bcdH=T0\u00145R*q)\u0013'0\u0587P\n\u0666T\n{a-\u00183\"h)KQ]\u00112\njf~[\u0018=2tl$8tzJO\u000e6dvS!T\\\n\u0001_\u00194S7`6$b:\u001et\u02d0U\u04607\u007fW\u0017$\u0003\u0000\u0018\u0019M* \u0004u](QA:hn-^O\u001cvJ\u0001\u042f(5ogwq\u0017KHg~S7G\u079e%o9\u0010IVOz{Z4\u0000s\u0011\u0013lWj@k_PJ%I'$1\u0002pH\f!\u0011k\u0257\u001cJO(`\u0666IW\u0001f5!v\t\u001as\u0207pwTw\u001bI\u001e!\u0013\u0227T\u007fG!/\u0013)\u022b}\ub2d5\u0000cl\u0011I\\\u001f\u047f]+,\u0006\u03c8?Y\u001dM\u000e\u0001k\u0004e\u007f; \u001b\rz5\u00044z\u04ba\u0000/\u001a(\u062b]\u0014G=\u0383ZZ>dh~\t%\u0006\u0014fp*O\u001aM:a\u0017+mt6u\u007f&\u0005P>\u0017Ka\f4%$$-XUJ\u040d\u0006\u0001Ogw9V\"\u0010\u0764\u0487v`I03|fX,\u0013/\u0001:AlE$+ys\u0006\u001c\u0011\u000bB\u000b\tY\u001f\u001fsw'MMZ'h\\'\u049e}U$\u007f\u03ea\u001dDl]/\u0004tL\u007f\u0014:\u007ft\u0007pH\u0004o\u0013j\u02adh\u95aal\u0014 }Jdm\u0013!\u0012U\\\u0670%=1T\"V\nX\twO\u079fX\u0431\u0456\fHs\u001eX\u000f7iC)\n\udadd\udce95+6a\u0013>lhA\u07ccIdm\u0002 uoq\n/67M #u\u0011+\u0007fTIc>i\u001f\\=1Nn5iF\\7]\u0017\u000fC|\u0003\u007fK`\u0018c\u0019\u0018|Ji&Vm\u0013D\u001c\u0002t\u03cfjP4U\fJJH'\u001b'%\u4b6c'8k\u001bL\u0014Z\u8109CU@$Eo\u0006tkhsM*Q6W\u001e\u05f2V9G\u0007n\u000f\u001acC4i]2\u0017Bf\u0011/\\U\u0018F!P\u0013Ls8\b(uG;n\u0002\n\u001ahdmsh&_]\u000bnV\ufc99;L>YR\u001a\u0004p~\t`\b\u0001\u000bJ\u0587~C`!N\u0018-\u0012#MCo]|'M&\u001b8Di^.\u0006b/J{\u00135\u007f\u0005\u0012u'\u0014S\u00112x2\u0000z\u0014\u0017i\u0091>pY$AC\u01b6\u00109m\u04cfp\u0004\u079b`L\u001b\u001a\u001aal\u0012!|5>\r#T|\"z\u06e5b\u0012\u0002_=\u001f]_\u001fa&pmWo7%\\<M%Ghh\u0019\n\u0016+s-bK\u0011l16\t_\u051d_s \rf\u0564\u7303 N-w\u0634O4A\tJ{[Y4\"k%G7JI=Y\u0012D_e(iS\"mQK@\u0001]`fa\u001eR\u007f?&E{\u027aim'-/~\u000fezI9\u0003\u0016!\u0016@t\u072fwSy2e$OOi5X\u001c&4\rk\u000eX_\u00158\u0007-\u0000m_\u0007v \u001c7\u00d7\u001c\u01e6DI\u02e74_BV`Ec\u001b6O\\W\u0695i;O\u0003\u04e6M\u001a\u000f.\u0013J~1k\u02c0E\u0010D\\\u001d\u0010cEEs\u001cqkzLm\u0002\u0003\u0002z^jUW1wW)AI;W\u0002p\u079dL&L\u00010c\u0017{mA MR\u072d\u0278\u001d\u0326~5$N\bW[l{)PHt6lB\rn9SZ\u0006g\u001a`\u0019<1dI|\u0755\u00061tq)z5C)-%i\u0198\\&\u0014Su\u0006&Mn\u0002\u0016,f\\\u0000<.2\u0002\u04e2'?\u0005zo==V,W6\u000eeY\u0004<SK{h\u0553|}fnT\u04abm@\rw_r's\u001fIHbo\u07ff\u0013\u0006\u0004$\u001a\u0005\u0566hmNx{CsGM'urwO\u0474'yhr\u07c4dedZ3\u0014Tl\u0019\u0518;FS\u060b\u001d\u000b\u001a7\u001b [[PG;.\uda33\udcccoM&b\u046078>\u6271\u0000F\u0004t9\u0007k\u000eUe\u0012I{dj\bkfg`h\u0014OC\r l\u007fo\ud92b\udd09m+D]\u0006,PIC\u001c5i|\u0003L\u0019JO\u001az1w\u0003 \u0018<6fW737\u0433uu\u000ec~*\fBNh\u0011[6\u000eA\u0019\u03ebY\\\u0004}\u0013mWu-:v\u0018IJ\u06b1 @.Z>iQ\u0013$\n\u0000i\u000b\u00150t7j:s.\u0019\u000f\u00164(u]/tK\u001e{\u05a2MoHD;\u000e<\u0017i`\u0016\u0011:v\r\u0001\rl']a\\\u0007=\t\u0018\u04be+sKLL\u0004.\u04d3'miIs4F\u02db\u0013\u0004@Gp\u0006\u0001\u0016\u02cd\u000e6-\u0007>\u0007\u016dX(n\u0018\u0001xdOBt]\u001fGM\u0016g\u000bV\u0012tc\rn[L\u0017\u0007-\u0010L{,:\u0616\\Xd#`\f\u0011\u00138\u0007\u0001t\u0002QeKM\u001a@\u0017]\u007fX\u0003z?\u03bez)!gy\u0002\u0017AO\u3fe37i_O\u07a0&mR\u0015#S\u0001\bC@\u0013N\u0019\u000b]8\ue9ee0j\u047ff\u001d\u001f\u069dk2\u001b?sG\u001b o\u0012k\u0002_6\u0001}oK\nS\u01f4H\u001cQ\u0018,2tmk`\u001e|l\u0177\u0016@-U(!L&\b\u0015e4m2\u05fcu\u0003:>:\u001eS*\u0016mA\u001b\u001eW=\\\u001b`\n/dKq\u067eVt\tf8\u001bE0N\u0013}\u0003\u07a7\u0013U`Cl'm\\G\nF\u0000Mq\u000fjTLr*U\u001aMX!jhV\u05d4tE>eoQc{`Y$iQG\u05a6=@&0i\u0005Ac-u\u000b?mf=C,I]e\u06a4=Se#E466c\nBS\u0015 \r\"\u0014yl\fw8\nQ>c{\u0006\r\u0000c\u06e6\u0015<\u000fI^>_Mm\u0106`tX\u01fan6-^s\u00018X\b\u0452^\n\\6M/RJaK\u0007\u0000>ID\u07b9\u0016\u0000ktM[\u03d1_ru\u0005$ \u02efJ\u001c\u019f\\\u001a\u0003>;@\u076f0C_tnKLiLM4u\u01b7o\u0000(x\u001d{xld\u001c{W\u0012'\r\u000e;\u0006\u0010J$!\u07f1s\u001d\u0017Ktw\u0019K\u007fh6\u0147l0?:_\u02d2!fQt-\u03c2IKM[h\uaa4f-cm3\u0007\u001aU'\u001f!mcO\uf359\u0001Kw\u0019\\\u0018sw\u007fY:\tP42K\u0019-f';w\u0017\u0019\u03d9\t\u02b4Wz\u001c!\u0434*nV@\u0003\u000e\u0002J\u0010\r2-$uR\u001ba\u0007|\u0017lesE6NzK3)U8|N/4<L>\u0013#vM}6\u04e0K[m&5M\u0016'\u000f+~4Cg~\u07151q}\u03f6=M}\u001f67s\u0013_\\%\u000f7\u001cg\u0007\u000fI\u0004}\u04ba6d\u0011t\u00077i\u0012\u0004z(gi\u00058oE\u001fEX_Rv!\u0016b]C\u0016K\u07b8^?S\u0019<u'xlR\n8McW:\u0001VIO\u0018\r\u0012j\u0013cS\u0006@mM_0X\u000bjow a*\u000eB\u9791!\u0002?!,Wwe\u0006n*U.TSI!\u0016#\u001e<L}h7I+\n4VBatu\u001a\u0013\u001cb2tN(fWAw\u0005MZK{\u001e\u05b1`h\u000bp1e:\u0010\u02cev;ccs\u001ee\u001f\u001fM\rk>i\u032bgZ\u0002c4Y\u0013\u0019!BL.xH\u0267>T\u0018M#L\u1e80{\u001dCL!\u0011\u001d>c$V\t\u000f\u001ec\u000eu#lNN}9\u0013z2\tXWwa-\u000e\u00b8PpY\rjirt\u0005=\u6c56f\uebb4mO\u001e^&A\u07c9GPts_}.oCk\u0015\u0018_CS`#\u0080\u0007\u00073i\u000eC\u075ehCtnyl\u001aOLY\u07e6.\u0016^!4\u007fmk\u00161ZyqWBNg\u0016cG^rUT\u0015n5\u0000\u001eus$I}q\u0010w\u000f?s&\u001ftY;I$\u065f>Rj\u0654c&cz8VT\u0010\"tW/(\u0012NR\ub91d4\u051f~\u001bCKM\u0012|`aa\ub213Ht\u0005\ua057vYW'1rDi(nE~8\b\u4fdfS+|\u000b\u0016-KgN\\\u0002[sn\u05136\u0013\u0017rW\u0279\u0002\u001b]+\u0135h\u02a60<%4yGK@O[lb4avbk?\ucb92\u055e\u058c\u0256\u0010\u0013\u001fsw'\u076aE\b\"Qe+t}\u001aM\u001b&\r\u0007!&*+znB\\G(\u001bk'\u001bb<.$tt|\u0019\u007fEM\b1Q\u070a\u0018o\u00109\u0012Bz6,\u0006\u0011B=XLg(Z#]\u001f)nA'\u001b-S75iBLd!hf\u0017&4w\t4\u001eiB>%\t \f\u0016%)\n\u05b8ei\u0452]2ln\u0013\u96ebZB\u0014`OQ<\f\u04c6/\u0012 i#C'-\u0018B\u0005yki\u047ff-Z>2f\u06b20lO\b1P-&\u001ek\u0000\u0000\u000bIDATV3hF_Al\u001fm\u0424&Kk\u000bV\u54e66m\u0626E\u0003-\u0001V<B::\u06ed\u001a\u06f0\b!\u0015} \u0444\u0010/>*%\u001e>iB}\u0466\ni\u0015_f\u000biS\u0005\t1wW\u001a4}\u0484th\u0001{6\u0005a\ub42f\u0011\"1qC\bY\u0001z\u04a0O\u0016(mkM*Z\u0001\r!]v\u001da\u07444h\u00173u\u0017OCX\u000en\u0013e\u0460\u0520\t\u000e\u0018S+\u07dc\u000b\u0006\u0011Fm4ji&\u0004V\u0002\u0000\u001c\u031f7vO4}\u0484thEMP\u0013Bt\u0001`ze:Zt\u001d]\nP-k\bh>iBj63V\u0006h\u001d:M& d|`U)AYO\u0010\u0000@&[JS1j]L\u000b\u0017rBIS&D_6%(nv\u0015h=$\u0012]\u0014\u001aR\"\u001bl\u0018]l!\u0017-NZ' R I\u00123%mYd\u06f4\nl\b\t\tdi~ p){PW\f.n\u0005Xi\u0553\u0006}\u0484T8h\u0017}\u0002\u0689=[ML\u001c\u0004R\t\udb31\udced8I3w7!\u0000t}K|Ju<\u001f;\t\u001dbFEzkE\u000e!/~>\u00b8\n\"$l d\u0013h4V\u0000\u007fP\u0002\u0002\u0665\u0016\u0007A2'3U\u051e\tS\n\u0002MZ\u0002`T*6$Kuy\u0002:\f\u0014\u04044i1z!B/m_h%\u0121['MH>A}\u007f\u0711\u0014\u0404(4+?\u0570\u000e4w\u0013\u0002\u0005*.\u0005$$C\nDL\bOg\u0015a\u0011AE_A\b\u0018\u001fsw\u0012t\u000fP@\u0013B\b!8Vi/..!\u0010BaW\nZ[P\u0013B\b!dNv8e&\u0010Be'\u0002mXH\u0013B\b!K`%4\u0525\t!Y\u04a4Gw?K\u0013B\b!s\u0013{$u_4\u067b:!\u00102\u0017-Xd&'M\b!\u000e\u0000\u0003\u00056^%\u001b\u0484\u0010B\\\u0000@'\u001b@\u0015M\u0011M\b!G)\u000fM\r\u0016I4!\u00102\u0017/M\u001a\u0000>jJf\u001f#\u0010Bf\u177b;=x\u0017(Mmf\u0011B\b!-!}\u0017x'\u0005V,B\b!d6>BzD4xob7!\u00102=\u007f\u0001d\u0000c\u00126M\b!LJCH~i>VM\u001fM\u0013B\b!\u0524\")\u0013&\u001d\u0010B\b]6_3j\u04c4\u0010BdtMs*\"\u001c\u0526\t!H_\u07856o\u0000x\u0002U \u074bdf\u0012B\b!\u06e3IW&S/\u0012\tj\u0504\u0010BHD4\u0000\u001c\u03c5\u00006]\u0002\u00005%$*F+]mk\u000fk\r=}w!\u001bm,yL\u000e=\u007fv:\u007f:!Y?\u02f9x>xI\u0003@zzU\u01aab|s\u0011G$Q}\u0310\u775b1}R}[n8&\u0378K,,\u001eNENhi\u049f\bo\tt\u0007\u0358\tn.\r\u07f6~~}2\u0004I;S}\u0002zk.\u0005x.\u0004\u001aB\u007f?\u0005\t1\u000fl\u0005_3P]{.X56D6G\fm\u000fS_N1\u0010cgcpg)~C=s?Cs`\u0564+4\u0011\u0000K(|qG9QJ%{>\u02f9C|c\u052as\u0013~#1\u01a4Ss>&a;\u0014'!\r\u00005W\u022a\r}>^$(aj{\u3049)-M2SI_!1}\u0017k>\u00187s-rb-\u05c2\u0016@r\u0010p\tlH\u001cLx\u0012\u0426e\u001fb>\u0011:\u0007[\f0\u0558\fy\r\u001fk-u\u0015\u04fcc8\u000biF_f YzwOx.\u0014u|\u0015\nzjB\u0013c2o^}B@\u007fw\r8\u0005\u0005\u0000\t\u0014\u0000\u01bf/M[\u001c\u0004\u04bd@z~PL\b\u0018>_3w>q9bs\b1I|H\u0013c\f\f3!y|\u001d2ngh\u000e\u0006\tw7\u0722\u0010{I =\u0010{|M\u0003q.!\u001dcR\ry\u0011\u03eeYH/yr5&c+9(a\u0006&UW4eL@B\u001cR4_1]H\u03e9[w\fcL1Iiw8\u000eC0ZH\u0003@q*>j4\u8da0h@z\u0000\u0004PHsn\u0015\nq1|\u0763rPBaBo!\u0012.2\u000eC\u0013DHWd\u007f*\u001eh$:]\u0013}\u0002\u02942=l\u007f)!k\u04728$bwL\u001c}BE!&\u000f9\u0012&\u01fe\u0016c\u001cnIH5\u001a{!s)\t*\u0001@>*n\u0012\r\u85ba\t\u001af7?U,FH^ol\u9684\u0010{\u0012s\u03964\u0010w\u001c\u0014;\u000e\u0003\u000e1\f\u0341\u0016,\u0017^$o\u072f\u050b\tO\ua7ea\u000b\u0017u!^}F'Q{^<\u011c,a\u0003\u0015b}\u0013j\u0012!]to3\u00123K+6t\u060b~5\u001a\u46fa6\r4\u001346\nYK\r~\u00020\u0687\u07ccN\u0018r!Gk%0T{\u001c7\n\u0018}\u0318s)&+*ay>\u05cf\u0017$(\r\u001a\u0001g >\u07866NW}P}\u001e\u00f5gu\u000e\u001dk\u0012G}Ln1jZ~\u000bK{\u0016*8$JS/M'7hib\u0016t[%D#Y9Q\u0017t/AN_ZUj\u0016oSG\u0016\u000f}_e\rxG=\\4?$bhk'e|\nKwC\u0017Z@\u0227TEJ\u0000Ud7PF{K\u0000\u0001\u0003=\u0016(\u00e1f@/ \u001e<7\u0018ss\u05ef]}S~7^?WeHX\u7319p!yb\u0005y\u000bVs1&CNS\u07cf\u0019x534+@(\u0016#;1\u0004s9<\u0014q\u001dcL\u001b})\u0016\u0014dRs7\tO\u0007[}o:;c1\u0019z\u001c\u0004\u0000~n\u0000G)\u001f$15\tN\u0215\u0016z1z\r\u000e\u07ffF\u072fo\\\u00065~(|Vm\u04bdr5?>[;|c1\u001cR?\u0015<\u00172%9\u007f\u0220%<x!\u001dNI\u0779c1\u06b4]\u0586X~5gBz\u0558LlCBk{Ie\u0303=O\\/!&RRkR\fb?ca.h^9C(|g?'\u0018}2kfIc\u059e}`Kc\u0185\u00075/\u001aV}_\u00034.}~\td\u0012@q\t!Bs7!\u0010P(\t!B!M\b!,\u0014\niB\b!dPH\u0013B\b!\u000bB\u0010B\bY(\u0014\u0484\u0010BB&\u0010B\u0016\nJ\u0005`{N\u0019\u0000\u0000\u0000\u0000IENDB`PK\u0003\u0004\n\u0000\u0000\u0000\u0000\u0000\u0000\u0000!\u0000j &2\u0000\u0000&2\u0000\u0000\u0015\u0000\u0000\u0000word/media/image3.pngPNG\r\n\u001a\n\u0000\u0000\u0000\rIHDR\u0000\u0000\u0001\u0000\u0000\u0000\b\u0006\u0000\u0000\u0000\u063d\u0000\u0000\u0003\u0000PLTE\u0000\u0000\u0000\u0000\u00003\u0000\u0000f\u0000\u0000\u0000\u0000\u0000\u0000\u0000+\u0000\u0000+3\u0000+f\u0000+\u0000+\u0000+\u0000U\u0000\u0000U3\u0000Uf\u0000U\u0000U\u0000U\u0000\u0000\u00003\u0000f\u0000\u0000\u0000\u0000\u0000\u00003\u0000f\u0000\u0000\u0000\u0000\u0000\u00003\u0000f\u0000\u0559\u0000\u0000\u0000\u0000\u00003\u0000f\u0000\u0000\u00003\u0000\u00003\u000033\u0000f3\u00003\u00003\u00003+\u00003+33+f3+3+3+3U\u00003U33Uf3U3U3U3\u0000333f3333\u0000333f3333\u0000333f3\u0559333\u0000333f333f\u0000\u0000f\u00003f\u0000ff\u0000f\u0000f\u0000f+\u0000f+3f+ff+f+f+fU\u0000fU3fUffUfUfUf\u0000f3ffffff\u0000f3ffffff\u0000f3fff\u0559fff\u0000f3fffff\u0000\u0000\u00003\u0000f\u0000\u0000\u0319\u0000+\u0000+3+f++\u0319+U\u0000U3UfUU\u0319U\u00003f\u0319\u00003f\u0319\u00003f\u0559\u0319\u00003f\u0319\u0000\u0000\u00003\u0000f\u0000\u0000\u0000+\u0000+3+f+++U\u0000U3UfUUU\u0300\u0000\u03003\u0300f\u0300\u0300\u0300\u032a\u0000\u032a3\u032af\u032a\u032a\u032a\u00003f\u0559\u00003f\u0000\u0000\u00003\u0000f\u0000\u0000\u0000+\u0000+3+f+++U\u0000U3UfUUU\u00003f\u00003f\u00003f\u0559\u00003f\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000(\u0000\u0000\u0000\u0006bKGD\u0000\u0000\u0000\u0000\u0000\u0000\tpHYs\u0000\u0000\u000e\u0000\u0000\u000e\u0001+\u000e\u001b\u0000\u0000 \u0000IDATx[,\u0013\u02ec=#SId\u0018:d*O\u007f!\u001e(\u0005\u0005>k\u001d P\t\u0012\u0014m$\uc5e6J\\eL\u000b\u000f->\u0018\r,\u0005\u0000a\u0007\r\f\u0014\f\u0001\u0000&\u001c.\u0000X%[oI(9\u0000\u0003x@8\u18beP\u0000\u0000\u001d0S\bSfPN\b$I`B]\u0006W\u007fs\u0004/\u0005\u0000\u0004NPJ%\u0018\u0005\u0569K!\r\u0000m wN@@8\u0003\u0013 \u0000\t0S\u0003k\u0184\u0012\"M6$1\u0019S\u037d9\u001d\u036d3mu\\1\\!\u06c2\u9f41? 1&\u001aT\u001eS<4!S\u007f\u055dzG\u0456B\u0545\r\r.Q\tcI#H\u0010Y=\f\"wJT\u001f$\u0004\u001c3 3\u07b1\f^k\u000e6\u0018\u0016\u000bg\u067e{\u000ez3c+`d\u0015TC$I|\u0012Q\u0012}D'\tj\u0004Q\u0012}{%\u008e<~\u03b5GNH\u0583\\\f^\u0002Lj)K/\u0017\u0017\u0019\u0010c\u0005.\u0017e\u055e!#f\\\nJm\u000b\u06e3(V-QF\u007fl]W\u000b2\u0010\u001b6r\n\b\u001b\u001f\u0016\u0003ev=\u0219\u059dz3y\u0006-}n\u001d-~`?\u0004.RJ\ue48a7\u0116 &F }j\r(kV\u000b\uc589Zv}#[\u7a2du\u0011`\u001btTsu_W,v}UW6l>\u0004;_kei\u01de?<\u0007,\u01eb0\u039eR%Be\u0014IZ\u0012vD]\u0001\u0016\u001da\u063bu\u0011\u05b5:Zyc^\u001bV<iF{>w\u0001ds]\b\u5634}E4-ZL\tls-\u0017/\u00b8pq/\u007fh|-\u0001\bI\u001a\u6c6fMnQ\u0003=\u05ea\u01274Dh\u001a\u001c,~Pv]%\u007f%b\u0002i\u0000W*{\u0582%ma\\[?\u0014'\"~\u0012x\u000b'IM$OX{\u000b\u0012'\\yA-5\u07a7>/H\u0412~\u0013\u0011\u0017A8\u001eQ\u001d\"k3\u01ae\u0019<f\u0000/_ei:t9\u0001Y\u068e|?e1\u00117#\u0007q$K~Hed[$F-/\u0014J-%\"1\u0019IEg55M\f\u001b\u0001`\u001d~z,\u0016#VPin\b&L\u0000>\u0012\u0017AZ\b_\u0000\u0158\u0006\u0007\r,\u000fp\"3u*K,J\u0000h@\u000f3Vw3t%Wd4\u001c[Y,Lgf\u000bIQ7)=_Y\nUMgs\u0001T\u001b\u0012{+fQkHJRO\burS?\u001c-\u05872c>\\.\u0017\u0019\u0012\u001fu\u0018S].]\u0002;Z(\u0658u\u0013Qz^\u0011\u01c5y\u00003g6c\u0010Yd\u024aI#c\u0015c-5du1\u0006\u0004~\u0019.UIU\"\tt\u0000jl|c\u05f8Z4*yI\u0019\\}7\u0019=js\u05b5m0}=`\".\u019aqv\u044aKJi]\u001aX\u0007\u001c<j$=\u03bd}{;E\u001dj\u01f1\u0545+!:e\r@.F\u00b8xJU\u000ee\u01348\no\u04cbUp<c\u027d\u0018tb2T\u0016\u001b|E\u001b\bQ0i\u001f\u05e2DO)K\r!q1\u001c}hK.L\u0733>D~&kX>f\"M>0SC|k/S+\u0004Pj&\u03b9}M=Y\u0017,K\u001d}cZX\u001c|'w\n1\u0019\u06d8i\u001a-\u0000M=X\u0378xV\u0001[\u0000K?\bb\u0000 I\u02ad\u0018'\u0005 MXa=[\u000ew\u0003\"j\u001a(0\u0011\u0018\u007f\u0007L~\u00170.Ri%IQP\u000eA\f@Tv|.6\u050a `>aJ\u0006\u00003\fl\u000f`\u0019gL\u000e1\u0013$\b\u0000\u0352Hpe\u0001;\fq~i6~h/u_\u0003\u0000\u0016W}\u001e\u001da\u000bUj-\u007fqG~I\u0012\u0000\u0011{\u63b5\b\u001f:X\u0013WXw-DO\u0003\u0000\u0000\u0000~h$*\u0017 \u0458eV~A\u0016\u0000\u0000\u00000~oVG!W\f\u0000\u0000\u0000x\u0011\u01732Ow$\u0012$4\u0000\u0000\u0000Ze\u0582E+^\\\u0000\u0000\u0000n8\u0010iV\u072aSH \t\u0000\u0000\u0000\u0301@4DPW:2L\u0000\u0000\u0000WJaJ\u001bW*\u00110Q\u0003\u0000\u0000\u0000)q\u0019DTM\u0004\u0000\u0000\u0000 7z\t_\f@\u0007]tz-w\u0000\u0000XWL\u000eBJ\u0013\u0000]O\u007fv\b\u0002\u0019)h\u000f\u007f\u0007A+|\u0016L\u0015+\u2225D\u007f\u0005ys3\u000fNX)\ue16aM/(?ROBB\u0007\u0013\u0011\ub759!,{[=q#\u001f9\b0HJP\u0018\u04fb\u001c1\u928bp)N\u001f\trv{3h\u0013|RK+\u0011#sW\u0010Wd\f\u001f@5\tx\u0016\u0003ALT\t\ubc0f.~\u07bdPm\u001f)\u0007\u0016\u001c\u001cc\r\u016d~gl]3\u001f\ta\u07afVc\u0006 ?R\tJ ;Yo\u0012^.#\fK\t0\u042cG\u001cc\u001bGYL~3 ^F'\\98-l_\u0005\u000fh~\u075a>b\u06b1M\u0006\t\u0010'9a8\u0006*\b\u0138?:r\u001de\u03e1\u0016\u0000X`\u02e1Iej;\u001bFQ>RA>\u0001\u040c\u024fTx\u0001q\u001aqhG6iMO0I#P\u001a\u000b\u000f\u040c@\u0015\u001e/\u001d3]\u000f\u0015\u0000F4\u0015@^7A\u0000h\u01ab\u6ddcE$B-:\u00135\u001c>cja6Ag\u0012\u001fF\u0019I\u0264 &f2G4\u04c9(+uiG?7Qc\u000438|0:)NC0:\n?\u0013R\u001d\u02a4\b\u0014W<\u000bsaJ.8\u0002\u001cz;F4(6C\u000ffX.q\u0018Eb\u001a\u00b6\u000f\u0013'dYL\u0018\ub019|kq#\u04688&;\u007f/eU\u00071^\u0005j\u0019:\u0013\u39dfn&0\u0261\u0014\u007f\u0010M=Ev\u001a\u000f\u0690=BG\u0006_L]Y\f&}P\u001d]IK&ih\u0007`.\u0016hLcdlY8-_\u0017|\u001b#<Ve/$(\u007f\u0678L\rr\u0007nA(\u0089f/q\u0014`c\u0019pO\\\u0213-\r/\u0000\u00137Y\u000e3{A\u001b>6\u001b{ %,\u0016q\u001dE\u0623\u07c3Mh\u0010\u0005\u001at\u007fDYew;\u0400\u0012#a\u0010\u000e\b<i(mLc\u0001\ruN\u0016\u001aV\u001bnQ5V\u001alDoRa#\u0005\ub8cb\u000eZLN\f~C'\u001bC3\u001eCM\u04cbgl\u0017\u001aPb\u0019#h',\u000eZr-*\u0002\u000e4&\u06a4[8f\u0010Y4\u001d_\u04a0p&`LN9\u049a\u0012\u000e\u0740-\u06a4E,Q\u03a7[h\u000f44wpZ/\bdPt&\u0016\u000b\n\\7f)tG42\u001cJ08+U\u04091\"\u0007\u000eCh>E\u0004{Hb%R*A>[8K;\u0010#\u00150\u0018vfa\u0002K7X\u001a\u000e\\H~\te'%UelCz\u0018\u000b\fi\u0003LR[(6[D0S\u007f\u0006hR\bbELx'&jb\n\n\u06f5I\u00042 3\u0015p>HS\u0004^k\b1X\u0321#kS\u0007\\\tSO]wF:K8b?\b\u0016rh~\udaec\udfc8)\uef06\u0014(  \u06a5\u000e\u0597A8\u001c& \u0002m`!&\n\\=tf5\u0004\u0002t8\r\u0018q\u0018U\u0002x\u0002\r\u001c\u0006\u0017+p5h[\u0010\u01bf\f\u0017#NBo&E?\t.2bU6\u0000l9t+3\u0018\u04500\u0003a\u0000-Vy2\bkGQ6X7gL\u0014L\u001cg,HH\u7d80y?#U\fV\u0011\u0013ur\u0002`k7M\u000f\u001c,\u0002\u0002\u0001@k1\u0011u\u00048\u0015M\"vg,?R|\u0018|\u007f\u001b5h>\u0408\u00a0\u000eV\r\u049aO\u0001\\\u001f*M;n`ZTd\u001bC\u0000[$iM,\u007f\u001d\u0012+=>\u0007pAg,\u0430\u001bbyV\u078aa=E0\u0016>\u000e\u0003ZkS\u000b+f14<\rIpAS\u0000\u001a&\u077di\u0003\u020e=0Q8c/u\"\u0684gt?VX\u001bCl1W\u0005\u0006iL;Oo[D\u0012)y\u03e8~_\u0004\u000bo:H.\b_\u00b84f5\u0001v\u0014\u03e2|~L\u027fr.QGR\u0010,~*/\n#(v\u0010.ZZK&ELV*6x\u0013u\u0015$I A#\u000fV\u0173P5\u0011)\u0348fZ#\u07b98~l\u022ed\u05cc\bKi\u0019\u05b5\u001dZB@\u02ad\u024fT\u04d9gA)x\u0016t\u001cdL\u001f\u0015\u0015\u017dDi>cv&A3\n'\\9Z\u0006#\u00146&v,\u0012nM\u001bC'\f[RvV\u0013#0\u0010;^:VX~:_3]|=\u007fg5h=30\u000bTfe\u0001D\u0014V\u0001\u000b[\u0005\u0227T7. b@#\u0798%1f%\"\u0011\u001bp\f*{G4\u0011\u0011}ox\u0016j/&\u001aO\u001bZ|?x\u0016~cJF\u001ej\ud768gLij&^j\u0013B5fK[q\u0015:Ye\u05cc\u03a73\u001bT\u0007b\u04d6F\u0016\u007fO\u0017|=\uc6a9&\u0003\u0173PSc\u0006\u001d113\u0016-/Ff\u284b\u04815\u001fM,N;\u0015\u0017|:Sv]\u0012&g1#/\u0b653e\t\u02ae`&\u0013Au\u0017V\u001d $\u0264\u001b/F\u000e\u001dAL_q%\r\u02a7F]3@j\u0010\\\u001f4/s.n\u000bt~T.+.Y]-T\u0000kw^==\u039b;\u0526z)\u031d.\u06ffhH\u0005\u0465\u001d\u00174\u029c9W<\u000bib\u000bfD-?\u0335)r]0w|`=V}\u04e7R23^2\u05b5jL\u0019C3& xkoSN-?r kk(Q9&Ib\\n_y\u00191=oq\u0011eablY\u0016\u0000^[}\u001e\u0004\u07d2nbg\rZ9|I@X;J\u007f\u061a)g/K;g.\u05ff\u000e)L[\u0013' }lH[mW\u0017\u06ef\u0014\u0004rL\r%Q\u06258%okb3qv\u051cJ\u001f\u0012np>\u06b0&\u0735\\F\u0736\u000be\u0372&\u001cDoZ[\u039c\u00046~\u01b4K1BW*og\u026eM~}#lz\f\u001f\u0002AY3b\u0014\u0017\u001a80w;6Ar\u077e~+\"\nc\u8653\u0000\u0013A\u0015w\u0005g\ufd69\u06ec\u0019/0Ss\u0003\u03a6=Wq!mf)\u0003W\u000b0\f\"Km\u00057\uc2dc\u0006#B\u076b/?R*\u001d[\u0010\u001dB\u0012M;\"\u0599\u04d24\u0007V\u0398r:bK27zI|W9i\"Kk\tYt[Df<rk\u001ff\f\u001d:&<\u0014\u014eH\u0017d#35cl\u0006 F\u03b9NX\r\u001c1B%I\u000bJ/)h \u0015}\u0301~l)wT\u0013V\u0004v3d$5\u0016UL\u0002v\u0012\u014eh3f?N\u001bs2Al|`n\u0006>r7\u0014\u012fG4I\r>EfSfjI]yj\u0006\u00028\u0001L\u0013b\u001b@\u06c26r\"7lR\u001d+.}\u01acf\u0012z&\u0019(lVu\udb55\uddd4\u0004mgQ^\fm\tL\u038cxq/\u0014c\u0010B.aCx]9\u01ad\u6da0VHm*\u001fL\u01aap6>\u37595cL7 l>{jL\u0013ZdL\u0019,\u0006\u000f:T}\u03789\u001d\u0000r`\u0007\u0355rG\u0019,8wY~\u000eVA\u00178 >\t%l\u0014QIo}b~I>4c\u067c|N/X\u0001\u0015I\u0000$RgV\u0017<\u000eBjfs&\u04b1\u001cc\u007fd59q[t\rcQ\f\u0016\u0379|RG]\u0019sN\u0011\u0014\u0017i\u001c\u0016yV\ud9e5\udce0\u37a8\u0016d\r\tTuH\u0013\u079c7+n\u0005su\u05c8g[jc\u0013&_\u0017\u0013%?|\u000e3;LLk\\5S\u001a| \u001cvD3^:C\u001f\u02e61Lb~b\"}Li\u0007+\u02f6gG\u031aqeV\u001f]#\u0693\u0019b\u0012\n]_\u00192;I\u06cc\u00183)rN\u0019\rlpEP\u7dfc{BWG\u0011lE)?4&\"\u0496yD\u001dza${\u0019?\u0011\u001d\u001d\u0000o[cybT,>%\rju\u0559Kg2E\\Mq\u0018\b\u075dM\u035ac=p\r\b\u0007nm8ksm\u040clujy\u0015v~A\u001b\u001f\u001f\u0017oU\"I\u0007aabi\b\u0015\u0013-k\u007fZAlX\u0018c\u0011\u001c\u0006\u001aq\u0004Q!%9^lZ\u0776ch\u0018\u0007I<MTZI\u0004\u0016tN3\u0001jlP\ufb06\u001d)\tf<\nZ1\u0002\u0307\u001bh\u079a6\u001eEgLcfda\u0001\u0004\u0516%3U|\u007f*[D\t0\u0277\f4u%hGif\u0005X\u6e88sD\u00189t\u001aJAhh$\u000ef\u007f\u01advf3V*z>c\u0012;'%13\u001a@P+f\u001b\u02c5\u0019%\u007fS7^o(\u02e0\u0006-_\\D\n\bb!X\u001c\u001bSI\u000fXo\\\u0010\u031dXi\"q\u0011:\u0017cLk\u001fp\u001c:hw>c\u0018\u0006\u00051\u0017?\u0019?~\u0006N6\u0014jj<\u001dKk\u0010G\u0007NUYc0\u0006=]\u0010CcXb7\u0011.E_G*}vW[z\u0013\u0011K$\u001cYX\u001c[\\oMMm~:\\]h`1f\u001aV~d\u0003\u02f3\u0705|:S$lpA[yTLJ5;PM<\u0018\u0002Y\u0012\t&Ns7\u043c+N@p>\u000b)f\u05ec\u0493kcJe\u000b\u0010,|=\u001cL5\".SV?sr_?KhpUk>\u067b\u1bb7|zIG}=^N\u0424<cuR?.L\u000eq\u0012w\t\u001a~Ow\u001fzf\u0547\u03c3Njfz\u04cf9K\u06d7\u0011N]\u001d_&\u001aq\u0012NL7WK\b`NUzs3~~p\\<&\rW\\\u001a\u0340MJ\u001a=77?K7`\u0013\u0664Ea\u0006\u0011\u01f6\u073a\\W\u0010\u000f\u0017\u0013c\u001d~?6\u03e5`\u04beKqm\u001bgt\u020e-\u00066A\u0018\u0018;0P3h~y)}\u00033>\u0006~N{}][wn0+\u0018t=\u043f'V\f\u0018\u054eF}qd\u04a9\u04e0k#\u000e^~C0\r\u06a7z\u00b6[\\\u05cdic-[090jo-/\u044c\u06576S,9\u0017D\u0431\u05d8\u04f2\t\u02c1eh;T\u007fj\u000fcj5j\u0010M'|XQQ0B\u0560pQ.\u000e\u0005B&ck&\u001ee8S0I/i#kPAXzI\u0003X)Uk_xo\fj\u03a1-eg&\r\u001cmA$j`Qj\\\b\u000e4\u0005\u0002c3)\u000e`\u001e\u0010Lf3\t\u6703\u001bB5E2\u0016$,NM\u00137\u06a9irUWw?V,q=M%\u0007Va\u0000Wnq\u0004&=8\bL\u001aTc\u001cH%\u0003\u053b\u0004\u073a\rq3?3\u07bd8\tzf\u0013\u0010\u018cJ0*\u0003RC^M(4Xe\u001a\u04e0=n\u0016'5L,z-\u060fQ\u04fbv9\f:LRi#\u0012F:\u0012kD`\u001bY\b{\u0018`tt\u000f\u0019lj`\u000et#u\u011aN~\u0002)\u0007:\u036dt|q\u06bdo\u007fm\u0115\\4c\u03dajO&udRr/MN\u0371^c\u0013\u0003n^XgO1tNc+#xn#\u001b\u001d F:\u0000\ty\"[w\u02d6wOS&Uk0\u001d+%3\u0797 1Ikx=^j,TY#G7#l\u0297^Vqv\u001fM]6Rw\u0005\u0005Nu>S\u001eL:\fX-`UwP;\u000f\r\u0002\u0001!\u0013m<(S~yL\u001b4pCc=\u00011^6\u07c7e[.twg<cTi\u001dX09lcL%&\r\u00e6/@JDNioI\u0007#pt<7cbcZ\u00156wEc\u03bb]zp\u05b691mS\u0124EL\naK\u0016 ~j'\u0006yB\u0013^}W*\u001b(?L\u001e46q0\u0015\"@^P9\u0002$\u01ac\u0379\u007f~\u02dbA0\u007f\u48fel0\u001bK\u00079ufke[\ufd82i 1o&8}h]\u551a\u001es\\jd'\u001eK\u0006`\u001d\\G\u000f5i/S>vEl\u001e\u05a768V\u05f6mK_m&\u0693\u02e5\u007fM\u07f5y]\u07fe4|uEp\u000bX\u0003c5|\u0016\u0000\u001b-8=-cR\u03bd\u0010\u0018R\\+>\u05d7J[\u0591IM\u001e~Y\u0002\uc153i\u001f]R.\u0005>W\u05e6\u07fb^\u001e7Dokx\u007f>c,b\u0019S\u0017|`\u001dC\u07af&u!\u007f**\u007f\u0236ta:\rupeVBL\u001a]-0\u04b4\u05b1\\Y\\\r\u024beBB\u001e5&_>r\u03fe6/\u001dx\u077a\u04e5@\ue333!\u07e9\u0013m;\u001bK\u001e\u001d^*\u0000\u0000\u000eIDAT\b]\u03f7p\u0005rH-4\u01a3g\u054e&\u0012\u018eT\u000em0vY>_\u000f_V1\u0005\u0001\u0003 \"Yn}joI=!\u0012qI\u0007gn*_<6\u007fnz\u000f\u000b*I\u00128]\u0004<`>f\u06f0/\u0012\u0011\u0015\u001fdt#\u007f^\u049fn\u001f n\u000e_[l\u0004\u0219AKyM\u02aeg^\u05ec{\u0002=$O\u0016'\u000fNi{X\u001cE+wq'f\u0092R\bb: &\"Hc}n_\bC\u0016w\u0001@~:wVzH\u001c\u0005:CXp'H~:\u0628+kig*&j%-&`\u001b\u001c\u07ce\u0013KoZZv|TJ cSw%\u074d &\u001a\u001ciuilr,R%%*1n]\u0017`;|\u001d>5c\"\u0019\u0000Fc#UvTx;\u0004OLL#@i[\u0017\u001fq,\u0271$4Ig\u0005b\u0010\u000fJ[P\t\u001aIo\"\u0003\u01cb=_o,H\u0705\"*\u0004\u02774#8-(k5Od&\u03e9&(qK4)N (/fo$I>d|\u01de\u0016`[WTMD\"\u000e|#R=|KUOEPzJ7k]\n7)\u072aM\u0007y-R\u0018\u000f& VMT7U$)=[d\r\u001aC\u0004\u007f\u0004HDkUJD\u001b\u001f\u0006aMR/n'j`\u001b\u001cQ5Qg&\u0013]@\u0017GzIx\u007f\u0004\u0018bI\u001eV\u0010G/4-q\u0012rRJ%_@\u0010\u0015\u0000>V\\\u0015K\u0015\u0011_?\u000f>)q*\b)%q\u00110E[\u0017\u0011GY(kU\\\u0004\u0013#\u001e\u0000\u000f\u0011\u001d%\u0011VG^ ?=\u0002&\t%MB\n6\u001d>c\u0000V`6\u0016\u0000{6\u00181/\u0016p\u00197\t-KQ\u0003g\u000e|\u000fvmj\u00006\u0007\u02ef\u0001Ufz)*\u00181\u0000\u001b\u0010G_\u0000L]k\u0019\u0003\u001d8\u0018i\u00006Eo?c\u0018-e?`\u0000\u00006a tw1\u0000\u044c\u0001\u00000\u0408k\u0002`;`]\u0000\u0000~V13\u001aMi>\u00008EK \u0003\u0000\u0007>c\u0000~CG\u0010\u0013g\f\u0019T/y\tg\u0000@g\fO5Sw|\u040c\u0001\u0004\u0019\u0003\u0013\u001c\u0006Y\u0004\u0000 j3\u0006'm\u0014!3\u0006`Kg\fO\u03d83\u0006`Kg\fO]\u0019cmj\u00006\u0003|\u0000\u0004\u0015\u075b\u0004L_\u0000l\u0005\u0001\t\u0001\\\u001f*M0S\u0003\u0000\u0000\u0000A\u0005|P\u0000l\bnD\t-ZZg\f\u0010\u0017gG\u0001\u0000\u0323$1\u0000\u001b#\u007f-\u000b\\\u0012\u0000\\\u000e4Nz\u0013\u0000 vKtp>4\u0000 >fz)#\u0011\u0001\u0016_\u001e&~&l\u0000@|k~5j\u0005.@\u0006`KH\u0005nb\u0000+t+t3\u0006\u0000\u0000\u0000@\b\u000etz\u0515\u001a\u0018\u0000\u0000\u0000\bA\u001c\u0005u\u04db\u029f0P\u0003\u0000\u0000\u0000a8D_\u0001ZCB7\u0006\u0000\u0000\u0000pS\u0019\u001fd;\u0003\u0018\u0000\u0000\u0000\bA\u001c)i1W\u0017O\u0003\u0000\u0000\u0000Z\u0007\u049a\u0000\u0000\u0000P\u001c\u0013u7P,<\u0000\u0000\u0000\u0003\u00118o$5\u0011\u0010\u0000\u0000\u0000\u007fJa|jr\u001f\u0001\u0000\u0000\u0000T1%\u001cf,&V\u0002\u0000\u0000\u0000l^_\r#JSu\\X\u0000\u0000\u0000~h8}+m\u0018)N\u0000\u0000\u0000wH\u8629IqBT5\u0000\u0000\u0000C?M \u0017\u0011$\u0011Ih\u0000\u0000\u0000\u0017:\u00b8\u001bj\\-\u00191\u0000\u0000\u0000f|\u0014I\u0000\b\u00042\u049c\u0000\u0000\u0000\u0000\u001c'K=#g\u040e\u0001\u0000\u0000\u0000\f8R\u001dWB<Kf\u0012\u040e\u0001\u0000\u0000\u0000$Jek_\r#\bk\"\u000fQ\u0010\u001eE\u0012\u0000\u0000\u00002\u040ck?Z\u001e#\u02fc$!h\u0000\u0000\u0000\u0003X\u0358|-l\u0007r5qz\b\"\u001c\u0013I\f^Rj;\u017d\u0797~\n_\u5dbd\u007fUWcvqos~]=u=s\u03dbz\u001am0T/\u054cKST\u0000%\u0004$\u001akS\u007f\u000f}_>X\u02ff\u01b3B\u0010u~VJ:\bbJ\u0018')mmXQo\",(\u0017?[9{\u01e6~\u05b6C\u00126\u0012Sx\u03fauy\u0010m?6fPICs5\u0011\u0447H\\^\u007f)+7\u0017\u06585vlT&\u001chk\u029b[&,\u007fgs~\\\u007f:U\u001c\u0003le5\u001ag\u001b1Q?$\u001b\u00135+t\t\u0012\u0004\tDY/aB|\u03a6\fK;\u06dc\u001cC\u007fg\u0535X0[!\u06e0X\u0018K\"u\u0016\u001a\u0378\u0004\u000b\u0002y\u0015tt 7\u7ea9F&lZ{\nQ-<ku\u00106\u05c7\u0010\n.\u0000?d\u001btP\b\u0012\u524fl\tb\u06587,\f6us|4`{y\\^5\u0007\u0438\u001c\u0003L\u0016[\tOa\u0019\u0227TM#\u001aM@2\u001a;@K\u000e\u00017\u0003\\<fw_\r}\u001f,\u007f\u03daa?\u02d5\ued46\u001aSX3\u0011\u0017\u001e\u0015\u075d+uU.f\u03c2B\u0015\u001fh>\u0019kt\\\\-t\n\rR\tSI1 \u35f1\u058c\u06dc*udI\u0011h\"!8\u0012:cJ]<\u007f\u0000\u001c2g~6t\ub9f46=c-\u001f]H\u0018\u0013\u0011eO\u0016\u0007\u0016\tiD\u001e\niA)B\brm\u0010\u0019\u00176yT0\u053dZ\u00186$1)r\u0016KLS\f\u0014\u007f\tuLwf0&\"*R+\u0004rG0\u5bd0NOD\u208d'\u0012:sr,\u0084PQ\u0010\ue7a5\u0014k\u05d8\\;\u05fc;\n%a\\sq\"C*{J*W\u001b\u0599\u03f2Z\u0010hm((%Ar$b\u0010R\u0018M'\u0015sM1\t\u0413${UW&b5sm\u0df9xi\n\u0006C\u053bk\t\nxJ*t+v5)PBkn\"t'\u0013\u05feF=,3\u001a^o+bz\u000e\u0019(cLmbmx.\u07efO\u000b5O`\u001dM=8$Kou-h\u0005C\u069bPT>\tu\u0754 >m\u001b\u0011cG\u0005qYw\u07ba\u07b5c E2z\u007f?\u0013J\u000b\u0015_M\u068e\u000b\u00182s\u017d}wQzw.kQ$G.)\u000b|\u0235pj\u000b3k5}M\u0775PkkmA9\u05fa/\u001dDWN\u0129U\u05b3\u06a6ntw\u0007,m,.\u001bM-\f\f\u0010z\u0006%\u0003k$h\u0014r\f\u001dd\u0003E$/\u0012D\u007feH*:`L\u0013DQW%\u0375M\\O\r2.\u0001\u069bD6y66Cfma\u000eJ\u0012>W BH^\u007fuwm\\em\u001e\u0019H/\t[U\u001asz\u0011$AMD\u0011m\u001fkoOv}Z{N\u001f\"\u0464\\,:\u0015UY^\tR\u0016u`Z\u0006\rD]\u001cl\n\bb\u001e\u04fajmzc\u00af|<k.#|W\u0013\u0149HDDsD$DT][]xO:UFg\u0016$N}N}ms\u001fsoA$[/\u007f\u0000LSpi>|zz]\u001f\u05fb2p\u055f|\u00131{k\u0671\bc`\u001a\u007f\u0015aJ\u001b0vW\ncu\u0005a&\u00045S6!WG0Wh\u0002-Slfu\u001a\u0019\u001f})\u0018\u00103&9{\u0000\u0017\\!\u000e4\u01b7\u000e%l$M>\u001f\u001dvc\fX2_\u044a\u0019\u0003\rK\u001bz@Psb\u00141jKbWS\u0006_\fZPmp\r\u0019o\b37T\u0015P>im\u06b3>.B=k,^`+\u0003e^\u001a\u0003E\u001b\\s1\u0001\u0018h\u96f1\\\fs97\u0000hN|?\u0004\u07a13~\u07eeU'V\t\u0006]\u053bdh`\b53O\u016cL]O!\u0019X\u0136\u06aa\u0000\n\u0018\u0003bW\u001b\\A3 \u001aI W,W\u001e9\f[%V\u0001];\u03b6.N6\\c@\fl\u0003\u001ec\u013eD\u0000\u0000\u0000\u0000IENDB`PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000\u0005\u0000\u0000P\u001b\u0000\u0000\u0015\u0000\u0000\u0000word/theme/theme1.xmlYKo\u0013G\u001cWw\u0018\u001d\u001d\b\u0007\u014e\r-\u0004Pq\u001cw\u0007f\tUpT*z(Ro=Tm@~T-\nzcT\u0002\u001f\u07cf/^\u001b3tD<iyU\u000f\u0001M\u0096w;!p\u0012`\u0013&Dz?\"R\u0011\t\u0002Dn\u0017)nU*\u0487e,$7\"\n\"\u0004\u0002\u001f\u0003\u07d8Uz%4Pc`{c8>A}\u06de22J\u000b>\u00135(\f6\u0018CNd\ttY\u00039\u0001?\ue4fbC\fK\u0005\u001b-j>^eb bj\tmg>9]N\u0010Nkl^-\u001b\u0000Sn\n~\u0006}\u001f,t)c\u001bZ{\u02b3\u0004\u0286;faK\u0016vi\r(\u001b6\u0016\u001bN\u001bP6l.t-\u0001e\u0005|z\u001bPh2Z@x\u0016) C\u03ae8\u001b\u0000\u07d8&\fU)eWFe\u0016;\\\u0000`\u0015Md}up<\u0010\u0014k\u0001xN\u02c5%-\u000bI_TS\f\u00151x\u32e7\u027d''~9\u007f\u000e+8\tT\u03ff\uf1df\u001e\u007fWn,\u007f~\rTe\u0cef\u001f\u0473o>\u0007\u000e2Oc\"ur\u000ex\f9\u0004x=~ib'\t%Nq*'\u0471pmb{\u0016\u0002^\u001e\u07f1\u0014>XQ\u0007j\u0014[=Y\u000bMW\u0017I\u0016.e\u0001G.\u065dv)4-mhD,5\u0019\u001c$!\n=>\"AvR\u02ef{\u0017\\B)jctI\u000el\u0011]1eR\u0010mf\u0016jsbKl$T\u0005f.Yn\nNqkXE.%\u000f'\u00b7\u001c.\u0015D:$n@t\u0010\u0013K\u076b\u0018z3{l\u0012H\u02059/#w\u00138uLH E1\u02a9\u0004+D!\u000e8Y\u001a[X~um\u07e4,AX}1M^\u058e\u0019~|\u0018\u001ao\u001f\u001a\u000e\\0~n=w\u0017}\u0002iob]V\u03eb6Yo5C5a4]YA\u000f\u0016\u0010\u0015\u00074a.\u0085\u00021\u0012\\}BUt\u0018\u0014\u050cPCR.\u001a`\u0006\u0015T\u059c^\u0000\u0001\u001e\u000f\u0170`cf|N\u0005i\u0006\n[p:a\fQmQZaSy\u0784j@X_kL4d\ff$~\u0018Lr!\u0011\u000eH\u001e#m!5\u0015\u0726/yKlO!m 5F4Q2EI\\9\u011ec\u042aYozi\u001b!\nq\nn@IUn+y`wZ\u05aaK\rDB],lD,_o6\u001f\u0000G7ZM\u007fyCKC%+i\u01ca(8F\u00036\u0016\u0007\u0018\u05a9\n\u0004T;\u469e\bP\u00033*}&\u000e\b=I\fn\u0185\u000efVR?#Si3\u0017k\u001ep\f\u0010\u0018\u001cmy\\C\u0017J#\u0004\u001c\u001c,\u000bAYh\u0010\u04ff6k]\u046coe<LA9D\u001d\u0010\t\nNE}\nf+\u65513LL\u001c\u0011\u057bP4&#\fn>h<w \u0505|yLPFR/\n6Okj \\U\u0003/hTlv\u0003>b\u0013%D<\u001d<.l4\u0000LfIQ\u0010\u0014r].3tvq\\s\u017dr\u001e9\\]Y,J\"cf\u000b:\u001d\u000b\u00171SGU3\u0000d\u0012\r?\u0000\u0000\u0000\u0003\u0000PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000\u001foR\u0003\u0000\u0000\n\u0000\u0000\u0011\u0000\u0000\u0000word/settings.xmlVn6\u0010}/\u007f0\\E\u0017\u02d7\b,&E\u0016u\u0016y$\"\u030b@RvECJHP\u0017k4gp8\u001cWFGG,\u0015\u0011|E77<\u0017\u0005y\u03fd\u0488\u0017\n\u0017\u0019+?}:\nk\raj\u0004\u0012\\,_xu\u001a\u0004*0CF\u0518\u0003X\n\u0250W\u000f\u0018sjIF( \u000e\u00e9\u0248Hv\u0012>#\u0014JPRQ$1Gm)k7\fsmW\f$\"rjG\u00006qd\u015d\u0003=\tY\\\u0018\u001fI\u0010j)r\u0014\u001c\u0010.A7Bo`nV\nQha\u00047\u0002\u001c^14\u0002`\u000euHqCF\u001fKf P4WIcy\u0018@K\u0015sg\u0014\u0018.\u04a8B\u0491bISL\u0006mQ\u001fM.g\u059fz;]B$H3ki\u000f{.$(\u0003=\u001c/\u001cyX\u0013Zmg\u0018P;\u0018i\u07c4`SZc\u00fdy8K\u0000pDHbjL\u001d9\b\u00128{\u00186\u7c5c\u0002\u0019e;-j\b:\",\u000e;X\u0013|\u0017|\u0013\\#Q\u000eN\u0017\u001cE.s\u001f\u001b\u0018g\u01c8B\u0012\u001aNp\u0005$)*B`\u0006K\u0018\u0011\u001dNdc5Y\"bS\u0016R\u0015#:F?\u0003~y\u000f\u0018+\u0000\u001c1(wI\u0014\u0614}b\b\u2fffP\u000bDCS!\u0014Z\u000bv\u007f+X\u001f\u000buaMX(g%va8\u06c4eA{$O7n\u000f#8\\7!ZpYt\u0016\u000esZ\nL\u00124z2_Dd$\u0019+\u022e\u001c-\u0018t\u000bEt:fnKk'$n\u0017!Bv27\t/R4u$\u001fxMDI1\t\u0016c\u03aflX\u001c.\u0000jxQ:9\u001a\u0018<\u0016a\u007fuD\u03b4\u0001~BuvS\u0016\u001e%JG\u00014\u0015'\u017edb-f_Pnv\u0006\u045db\u001b\u010do\u0012Kz&o|S0`\u001ciTpqo\\n0\u0004N|wfY?\u0012nZ\u0012\u00057\u9845t/\u0016\u0010\u0019I\ub7c4l\uba85'\u0017x\u007fox\tC?Z'c\u007fMmZl6mdO\u077f\u0000\u0000\u0000\u0003\u0000PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000HuL\f\u0000\u0000Nw\u0000\u0000\u000f\u0000\u0000\u0000word/styles.xmlr8\u0012j\u07c1\u064bD>;I385q\u00199k,l@BKR>/\u0000\u0012&(6\u001b[\u001f\u0001\u001b\u0000OTF</&&\u0011bl7(Y02~6y\u01ef\u000fI\"\u0480xgeYME)+^\u0015\u000boi\u056bX+V|\u001eLjL>\u0016\u000b\u0011*^<+m4R\u0013UV,\u016ahh\u000fCh\u000f*OVyQJLd\u001b\u0011\u0000\"U\u0016k]D\u0016Tn\u00018\u0001\u0000\u0011xS3:\u00049pDp\n\u00005\nqp\u06143\u000eHd5\u001aMM,+\u0652\u00156q!q#Xu0.\u001ax\u0003|Ji.S9KM\u04bd2\u001d+`Wc\u0657n7RXHB{mD\u001feYM^\u007fUV\u0016;VB\ua766B<+D\u007fYQ\u0017u~4/:?A$b25{,?g\u000f\u000e-\u0017\u0004mew6>sKlk\u0644f&pZWTw \u0012p\u001b W^\u007f.lt\u0002kiov6\u0005:\u0014\u0013\u06ac\u02abS{\u0010Of\u07efnrr;&o\u001bg<\u0015\"Ix|1[X{?>Yo:\u04ef\u000fOOl\u07d0E1+M\u00193J}5\u0001|{-;m`>]K\u0310\u0012?G\u0010\u0007&pj\\?\u0016jG/KvtR;zR;sG\"K`\u000fw\u00038\u001e79\u001e9\u001e/9\u001e9\u001e'9x1\bNb_/t:sw\u0011aCB\u0018w\b\u0010\u075d\u00f8{\u0018ww:\u000fa\u001a\u03edZ\u0455YVvB2S%J82\u0372l\u001a\u0019xNRI\u0002Lx4-f\u001ebM\u001a>f9\u0018E\u0010w\u0017\u000b\u03b3{.\u054aG,I4\u0010r{Z$O|s\u015ccAx9A\\;2\u0016\u0012k$Ia\u04e1zziL\"\b:u\\/bd(\u01b7D\u001fRr\"W.fY\u0006\u00163~i`1W\u0006\u00163~ahFD5j\u001aQ4v'U4viDV\u01b7\u06ed(Mc\u007f\u000b\u0319\u5609\t>f\u001a\u0770l\u0331n[g~>)\u00186$y\"\u0000\u001bE2\u05c6Gd\r`\u001bx]i]\u04acgfyiZK\u001ad\u0019jB;m\u001c\u00f6\u0006,\u0006X\u001eLg\u0014o[\u0005\u06f2yV\"-^$(9J/V<\u02f2I'tY?\ftdk\u0016bP\\S\u0011]\nH&2\u001a>J\u0011\fKtVfi\u001a\u0006AJ\u0258_~h\nx\u0017\u0013Qm\u03c9\u000e\u000fY\u0605 \u0018d*JHz)2A2ZiXnr^]eRr\"\u2325jA-\u0017\u001ft!\rY_,\u0017\u0010nI`ab=\u000f\u01e7*\"92m]vkp\t-)US\u000f\u000f\u0012T\u001b_\u0016\u0017\u0015B\rQUQw)Z5`\u0003$k\u0006H\u0584J\u04ec\u0011VKe,;\u0017\t\u0018\u0016FQ`aT\u001aX\u0018\u0000q`/q`\u0569`DS\u0000\u0007FH\u007f<\u000eY\u0018U?0~faTc\u0017\u000b=\t\u001bb\u001c$Ust\u0003MVtr?\u0011!?I~\b\u000eV\\--*.&@c\u0512p]DdE3,r\u0011\u001c\u0011eR*Etlm;k\u001dp#Y\u0317J&<\u001f\u678b0=87\u0017q,rs\u015cwwD6\u000bV\u001dvIsKW5O:m\n\no89\u001c\u001el{t+hwv&\u044a<\u001e\u0018\ty;r;KnE\u000e|30\u0015\u71cf,\u0011Nf|}h\u0013\u0739\u06fe\ua0a7}e<\u00020\u31d9\u001fq2W~D\u008c\uc624iz\u0002};\u001e9X}\ud82f\udeae)+x9\u001c~\u2a95e88\u0011\u001f18\u0001\u001127\u001c\u024f\u0018\bt#\u0002.[x\\!\nRB\u0548Y\u001f1x:G\n\u0011h)\u0011( B\n\u06a8\u00106*D\n'`8xQa|Q!%\u01286*D\n\u0011hB\u0004\u06a8\u00106j\u001b\u001edTHA\u001b\u0015\"F\bQ|qQa<\u03a80>\u0128\u0012bTHA\u001b\u0015\"F\bQ!\u0002mT@\u001b\u0015\"PF\u0005AF\u0014Q!\u0002mT@\u001b0\u07280\u001egT\u0018\u001fbTH\t1*\n\u0011hB\u0004\u06a8\u00106*D\n\u0011( B\n\u06a8\u00106*DjO\u00160*\u0019\u0015\u0187\u0018\u0015RB\n)hB\u0004\u06a8\u00106*D\n\u0011hB\u0004\u02a8 <\u02286*D\n\u0011}>E~\u001f\u007f{SWutovQQM\"|Pgy]o\f\u0014\u001eVw\b\u0509o\u0017w\u000f]\uf170L\u0001hh$8rH;n$u\u001ee_7\u0012\fG}I(E\u000fG /8l&N l\u0004\u0006Nqdt\u0014\u0010C8\u0013%\u052aI\u0018CE\u0013'\fO@\nQaRCa\u000e7\u001a\u0012\u0006p!*Xj\n\u001a&F\u0510:<9\tAR\u0003L\u0010\u0015,5DI\r2\u0510\u001a\u0012R\u001cp!*Xj\n\u001aNRC\u0002VjHJ\r\tAR\u0003L\u0010\u0015,5DI\rVh!\u0001+5$` \u0001&\\j\n\u001aGQZR\u0014vq0'\u00107 ;\u0004\u0006\u0552C\b\\-A\u001aq%W4?az~P\u0019\u0004^\f^X?\n\u001f\u0015&5n%uQ\u0004\u0538\u0552WjjWjjWjj/5n%5n%uxr\u0013\u01adz\u01adz\u01adRVK]RVK]RVK]R\u001cpq^q%\u0538R\u0538R\u0538R\u0538\u0552WjjWjjWjj/5n%5n%5n%5n\u001aZ\u001aZ\u001aZ!\u0011PeDKV,K6\u07f3\u0017J$\u0017T-\u000f2l\u0003n3\u0004tvz\u0002l\r_J6?SeMIW\u0376Z&`25\u000f[o7\u0145O{cxBR(P\u036dZ9\u03eby\u001c\u2d9b7\u07ee\u06eaR}IU~OKc2[*Q9WuUB]\u0014/D\u0003\u001e\u001f%J<\n?R^j\u42f2t\u007f>\u0018\u0019\u007f\u000e\u0006^]m\u007f?__&u4dflK24!>>PjKL\u00006[\u05ff\t+\u0011N\u007fpI'o\ue84a^]\u05802]Gu\u0379y.~s\u0001S>\u0007V>Xb}AF\u00129\u0011L\u001d1\u063a@\u0241\u05c5\u001d\u001f:sLo*sx\u007f\u0000\u0000\u0000\u0003\u0000PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000;\nO\u0001\u0000\u0000\u0003\u0000\u0000\u0014\u0000\u0000\u0000word/webSettings.xmlQo \u0010\u0000%\u000f\rJujLceYm?\u0000\u0012k\u0000WZ]\u0017_d/h{_;6V7X'\u0454d6I\u0006.dM2\u0011Li\u0015\u001d?\u02c2b\\yI\u001a\u06c2R\u001bM\u0005\u0013>Vh5akk=\u001c\tG2/RI\u007f<_(XU+\u0006|jA\u0005\u0011kdZ\u05a1\u0015E\u000e\u0385hu4\u0016w\u0722Oaz*>\u0017X\u0001;`f\u0007\u0331#E9R\u00153\u00021\\KL\u001fYNx\u0464q\u0019\u0458<kkJ\u0013\u0017#r\u0014\u0604-oY\u0019j^\u0006-\u06eb [p|\u0125\u000f\u053fm\u0019J tn\u007f\u0000\u0000\u0000\u0003\u0000PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000;V\u0002\u0000\u0000\b\u0000\u0000\u0012\u0000\u0000\u0000word/fontTable.xml\u0113n0\u0014'\u001d\u0010\r4TmHX/\u0001\u001ccU \t-K\u0017i\u00029\u075bj\u00d4\\\b\u0001DeLn\u0017j\u0016\u0006ba$]\u0007j\u00bbO<W\u049a\u0000K3\u0017d\u0011\u0016\u0596(2\u0002*d\u0016^6\u0012X+D-0!J\u0010\rFCQy\bNPiHS\u000eD%MJ\u04aashY\u0015\u0005y\u00023a\b$\u0018\u02a8\u070e`1ME\u001e\u0005cG\u0003&\u0000\u0011`J0\u01acaD0a0\u03b4\u3c2c\u01f9\u001e \rB$\u000ep{,\u066c\u0018k(rs\u00056\u011c\u000f#=b`\\>\u000e6\u0007P\u05edT\u001ao8+\u0003h\u001d=\fr\u0006`m\u065c\u0720K,\u00009h\u0013%\u0018r{\f\u0007M+4ANWR4v0r\u001f\u0002kC\u001d\u0010\u001c\u000b\u000fmT\u0318:Q2K6\u01daE)\u00f6\u0619\rZO\b~\nH\f\u0579HzD\u0012/\u007f4q\u0017A.B<\u01ff5xN\r3\r\u001cX3AMLE\t,O\u0018I\u0014LL33\u001edD{`#O\u001aM{(\u0007^\u0005\u0019m>\u05ecH\u0003HJ{Ima'6\u031af+{\u00024>a\u00b5n\u00ae\u0474o\"M\u0721\"DMD30\u001f\u0000\u0000\u0000\u0003\u0000PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000 00Yh\u0001\u0000\u0000\u0002\u0000\u0000\u0011\u0000\b\u0001docProps/core.xml \u0004\u0001(\u0000\u0001\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000]K0\u0014\u0005C4-+]Nv :Q\u000b\u001a\u0017I\\\u077f[U>9\u0017F\u001dc:1\u0002+Tv;\u01cfUvQLJ9C\u000bvzR\u000b_\t\u0017.8\u000f!)3X\t?MJ\"$\u0006\f\u04ce]q\u001d\u00d6x.^\u0016H@'NzaG#>(\u0018-A \u0005\u0001\r\u0006lN)b\u0013\u0004\u0013,\u0018oQiO\u0018{T#\u0636-\u0007\ub7d2\u06db\u1a59\u0004`VKQ%4K\u001fF :j2\u0006=\"\u0002\u0002[;.&\r1yLJ6\n\u055e\udb35\udea0{ml\u0018l\\+y7\u0007\u0629~\u0018X\u001fy\u0019H=\u001c1y*\u0015fE^efe.hU^TyKh\u000e\rx\u0014\u001f}\u0000\u0000\u0000\u0003\u0000PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000Hz\u0001\u0000\u0000\u0002\u0000\u0000\u0010\u0000\b\u0001docProps/app.xml \u0004\u0001(\u0000\u0001\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000RN0\u0010#\u000fQi\u0005\u0011*B\u001cxI\rpMb\u0616m\u0010{\u0584 n;\u001dL\f\u0017\u001f)1D\uce9c\u03ea@+\u04b6]OYY$\u0012Y\\;\u0005?<<1\u0016DaREa/\u0196&\u000bH\u0506\u0012|&\u0015\u00cfV:#a90*'\\<qF$y\u0314K=\u0011%aj#\b\u001e\u001bx\u0014-F>\u00076\u0014\u208a|\\\u0002\u001bJt\"\b(A>?YM\u0000h)\u0012\f.&\u0015\u000f_L\u0000lz\u0004\u0016[iL[6KY\u0000\u001b*\u0016D\u001b\"?\u0002\u000eR\u0018P\u0000\u0011&\"\u001f\u00006\u0012\u001f\u001b+{OvW9N\u000b\u015cVgS\u00d3\u0011l\tEE\u000eF\r#\u00007W\u0017\u042emQ\u001d\bYEWf{\u007f\u0002\u0000\u0000\u0003\u0000PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000\\\u0001\u0000\u0000\u001d\u0003\u0000\u0000\u0013\u0000\b\u0001docProps/custom.xml \u0004\u0001(\u0000\u0001\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000N0\u0018MRd\u001b\u0004X\u001cl'Nd8\u0013H)[\u0013hI\u06e1\bL`'$=i7Om8|+2\u0014\u0011tl\f\u0001\u0013T\u0016\\,#xM\u0001\u0004+)X\u00047La|y\u0011\u0394l2i!\u0298&@H\u0015smwcMJt[D,9e\t\b=Dj>qp\u000bZSd!N/M\u0000\u07c06K%ia\"c?\u001c,\u0016\u001e`LF$W\bm@ zXnXZ\u0013b,&xXa\u001cc'Bt<&\ue249T{yF\u0177*eiT\u0005fd'r\bQck3\u06f3+.\u0743\u0017kN;\u001bnq\u0006\u001cbv\u0018\u000b\u0007k\u0006}\u0003\u0000\u0000\u0003\u0000PK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000\u0002GOx\u0001\u0000\u0000\u0003\u0006\u0000\u0000\u0013\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000[Content_Types].xmlPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000U~\u0005\u0000\u0000\u0000\u0002\u0000\u0000\u000b\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0003\u0000\u0000_rels/.relsPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000yw\u0005\u0014\u0000\u0000\u0000\u0000\u0011\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0006\u0000\u0000word/document.xmlPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000E\u04cfcW\u0001\u0000\u0000\u0006\u0006\u0000\u0000\u001c\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\r\u001c\u0000\u0000word/_rels/document.xml.relsPK\u0001\u0002-\u0000\n\u0000\u0000\u0000\u0000\u0000\u0000\u0000!\u0000fY9h:\u0000\u0000:\u0000\u0000\u0016\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u001e\u0000\u0000word/media/image1.jpegPK\u0001\u0002-\u0000\n\u0000\u0000\u0000\u0000\u0000\u0000\u0000!\u0000\u0301H^/\u0000\u0000^/\u0000\u0000\u0015\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000Y\u0000\u0000word/media/image2.pngPK\u0001\u0002-\u0000\n\u0000\u0000\u0000\u0000\u0000\u0000\u0000!\u0000j &2\u0000\u0000&2\u0000\u0000\u0015\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000e\u0000\u0000word/media/image3.pngPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000\u0005\u0000\u0000P\u001b\u0000\u0000\u0015\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000word/theme/theme1.xmlPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000\u001foR\u0003\u0000\u0000\n\u0000\u0000\u0011\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000word/settings.xmlPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000HuL\f\u0000\u0000Nw\u0000\u0000\u000f\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000word/styles.xmlPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000;\nO\u0001\u0000\u0000\u0003\u0000\u0000\u0014\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000d\u0000\u0000word/webSettings.xmlPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000;V\u0002\u0000\u0000\b\u0000\u0000\u0012\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000word/fontTable.xmlPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000 00Yh\u0001\u0000\u0000\u0002\u0000\u0000\u0011\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000k\u0000\u0000docProps/core.xmlPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000Hz\u0001\u0000\u0000\u0002\u0000\u0000\u0010\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\n\u0000\u0000docProps/app.xmlPK\u0001\u0002-\u0000\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000\\\u0001\u0000\u0000\u001d\u0003\u0000\u0000\u0013\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000docProps/custom.xmlPK\u0005\u0006\u0000\u0000\u0000\u0000\u000f\u0000\u000f\u0000\u0003\u0000\u0000O\u0000\u0000\u0000\u0000",
    "preview": "PK\u0003\u0004\u0014\u0000\u0006\u0000\b\u0000\u0000\u0000!\u0000\u0002GOx\u0001\u0000\u0000\u0003\u0006\u0000\u0000\u0013\u0000\b\u0002[Content_Types].xml \u0004\u0002(\u0000\u0002\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000\u0000..."
  }
}